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ABSTRACT 
During exercise-induced mitochondrial biogenesis, a rapid increase in the transcription 
and translation of nuclear-encoded mitochondrial proteins, under the influence of PGC-
1α, require integration with mitochondria-derived proteins. This has the potential to 
perturb cellular proteostasis and thus induce an unfolded protein response from the 
mitochondria (UPRmt) and/or endoplasmic reticulum (UPRER). The role of the UPR in 
skeletal muscle, particularly with respect to exercise is not well established. We used a 
chronic contractile activity model over 7 days to examine the chronology of 
mitochondrial biogenesis, autophagy, UPRER, and UPRmt activation, and used a drug 
(TUDCA) to block the ER stress-induced UPR to test its role in adaptations to CCA. Our 
data reveal that the UPRs are involved in acute and chronic muscle adaptations, 
independent of CHOP signaling, to augment protein quality control. However the specific 
mechanism by which the UPR influences these adaptations is an important avenue of 
future work. 
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1.1.0 SKELETAL MUSCLE PHYSIOLOGY 
In order to properly understand the factors that govern muscle function and plasticity, 
it’s important to first attempt to understand the constituent components that comprise 
skeletal muscle and its unique characteristics. Along with muscle fibers, skeletal muscle 
contains a variety of tissues including neural (motor neurons), vascular (capillaries), as 
well as various types of connective tissues. Muscle cells, while retaining many of the 
organelles found within other cell types, are unique in their long cylindrical shape and 
multinucleated composition, whereby nuclei are arranged along the periphery of the fiber, 
under the sarcolemma. Furthermore, mitochondria are divided into two subfractions 
within the myofiber, subsarcolemmal (SS) and intermyofibrillar (IMF) (87). Skeletal 
muscle gets its contractile ability through the physical interaction of overlapping 
myofilaments, actin and myosin, which make up the sarcomere. Each muscle cell 
contains repeating sarcomere subunits that facilitate muscle contraction through the 
interaction of the myofibrillar proteins in an ATP-dependent manner (193). Overall, 
muscle exists in a highly organized, yet heterogeneous, arrangement such that differences 
in myosin isoforms expressed as well as intracellular mitochondrial density within the 
muscle contribute to differences in performance capability (192). Skeletal muscle is 
extremely sensitive to its environment, adjusting the internal phenotype of the cell to 
match the level of activity. Many of the physiological adaptations are well characterized, 
however the molecular mechanisms that mediate these changes have yet to be fully 
elucidated. 
1.1.1.1. Skeletal Muscle Fiber Types 
Skeletal muscle is divided into three sub-classes of fibers, with the designation of 
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fiber-type dependent on their metabolic and contractile components. Repeated studies 
have classified muscle fibers based on the immunoprobing of myosin heavy chains 
(MHC) isoforms within various muscle groups (190, 193). The standard classifications of 
skeletal muscle is as follows: 1) slow-twitch red (STR) fibers comprised predominantly 
of MHC type I isoform, 2) fast-twitch red (FTR) fibers containing mainly MHC type IIa 
isoform, and 3) fast-twitch white (FTW) fibers, of which MHC type IIb or IIx isoforms 
are most abundant, depending on the species. Despite their classification as being either 
fast or slow muscle, most muscle groups are heterogeneous in their fiber type 
composition. Rat soleus (slow) muscle is comprised of 83% STR and 17% FTR, whereas 
tibialis anterior (TA; fast) muscle is 3% STR, 61% FTR, and 36% FTW (117). 
Each fiber type maintains a distinct array of contractile and regulatory proteins, as 
well as enzymes involved in intermediary metabolism that function in conserving a 
particular fiber phenotype (27, 89, 181). Specifically, slow-twitch type I fibers contain 
heightened mitochondrial and oxidative enzyme content, along with an elaborate 
capillary network which dispose these fibers for prolonged sub-maximal muscle activity 
(60, 200). STR fibers also maintain a slower contraction velocity and reduced total force 
output when compared to type II fast-twitch fibers. Moreover, fast-twitch fibers are 
typically recruited during phasic activity, but remain significantly more diverse in overall 
composition. These fibers generally produce greater force, however are more prone to 
fatigue, particularly FTW fibers (20, 51). This reduced fatigue resistance is largely a 
result of a higher glycolytic enzyme expression relative to mitochondrial oxidative 
enzymes, and thus enhanced reliance on glycolytic metabolism leading to acidification of 
the muscle bed. Interestingly, mitochondrial distribution within human skeletal muscle 
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fiber-types may differ from other animal models (92). For instance, rodent FTR muscle 
fibers exhibit a higher mitochondrial content and are therefore more oxidative than STR 
fibers (51, 111). Additionally, other fiber-type specific cellular structures contribute to 
the contractile differences in muscle fibers. Fast fibers have been shown to have greater 
density of acetylcholine receptors (AchR) and release of Ach, along with a higher 
abundance of Na+ channels on the post-synaptic membrane. Furthermore, these fibers 
have a more developed sarcoplasmic reticulum (SR) for greater release and uptake of 
calcium (138, 179, 191). Therefore, overall muscle fiber composition such as contractile 
characteristics of myosin isoform, along with density of mitochondria and additional 
subcellular structures govern the differences observed between fiber-types. 
1.1.2.1. Mitochondrial Structure 
Cellular ATP, required for the function and maintenance of the cell, is primarily 
derived from mitochondrial respiration. Mitochondria are structurally unique in that they 
maintain two intra-organelle subdivisions separated by phospholipid membranes, these 
are: 1) the inner mitochondrial matrix bound by the innermembrane; and 2) the 
intermembrane space, designated between the outer and innermembrane. The 
mitochondrial matrix is biochemically dissimilar from the cytosol of the cell, maintained 
by specialized protein import machinery that lies within the innermembrane in which 
proteins must pass through to enter the matrix (104, 173). This regulation of the matrix 
milieu is of critical importance since it houses multiple copies of mitochondrial DNA 
(mtDNA), a 16kb circular genome that encodes 13 essential respiratory proteins as well 
as 22 tRNAs and 2 rRNAs (87). Conversely, the outermembrane is porous and allows 
small molecules (<10kDa) to enter the intermembrane space, independent of import 
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machineries, and therefore is chemically equivalent to the cytosol (235). Measurement of 
mitochondrial content within muscle can be made using morphometric techniques such as 
electron microscopy. More commonly, estimates can be made based on changes in 
maximal activity under optimal conditions of a typical marker enzyme such as citrate 
synthase or cytochrome c oxidase, or change in expression of a protein such as 
cytochrome c (89). 
Mitochondria in muscle exist as interconnected networks often referred to as a 
reticulum. The oxidative capacity of the muscle, along with the region of the fiber in 
which the mitochondria are located, govern the extensiveness of the reticulum (158). The 
maintenance of such a network is regulated by dynamic fission and fusion events in order 
to add new, or remove damaged, mitochondria (213). From a functional standpoint these 
processes are vital to allow passage of proteins, lipids and mtDNA along the network and 
maintains a healthy, viable mitochondrial pool (81).  
1.1.2.2. Mitochondrial Subfractions 
Mitochondria within skeletal muscle are divided into two subcellular localizations 
with similar, but distinct functional and biochemical properties. SS mitochondria reside 
along the surface of the muscle fiber below the sarcolemmal membrane, and lye proximal 
to the myonuclei (90). As this locale may imply, these mitochondria serve to supply ATP 
for membrane functions, such as NA+/K+ ATPase. Conversely, the IMF fraction of 
mitochondria is primarily responsible for the provision of ATP for actin/myosin 
interaction and contraction, as this pool of mitochondria are interspersed amongst the 
skeletal muscle myofibrils (42). SS and IMF mitochondria have been isolated into their 
respective subfractions in order to experimentally define the exact biochemical profile of 
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either population. IMF mitochondria make up the majority (80-85%) of the total 
mitochondrial volume, and they exhibit a markedly elevated level of oxidative enzymes 
and protein synthesis rate, contributing to a 2-3-fold greater rate of oxygen consumption 
and higher state 3 and state 4 respiration rates (42, 44, 124, 126, 164, 210). Moreover, 
IMF mitochondria also display a significantly higher rate of protein import (210). 
Conversely, SS mitochondria retain a significantly greater membrane potential while 
producing nearly 3-fold more reactive oxygen species (ROS) (4). Finally, variations in 
both muscle and activity level can promote changes in electron transport chain and 
mitochondrial matrix protein stoichiometry, resulting in a change in the respiratory 
capacity within SS and IMF mitochondria (3, 90, 114, 155). Furthermore, the distinctive 
localizations as well as biochemical make-up render the subpopulations differentially 
sensitive to changes in the environment, as SS mitochondria repeatedly exhibit an 
enhanced lability possibly due to proximity to peripheral myonuclei, or an altered 
capacity for protein synthesis and import (44, 210). 
1.2.0. ADAPTATIONS TO EXERCISE 
Skeletal muscle, malleable as it is, responds to stressful conditions in order to 
match the new demands being placed upon it. Such is the case with exercise in eliciting 
various changes to the cellular environment in order to sustain optimal function. In the 
context of muscle performance, repetitive contractile episodes create an augmented 
energy deficit in the form of ATP, which in turn elicits a reprogramming of the cellular 
mitochondrial network in order to match the newly imposed demand. Mitochondria, as 
the cellular powerhouse, undergo remodeling through both synthesis (mitochondrial 
biogenesis) and turnover (mitophagy) in order to match ATP demand and provide an 
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optimal cellular network in which to do so, thus shifting to a more oxidative, less 
glycolytic phenotype (13, 89). The coordinated remodeling of the organelle reticulum has 
been well studied, as it is important not only to muscle performance but also overall 
metabolic health. This chapter will provide a description of the processes involved in 
mitochondrial adaptations with exercise. 
1.2.1.1. Mitochondrial Biogenesis with Exercise  
While mitochondria contain its own circular DNA, it contributes less than 1% of 
total mitochondrial proteins with the remainder provided by the nucleus (Fig. 1A). 
Nevertheless, 13 essential respiratory chain components are derived from mtDNA along 
with 22 tRNAs and 2 rRNAs which are integral to mitochondrial biogenesis and health 
(12, 82, 188). Therefore, there exists a complex cascade of events that allow the products 
of either genome to shuttle to, and integrate within the mitochondrion to facilitate in 
reticular expansion of the organelle.  
Early signaling events involved in mitochondrial biogenesis are initiated during the 
onset of contractile activity within skeletal muscle and converge largely on the activation 
of the transcriptional coactivator PGC-1α, regarded as the master regulator of 
mitochondrial biogenesis (72, 89, 185, 189). The preeminent signaling molecules 
considered to initiate biogenesis with prolonged exercise include (1) calcium/calmodulin-
dependent protein kinase (CaMK; specifically CaMKII), via increased intracellular Ca2+ 
released by the sarcoplasmic reticulum during contraction (160); (2) p38 mitogen-
activated protein kinase (MAPK) which is sensitive to a variety of stressors including 
exercise (6, 172, 174); (3) AMP-activated protein kinase (AMPK), activated by increased 
ADP:ATP   (97,  99,  100,  223);   and   (4)   reactive   oxygen   species  (ROS)  generated 
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Figure 1. The unfolded protein responses related to mitochondrial biogenesis and 
autophagy. A) Exercise induces mitochondrial biogenesis through the transcription of 
Nuclear Genes Encoding Mitochondrial Proteins (NuGEMPs). Transcripts are translated 
in the cytosol and require appropriate cytosolic and mitochondrial chaperones for 
trafficking. If the cell is ill-prepared to meet this influx, proteins will accumulate 
triggering two separate pathways aimed at restoring cellular homeostasis. B) The UPRER 
contains three independent cascades, stemming from ATF6, PERK and IRE1α, which 
remain inactive under steady state conditions bound with BiP. BiP releases to bind 
misfolded proteins as they accumulate in the ER lumen, thus activating the three branches 
of the UPR ultimately resulting in activation of downstream effectors in order to regain 
homeostasis by increasing overall cellular protein handling. C) If the proteotoxic stress 
within the mitochondria is too great, it can cause oxidative stress leading to activation of 
kinases such as Akt or JNK2, ultimately signalling for increased proteasome activity and 
expression of mitochondrial specific chaperones and proteases, respectively. Likewise, 
activation of SirT3 induces mitophagy and antioxidant machinery. Ultimately, if the 
UPRER and UPRmt are insufficient to restore homeostasis then mitophagy will ensue. D) 
Mitochondria are tagged for degradation by NIX or by Ubiquitin (with p62 acting as an 
anchor between ubiquitin and LC3-II) ultimately leading to full encapsulation and 
breakdown. E) TUDCA is a chaperone mimetic drug capable of alleviating ER stress and 
UPR activation, thus reducing the proteotoxic burden to the cell. 
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throughout the muscle cell and mitochondria (63, 86, 99, 180). Thus during exercise 
conditions PGC-1α expression can be regulated in a multitude of ways. For instance, 
elevated intramuscular Ca2+-induced CaMK activation, as well as activation of ATF in a 
p38-dependent manner, upregulate binding of the cAMP response element (CRE) binding 
protein (CREB) to the PGC-1α promoter (228). Further, ROS, in an AMPK-dependent 
manner as well as AMPK directly, can enhance NAD-dependent deacetylase Sirt1 
resulting in PGC-1α deacetylation and promote DNA binding (11, 70). PGC-1α is known 
for its importance in mitochondrial biogenesis, such that its expression is highest in 
highly oxidative tissues such as heart and type I skeletal muscle fibers (54). Likewise, its 
expression is typically most regulated with endurance-type exercise (16). PGC-1α has a 
paramount role in regulating the activity of various transcription factors in order to 
coordinate the expression of mitochondrial genes both emanating from the nucleus and 
mitochondria. 
While PGC-1α is the master regulator of mitochondrial biogenesis, the regulatory 
region of mitochondrial genes that are nuclear-encoded are heterogeneous, therefore the 
regulation of organelle synthesis requires multiple regulators of transcription (89, 119). A 
number of transcription factors associated with exercise-induced mitochondrial 
biogenesis have been established, such as CREB, the estrogen related receptors 
(ERRα,β,γ), early growth-response gene-1 (Erg-1), c-fos, c-myc, specificity protein-1 
(Sp-1), upstream stimulatory factor-1 (USF-1),  as well as nuclear respiratory factors 1 
and 2 (NRF1 and NRF2) (84). Each transcription factor when bound to target gene 
promoter sequences can upregulate the expression of mitochondrial proteins. Both acute 
and prolonged contractile activity have been shown to induce transcription of Sp-1, and 
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Erg-1, regulators of mitochondrial proteins such as cytochrome c (98, 137, 147, 226). 
Similarly, exercise upregulates NRF-1, which is important in the regulation of proteins 
which mediate mtDNA expression such as mitochondrial transcription factor B-1M 
(TFB1M), and -2M (TFB2M) and the mitochondrial transcription factor A (Tfam) which 
is integral for cytochrome c oxidase complex formation (52, 62, 186, 187). Following an 
acute exercise bout, PGC-1α promoter activity increases along with mRNA levels, while 
NRF-1 and -2 increase their DNA binding during the recovery (5, 16). Further regulation 
of the process is accomplished by an auto-regulatory feedback loop, whereby 
transcription factors such as USF-1 and CREB can enhance PGC-1α expression (100). 
Altogether, the coordinated expression and function of these transcription factors along 
with PGC-1α regulate, and facilitate, overall nuclear-mitochondrial gene expression 
leading to organelle biogenesis. 
1.2.1.2. Protein Handling Machinery and Import 
As previously described, the mechanism by which mitochondrial proteins are 
transcribed and translated is regulated through the collaboration of the mitochondrial and 
nuclear genomes, with the vast majority of proteins originating outside of the 
mitochondrion. Thus, handling of these precursor proteins is integral to the expansion of 
the mitochondrial pool. Newly translated nuclear-encoded proteins are initially 
synthesized as precursor proteins with a positively charged N-terminal presequence that 
dictates the protein’s destination within the organelle (18). These precursor proteins 
remain in an unfolded state in order to allow easier passage, however this confirmation 
leaves them more susceptible to aggregation through unwanted protein-protein 
interactions (19, 113, 167, 178). Heat shock proteins such as HSP70 and HSP90 exist to 
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overcome such maladaptive outcomes, and are involved in shuttling of mitochondrial 
precursor proteins to the mitochondria where they may be imported through the 
mitochondrial protein import machinery (PIM) (53, 232). 
The mitochondrial PIM is composed of the translocase of the outer- and inner- 
mitochondrial membrane (TOM and TIM).  Precursor proteins are translocated to the 
TOM complex receptors Tom20, and Tom70, where they will continue through the pore, 
which is comprised predominately of Tom22 and Tom40, as well as Tom6, Tom7, and 
Tom5 (7, 33, 50, 83, 106). On the outer membrane there exists, along with the TOM 
complex, a sorting and assembly (SAM) complex responsible for insertion of outer 
membrane proteins (116). Once proteins have passed through the TOM complex, they are 
subsequently delivered through the TIM complex forming the TOM-TIM supercomplex 
(38). The TIM machinery consists of the Tim23 complex, in which Tim17 and Tim23 
form a pore that a majority of precursor proteins pass through to reach the matrix. As 
well, the Tim22 complex facilitates proteins targeted to the innermembrane. Once 
through the TIM complex mtHSP70 helps pull the preprotein into the matrix in an ATP-
dependent manner where the positively charged presequence can be cleaved by matrix 
proteases. Mitochondrial-specific chaperones HSP10 and HSP60 can then facilitate 
proper protein conformation and translocation to the final destination within the 
mitochondrion (19, 24, 25). In the context of exercise-induced mitochondrial adaptations, 
there is evidence of consensus binding sites for NRF-1 and NRF-2 in the promoter region 
of various import genes (23, 80). Likewise, import rates of important matrix destined 
proteins such as Tfam have been found to increase with chronic contractile activity via 
augmented expression of PIM components as well as an enhanced expression of import 
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chaperones (66, 161, 208).  
1.2.2.1. Autophagy with Exercise 
Another important regulator of skeletal muscle health and adaptation to exercise is 
autophagy, or mitophagy in the context of mitochondria. The process is characterized as 
the selective degradation of protein aggregates and worn-out organelles through the 
encapsulation by a double-membrane autophagosome (Fig. 1D). Once fully engulfed, the 
autophagosome undergoes fusion with a lysosome in order to degrade the selected cargo 
and allow amino acid recycling (120, 141, 142). Given that the primary role of autophagy 
is to degrade cellular components, it seems counter-intuitive that it would be of critical 
importance to muscle health and function (35). Research has discovered that lack of 
autophagy results in muscle degeneration, wasting, and reduced strength, as well as 
accumulated protein aggregates, and dysfunctional organelles (such as the sarcoplasmic 
reticulum and mitochondria) contributing to excessive oxidative stress (35, 67, 133, 134).  
Autophagosome formation is dependent on three key molecular events: 1) 
conjugation of LC3, as well as upstream regulation provided by 2) ULK1, and 3) Beclin1 
complexes. Inactive LC3-I requires conjugation to the phospholipid 
phosphatidylethanolamine to become the active form LC3-II through a series of events 
regulated by a number of autophagy proteins (Atgs), particularly Atg6-Atg12-Atg16L1 
and Atg7. Once activated LC3-II can integrate within the double-membrane phagophore 
allowing for elongation and interaction with tagged cargo. Generally, LC3 interacts with 
p62 which provides a bridge between ubiquitin-flagged organelles and LC3-II (120, 140).  
Activation of this process is under the regulation of ULK1 and Beclin1 complexes, which 
facilitate phagosome expansion and are integral in sensing the energy status of the cell 
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under inhibition by the mTORC1 complex (140). mTORC1 acts downstream of the 
insulin/Akt pathway and can be negatively regulated by AMPK phosphorylation of 
tuberous sclerosis complex (TSC)-2 tumor suppressor, an upstream regulator, and raptor, 
a component of mTORC1 (96, 101, 139). Furthermore, AMPK can act directly on both 
ULK1 and Beclin1 complexes to directly induce complex formation, providing a similar 
mode of energy-sensing activation to that of mitochondrial biogenesis (108).  
Autophagy activation has been of focus in recently published works for its role as a 
cellular homeostatic response, and not solely degradation, as its absence leads to muscle 
myopathies (68, 133). Exercise has been shown to be a potent activator of autophagy, 
contributing to beneficial skeletal muscle remodeling (78, 122). Exercise-induced 
increases in AMPK, as mentioned, are capable of relieving mTORC1 suppression of 
ULK1 and Beclin1 complexes. Likewise, a link between p38 MAPK and autophagy in an 
oxidative stress-induced manner has been reported, similar to the hallmark signaling 
events that occur with exercise in mediating mitochondrial biogenesis (135). Work 
investigating basal autophagy in various fiber types discovered enhanced autophagy flux, 
as well as autophagy and mitophagy protein expression in muscles with the highest 
oxidative capacity compared to mixed or glycolytic muscle. Moreover, long-term 
voluntary wheel running resulted in increased autophagy flux, and mitophagy proteins 
concomitant with mitochondrial biogenesis (122). Recently, PGC-1α has been implicated 
in mediating autophagy in denervation-induced mitophagy activation, thus providing an 
overall link between muscle health and metabolic profile, to autophagy (218). 
1.2.3.1. CCA as a Model of Exercise 
Given that PGC-1α and mitochondrial biogenesis respond most significantly to 
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endurance exercise in skeletal muscle, it becomes important to utilize practical 
physiological models capable of eliciting mitochondrial adaptations in a similar manner. 
The chronic contractile activity (CCA) model of exercise is one such example, which 
replicates the continuous muscle contractions of skeletal muscle, specifically slow-twitch 
motor units, during endurance exercise, and can be accomplished both in vivo and in vitro 
(45, 184, 209). Both models provide an advantage in their ability to regulate the stimulus, 
while the animal model further affords the ability to have intra-animal control (non-
exercised) muscle matched to the stimulated muscle of the contralateral limb. In vivo 
stimulation involves the implantation of two wire electrodes spanning the common 
peroneal nerve delivering electrical impulses at a fixed setting (6 volts; 10Hz, 0.1ms) 
causing muscle contraction of the innervated leg, particularly the tibialis anterior and 
extensor digitorum longus (125, 209). The same concept of electrical stimulation can be 
applied in a cell culture model using skeletal muscle cells. With this in vitro procedure, 
platinum wire electrodes are placed on either side of the cell dish, which are attached to 
an external stimulator to elicit contraction of the muscle cells (45, 214, 222). Similar 
levels of adaptation can be achieved between both animal and cell models with the only 
added disadvantage in vitro being that isolated cells lack the whole-body effects of 
contracting within the organism (209, 214). 
Some key considerations are to be made with respect to the use of CCA; the 
stimulator unit must be able to provide a consistent and sufficient current intensity 
without prolonged disruption, and the integrity of the electrodes must remain intact. As 
well, differences in the recruitment of muscle fibers exist between CCA and regular 
exercise in that the asynchronous-hierarchical order of recruitment involved in normal 
 15 
contractions is abolished, as all motor units are recruited with electrical stimulation. 
However, these differences can also provide further advantages. In engaging all motor 
units we are able to elicit a response in fibers normally not recruited with exercise in a 
target muscle in a reproducible pattern of activation between subject animals (125).  
Regular endurance exercise, with incrementally increasing intensity, results in 
mitochondrial biogenesis within 6-8 weeks (2, 87, 89). A similar level of adaptation can 
be elicited in a single week of CCA thus providing another distinct advantage of time 
efficiency (209). Increases in expression and stability of mitochondrial ETC constituent 
transcripts, and increase protein synthesis and turnover rates were observed with CCA in 
line with adaptations to regular exercise (44, 55, 85). Additionally, increases in the 
overall protein handling ability of the muscle was upregulated with prolonged CCA 
indicating a newly adapted phenotype (161). This increase in mitochondrial content is 
likely through similar mechanisms of activation as seen with traditional exercise. CCA 
has been shown to enhance intracellular Ca2+, thus likely contributing to the activation of 
upstream regulatory kinases such as CaMK (34, 125, 201). Further, a close correlation 
has been established between CCA-induced increases in PGC-1α and COX activity, as 
well as nuclear-encoded protein import into the mitochondria such as Tfam (64, 97). 
Finally, CCA produces a metabolic switch from muscle-specific lactate dehydrogenase 
(M-LDH) to heart-specific (H-LDH), which coincides with an increase in fatty acid (FA) 
oxidation (88, 94, 125). Therefore CCA is an important and powerful model in eliciting 
skeletal muscle adaptations such as mitochondrial biogenesis similar to normal endurance 
exercise.  
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1.3.0. THE UNFOLDED PROTEIN RESPONSE 
 Along with mitochondria, the endoplasmic reticulum (ER) is a vital organelle that 
plays an important role in protein translation and processing, principally in highly 
secretory cells such as those found in pancreatic islets, liver and adipose tissue. Of 
considerable interest to researchers has been the impact of ER stress on cell function and 
viability, as perturbations within the ER can have considerable consequences on cellular 
proteostasis and can contribute to various pathologies. In particular, work has focused on 
a primary response to ER stress, termed the unfolded protein response (UPR). Overall, 
the UPR serves to balance protein translation with processing in order to maintain, or 
regain, cellular homeostasis during normal, and stressful conditions, respectively. 
Generally, this is accomplished through two mechanisms of action: 1) upregulation of 
folding capacity, through increased chaperones, foldases, and ER enlargement; and 2) 
down-regulation of protein biosynthetic load by decreasing transcription and translation 
as well as increasing clearance of misfolded proteins (195).  
Skeletal muscle, while not especially secretory in nature, is an intriguing tissue in 
that it has an expansive network of specialized ER termed the sarcoplasmic reticulum 
(SR). As mitochondria are critical in skeletal muscle function, their relationship to the ER 
is of considerable interest as the two exist as tightly connected organelles both 
functionally and physically, which synchronously regulate, and communicate via 
intracellular Ca2+ (205). Furthermore, interest in a second UPR emanating from the 
mitochondria (UPRmt) is gaining momentum, although the majority of research has been 
conducted in lower organisms. Nonetheless, the ability of mitochondria to monitor 
protein status within the organelle in a similar manner to the ER is of particular interest in 
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the context of skeletal muscle health and adaptation, especially considering that 
mitochondria rely on the integration of mtDNA and nDNA-derived proteins.  
1.3.1.1. The ER Stress Response – the UPRER  
Stress to the ER can result from various conditions such as elevated intracellular 
lipids, glucose deprivation, calcium imbalances, as well as marked increases in protein 
synthesis (Fig.1B). Given the importance of the ER in protein maturation into active 
cellular components, this stress can be highly damaging, therefore the UPR plays an 
integral role in maintaining proper function (236).  In mammals the UPR has three 
independent, yet interrelated, branches mediated by the activation of transmembrane 
proteins imbedded in the ER membrane, those being activating transcription factor-6 
(ATF6), protein kinase RNA (PKR)-like ER kinase (PERK), and inositol-requiring 
enzyme-1 (IRE1), which is a conserved branch across all eukaryotes, indicating the 
importance of this adaptive response in general cellular function (195). Together, these 
ER signal transducers carry out three phases of the UPR: 1) an acute response reduces ER 
protein load; 2) the ER adapts to increase in its protein handling capability; and 3) cell 
death is invoked if the stress proves to be too great and homeostasis can not be achieved 
(182).  
Proteins are considered unfolded based on their thermodynamic and kinetic 
conformation. Free energy of each configuration is determined by contacts of its nonpolar 
groups. Thus, proteins will continuously fold to bury the polar groups at their core, 
reduce the free energy to the lowest possible, and in this way prevent hydrophobic side 
chains from being exposed. When these parameters are not met, the protein is deemed 
unfolded and are sensed by binding immunoglobulin protein (BiP), also referred to as 78 
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kDa glucose-related protein (GRP78) (203). Under normal conditions, BiP remains 
bound to the ER luminal domains of the three UPR signaling transducers. As unfolded 
proteins accumulate, BiP releases and preferentially binds to the hydrophobic peptides 
exposed on the surface of misfolded proteins in order maintain the protein conformation 
and prevent further misfolding (61). This release of BiP allows activation of the distinct 
UPR branches, which will be discussed further below. A similar mode of unfolded 
protein recognition exists in the cytosol through the cytosolic heat-shock response and is 
related to the UPR in general function. In a manner reminiscent to BiP, cytosolic 
chaperones such as HSP70 bind the transactivating domain of heat shock factor-1 (HSF1) 
thereby repressing its transcriptional activity. As protein folding within the cytosol is 
perturbed, HSP70 releases to preferentially bind the unfolded proteins, thus allowing 
HSF1 to translocate to the nucleus and upregulate transcription of chaperones and 
proteasomal subunits (169, 199).   
While IRE1 is the conserved UPR branch, PERK shares many similarities both 
structurally and functionally (123). Both proteins are type I transmembrane protein 
kinases, which become active upon BiP release leading to di- or oligomerization and 
transautophosphorylation of the cytosolic kinase domain (22, 123). IRE1, within its 
cytosolic region, carries out two enzymatic functions: the first, an endoribonuclease 
(RNase) which splices a 26 nucleotide intron from the mRNA transcript encoding X-box 
binding protein 1 (XBP1) (32, 118, 231); and second, a serine/threonine kinase (46). 
Spliced XBP1 mRNA encodes a potent transcription factor (XBP1s) to modulate the 
expression of multiple UPR target genes including ER chaperones, phospholipid 
processing proteins, ER tanslocon components, and ER-associated degradation (ERAD) 
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factors (118, 182). Additionally, IRE1 can modulate signaling events that crosstalk with 
other stress pathways, such as apoptosis, autophagy, proliferation, metabolism, and 
inflammation. In particular, IRE1 binds to TNF-receptor-associated factor 2 (TRAF2), 
promoting activation of the c-Jun NH2-terminal kinase (JNK) pathway, and can modulate 
other pathways including p38, ERK and NF-kB (93, 152, 153, 216). PERK conversely, 
contains a cytosolic kinase domain, which plays an important role in the acute response 
of the UPR. Activated PERK phosphorylates eukaryotic translation initiation factor 2 
(eIF2α) at serine-51, thus deactivating it and reducing protein synthesis in order to 
alleviate the misfolded protein burden (74, 123). However, despite this decrease in 
protein translation, some mRNAs are preferentially translated while eIF2α is suppressed. 
One example is ATF4, a transcription factor that positively regulates UPR genes involved 
in amino acid metabolism, antioxidant response, protein folding, autophagy and apoptosis 
(73, 79, 110). Of the more important ATF4 target genes is CCAAT enhancer binding 
protein (C/EBP) homologous protein (CHOP), widely considered a pro-apoptotic 
transcription factor (131, 206, 217). Furthermore, PERK activation leads to 
phosphorylation, and activation, of the pro-survival transcription factor NF-E2 related 
factor 2 (Nrf2) to promote transcription of the antioxidant machinery (47).  
ATF6 is a type II transmembrane domain protein containing a basic leucine zipper 
(bZIP) transcription factor in its cytosolic domain (77). Upon BiP release, ATF6 
translocates from the ER membrane to the Golgi apparatus where site-1 and site-2 
proteases (S1P and S2P) process and release the cytosolic bZIP domain (39, 77, 230). 
Active ATF6 will then shuttle to the nucleus where it binds to the ATF/cAMP response 
element (CRE) and the ER stress response elements I and II (ERSE-I and -II) to initiate 
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transcription of quality control chaperones BiP and GRP94, foldases such as protein 
disulfide isomerase (PDI), ER proteins involved in glycosylation and Ca2+ handling, 
ERAD components, as well as transcription factors XBP-1 and CHOP (1, 77, 112, 194, 
221, 225). Furthermore, ATF6 along with XBP1 contribute to ER biogenesis through 
expansion of the tubular networks of the rough ER (26, 198, 202). Altogether this 
suggests a tightly coordinated regulation of cell fate during acute and chronic ER stress.  
1.3.1.2. The UPRER, CHOP, Autophagy, and Apoptosis 
The UPR acts as a cell rheostat monitoring the duration and intensity of stress in 
order to mount appropriate responses to maintain optimal function. In doing so the UPR 
is capable of shifting from acute phase protein handling to more adaptive processes such 
as autophagy or apoptosis, largely through CHOP signaling. In particular, CHOP 
transcribes growth arrest and DNA damage-inducible 34 (GADD34), which 
dephosphorylates eIF2α, therefore reversing the action of PERK, and has been shown to 
upregulate over a dozen autophagy genes (Atgs) during prolonged stress (15, 43, 105, 
154). CHOP-induced autophagy signaling is further enhanced by the activation of 
Beclin1 through the IRE1 branch of the UPR in a TRAF2-JNK-dependent manner (156). 
Additionally, it has been shown that activation of autophagy associated with ER stress 
can be induced independently of common autophagic activators such as Akt and Foxo, 
indicating the direct effect the UPRER has in moderating cell fate (128). Furthermore, 
while studies have shown that CHOP supports cell-survival signaling, it is typically 
depicted as pro-apoptotic in function and can facilitate the switch from autophagy in 
favor of cell-death (14). Primarily, CHOP exerts its influence on apoptosis through 
inhibition of the anti-apoptotic factor Bcl-2, which otherwise promotes cell survival 
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through sequestration of BH3-only proteins, such as Bim and PUMA – factors involved 
in Bax-Bak-mediated mitochondrial permeablization (40, 41, 56, 136). Moreover, 
research has shown that CHOP, through its transcriptional target ER oxidase 1α 
(ERO1α), activates the ER calcium release channel inositol triphosphate receptor-1 
(IP3R1), important in a variety of mitochondrial processes and can also initiate apoptosis 
as a consequence of organelle dysfunction (121, 162). Likewise, IRE1 contributes to the 
apoptotic signaling through a few proposed mechanisms: 1) the activation of JNK via 
TRAF2 and consequent activation of pro-apoptotic factors such as Bax/Bak (216); 2) 
regulated IRE1-dependent decay (RIDD), a process that becomes pro-apoptotic with 
prolonged stress by degrading mRNAs encoding ER chaperones (71, 215); and 3) the 
activation of murine caspases-12 (or human caspase 4) (143). In part, these events 
converge on the mitochondrial intrinsic apoptotic-signaling pathway, and reinforce the 
integrated function of the two organelles as they pertain to cellular viability and 
adaptation. 
1.3.1.3. The UPRER and Mitochondria 
As mentioned, the ER and mitochondria are closely linked organelles both 
physically and functionally. Specifically, the close-contact communication sites between 
the ER and mitochondria are termed mitochondria-associated membrane (MAM), with 
the functional implication of this interaction being a collaborative handling of lipids and 
calcium homeostasis (21, 205). As well, this physical association between these 
organelles is reinforced by dimeric bridges formed between the mitochondrial 
morphology protein mitofusin-2 (Mfn2) localized to both the mitochondria and at the 
MAM, on the ER (30). The regulated interaction by Mfn2 plays a critical role in 
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mitochondrial calcium uptake from the ER, and regulates mitochondrial morphology 
through interaction with PERK (30, 31, 146). As described in the previous section, 
chronic ER stress is capable of eliciting an apoptotic response through UPR activation, 
partly dependent on the mitochondrial intrinsic apoptotic pathway, which results in the 
mtPTP opening and cytochrome c release (207, 219). Moreover, recent work has found 
that at early stages of ER stress, the ER and mitochondria become more physically 
connected in order to initially increase mitochondrial metabolism through enhanced 
calcium transfer and provision of energy substrates, or lead to apoptotic activation 
following prolonged stress (29). Conversely, while ER stress and UPR activation can 
affect mitochondrial function, a similar effect can occur through mitochondrial stress on 
the ER. Recent studies have shown a link between mtDNA damage contributing to 
oxidative stress and the induction of a number of UPR target genes, ultimately leading to 
autophagy and apoptosis (233, 234). This indicates a considerable co-reliance and 
crosstalk between the two cellular networks during perturbations in the organelle milieu.  
1.3.2.1. The UPRmt 
The coreliance on nuclear and mitochondrial transcribed proteins that require 
various factors to facilitate the import and assembly into stoichiometric complexes leaves 
mitochondria susceptible to perturbations in homeostasis. Such events as mitochondrial 
biogenesis and protein import, mutations in constituent proteins, the presence of 
damaging reactive oxygen species (ROS), or harsh environmental conditions can 
negatively impact mitochondrial protein folding and overall function (75). Fortunately, 
mitochondria launch an organelle-specific unfolded protein response comparable to the 
ER, to initiate a retrograde signaling cascade to the nucleus and increase transcription of 
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mitochondrial protein quality control (PQC) genes (Fig. 1C). The UPRmt was first 
documented in mammalian cells when mtDNA mutations and the accumulation of 
terminally misfolded proteins resulted in an increase in mitochondrial chaperones and 
proteases (132, 183, 237). However despite these findings, an understanding of the 
UPRmt signaling cascade has not been well characterized in mammalian cells, and only 
recently has a more in-depth clarification of the specific events been resolved in 
Caenorhabditis elegans.  
 1.3.2.2. The UPRmt in C. elegans  
Discovery of a novel master transcription factor capable of integrating a complex 
web of UPRmt pathways has been observed in worms (76). Unfortunately, no mammalian 
homolog has been identified, however the possibility remains that such a factor does exist 
(196). Nevertheless, this transcription factor, termed activating transcription factor 
associated with stress-1 (ATFS-1), provides a unique and novel understanding of the 
potential integration of the UPRmt. ATFS-1 contains both a nuclear loacalization signal 
(NLS) as well as a mitochondrial targeting sequence (MTS) and it is degraded under 
basal conditions in the mitochondrial matrix by LonP (151). However under stressful 
conditions, accumulated protein aggregates are degraded by proteases, releasing peptide 
fragments through the mitochondrial HAF-1 transporter into the cytosol (151). These 
protein fragments in turn reduce ATFS-1 import into the mitochondria allowing it to 
move to the nucleus where it activates transcription of a host of genes to recover 
mitochondrial homeostasis. Specifically, it activates mitochondrial chaperones, proteases, 
and import/transport machineries, detoxification enzymes, as well as autophagy markers, 
while simultaneously reducing ETC and TCA components but inducing a range of 
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glycolysis genes (150). This unique mechanism of signaling provides an initial switch in 
energy supply away from mitochondria during initial repair thus matching biogenesis to 
mitochondrial proteostatic capacity, and equips the organelle with a greater protein 
handling for the future. 
1.3.2.3. The Mammalian UPRmt 
While UPRmt in C. elegans has been studied to a greater degree, there are a 
variety of signaling events that have been observed in mammalian cell models. 
Mitochondrial chaperones, and proteases in the matrix, as well as the intermembrane 
space are the prime sensors of misfolded mitochondrial proteins and are capable of 
sensing, and eliciting, compartment-specific responses (17, 168, 212). Proteotoxic stress 
localized to the intermembrane space induces an increase in ROS leading to 
phosphorylation of estrogen receptor α (ERα) through AKT activation.  Activated ERα 
can then enter the nucleus and drive expression of the IMS protease OMI/HtrA2 in order 
to degrade and remove the accumulated proteins (165). Similarly, proteases ClpP and 
LonP monitor mitochondrial matrix protein status and can help facilitate the activation of 
a set of pathways in response to misfolded protein aggregates. In particular, this 
perturbed compartmental proteostasis prevents further protein accumulation through two 
mechanisms: first, by blocking protein import via degradation of TIM17A by the protease 
Yme1l (176); and second, through the activation of dsRNA-activated protein kinase 
(PKR) and subsequent phosphorylation of eIF2α to reduce global translation similar to 
the UPRER (177). Furthermore, the transcription factor c-Jun is activated during the 
UPRmt through JNK2, which increases the expression of CHOP and C/EBPβ (91, 237). In 
turn, these two transcription factors heterodimerize and bind to CHOP binding regions 
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flanked on either side by a UPRmt response element (MURE) in promoter regions of 
various quality control proteins to induce transcription (8). Antioxidant machinery was 
shown to increase through c-Jun activation of Nrf2, possibly linking this response to 
CHOP-C/EBPβ activity (102, 175). Similarly, a secondary responder to mitochondrial 
proteotoxic stress, SirT3 upregulates antioxidants through deacetylation of Foxo3 (175). 
Our evolving understanding of the UPRmt suggests that these signaling events associated 
with mitochondrial stress help align the mitochondrial and nuclear genomes at the protein 
level, thus helping to coordinate mitochondrial adaptations and remodeling. 
1.3.2.4. The UPRmt and Mitophagy 
Consistent with the putative role in regulating changes in mitochondria subject to 
stress, a link between the UPRmt and mitophagy has been gaining traction in the 
literature. While a potential link could be made to mitophagy through activation of 
ATFS-1 and AMPK, this has only to this point been observed in lower organisms (69, 
170). However, in mammals, an activation of mitophagy has been linked to SirT3 
activation and action through Foxo3 (166). During parkin-mediated mitophagy PINK1, 
which is normally degraded in the matrix by LonP, accumulates on the depolarized OMM 
and recruits the E3 ubiquitin ligase Parkin, thus targeting the mitochondria to the 
autophagosome for subsequent degradation (115).  The UPRmt is purported to play a role 
in parkin-mediated mitophagy as the inclusion of a terminally misfolded matrix protein 
caused PINK1 and Parkin to accumulate on the stressed mitochondria, despite no change 
in membrane potential (103). This may be regulated through LonP, in that as misfolded 
proteins accumulate, they compete with PINK1 for degradation by LonP and allow 
PINK1 to stabilize on the outer membrane, unscathed.  
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1.3.3.1. The UPR in Skeletal Muscle and Exercise 
Increasingly, evidence is continuing to mount to support a role of the UPR in 
skeletal muscle in response to exercise, despite the low secretory output of this tissue. 
From a developmental perspective, induction of the UPR has been described to facilitate 
myoblast differentiation. UPR factors CHOP and BiP were upregulated during 
myogenesis, while ATF6 activation further proved to be critical in myotube formation 
(149). Conversely, in aging animal studies specific chaperones were decreased relative to 
young animals, while ER-stress and apoptotic markers were also elevated (37, 127, 148, 
157). Together, these results indicate a potential link between ER function and UPR 
signaling in the maintenance of skeletal muscle throughout the lifespan. As well, growing 
evidence indicates that the ER senses alterations in the cellular nutritional and metabolic 
states and appropriately activates the UPR to adjust, and balance metabolic activities 
(130). Deldique and colleagues found that excessive nutrient feeding, specifically of fats, 
resulted in heightened UPR signaling in skeletal muscle (49). In the same study, they 
observed a crosstalk between ER stress and the mammalian target of rapamycin (mTOR) 
pathway, which they proposed was responsible for ER stress-induced downregulation of 
protein synthesis in C2C12 cells. Following this up, they found that the presence of ER 
stress prevented activation of the mTOR complex 1 (mTORC1), contributing to an 
increased anabolic resistance (48). Thus further providing a link between ER stress and 
other conditions of anabolic resistance such as aging, immobilization, and disuse. 
It has been established that skeletal muscle is a dynamic and malleable tissue 
responding to the external conditions placed upon it. Resistance and endurance type 
exercise can adapt the skeletal muscle phenotype to increase, muscle fiber mass or 
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oxidative output, respectively, whereas disuse can contribute to a reduction in both. As 
exercise plays a positive role in skeletal muscle health, research has turned its attention to 
this phenomena and the potential role of the UPR. Recently, UPR activation was 
observed in skeletal muscle following a single unaccustomed bout of resistance exercise 
(159). These results corroborated a previous report that found an association between 
activation of UPR transcripts in muscle subject to a single bout of resistance exercise, 
which was attenuated with prolonged training (65). As well, endurance exercise has been 
shown to elicit the UPR following a single bout of treadmill running, with the intensity of 
the exercise contributing to the magnitude of the response, while training contributed to 
an attenuated UPR activation (107, 109, 224). The activation of the UPR during acute 
endurance and resistance exercise indicates a putative role of the UPR in initial onset 
adaptations, and to provide protection against future stress as a host of cellular 
chaperones are increased following a prolonged training program (161). Conversely, with 
prolonged disuse the results seem mixed as neither 7 days, nor 2 weeks of hindlimb 
unloading in rats resulted in UPR activation or ER stress, however in a human study 
several UPR genes were upregulated following 9 days of bed rest (9, 95, 157). Moreover, 
a major regulator of skeletal muscle adaptation and mitochondrial content, PGC-1α, has 
been shown to be induced by, and regulate, UPR signaling in an ATF6-dependent 
manner, indicating an integrated link between these responsive pathways (224). Lastly, a 
link has been drawn between activation of the UPRmt and mitochondrial biogenesis, 
despite very little studies focused on this response in skeletal muscle or exercise. 
Nevertheless, it appears that activation of sirtuins, namely SirT1, could mediate this 
coordinated expression, indicating a potential role of the UPRmt in skeletal muscle 
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adaptations to exercise (36, 145, 171).  
1.3.4.1. Tauroursodeoxycholic Acid (TUDCA)  
As described above, the UPR monitors the cellular environment to regulate its 
fate. Acute stress and UPR signaling can bring about positive adaptations, whereas 
chronic stress can result in potentially maladaptive outcomes such as cell death 
contributing to pathogenesis of various diseases. In particular, both the UPRER, and to 
lesser extent the UPRmt, have putative roles in metabolic diseases, neurodegenerative 
disorders, aging/longevity and cancer among others. Therefore, drugs targeting the ER to 
reduce overall stress have been utilized in a multitude of studies to analyze their effect on 
maintaining cell homeostasis. One such example is ursodeoxycholic acid (UDCA) and its 
taurine conjugated from TUDCA (Fig. 1E). These hydrophilic primary bile acids are 
generated at low levels, produced by the liver (10, 59). TUDCA is an FDA approved drug 
for treatment of liver cirrhosis, and has also been shown to reduce symptoms of 
Alzheimer’s and Huntington’s diseases, ischemia and stroke, as well as decrease insulin 
resistance in obese mice (59, 163). TUDCA acts primarily through inhibition of 
apoptosis, particularly by inhibiting Bax translocation to the mitochondria and caspase 
activation (10). This mode of action is in line with the UPRER activation of apoptosis 
through PERK, IRE1α, and CHOP. Not surprisingly then, recent research in vitro has 
observed a reduced activation of PERK, eIF2α, JNK, as well as IRE1α, and in turn 
XBP1 splicing (57, 129, 163, 197). As well, it is important to note that the opposite 
effects of TUDCA treatment have been observed, and that further work elucidating the 
exact mechanism of TUDCA on the UPR and apoptosis is required (229). Nevertheless, 
TUDCA has been observed to be a negative regulator of the transcription factor CHOP in 
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various disease models, as well as other UPR related proteins such as capase-12 and BiP 
(58, 129, 144, 163, 197, 211, 227). Additionally, TUDCA is proposed to ameliorate ER 
stress by binding to the hydrophobic regions of unfolded proteins preventing aggregate 
formation and allowing them to be more easily degraded while concurrently modulating 
cytosolic Ca2+ through modulation of SR/ER ATPases (28, 57, 220). Therefore, TUDCA 
appears to be a potent regulator of ER stress-induced apoptosis, particularly through 
UPRER signaling.  
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RESEARCH OBJECTIVES 
Thus, based on my review of literature, the objectives of my thesis were to:  
1. Examine the chronology of responses between the UPR pathways in response to 
contractile activity; 
2. Investigate the UPRER and UPRmt adaptations associated with acute contractile 
activity, and whether these responses are attenuated after repeated bouts of muscle 
activity;  
3. Study the relationship of these changes to adaptations and remodeling that occur 
with exercise in muscle, such as autophagy and mitochondrial biogenesis;  
4. Determine whether the UPR is required for adaptations associated with exercise, 
by reducing ER stress-induced UPRER activation with the chemical chaperone 
mimetic drug TUDCA.  
HYPOTHESES 
1. The UPRmt and the UPRER will be rapidly activated in the early stages of the 
CCA-induced training period,  
2. Early UPR activation will induce protein handling machinery chaperones and 
proteases which may facilitate the adaptations typically seen with chronic muscle 
stimulation, namely mitochondrial biogenesis and autophagy; 
3. UPR signaling will be attenuated as CCA persists over multiple days; 
4. Blocking the UPR with TUDCA will attenuate some of the adaptations in 
mitochondrial content and autophagy, as translated proteins may not be properly 
folded and/or transported to their proper confirmation, or destination within the 
cell. 
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ABSTRACT 
The mitochondrial (UPRmt) and the endoplasmic reticulum (UPRER) unfolded protein 
responses are important in maintaining cellular homeostasis during stimulus-induced 
increases in protein synthesis. Exercise is a well-established trigger for the synthesis of 
mitochondrial proteins via organelle biogenesis, regulated by PGC-1α. To investigate the 
role of the UPRmt and the UPRER in exercise-induced adaptations, we subjected rats to 3-
hrs of chronic contractile activity (CCA) for 1, 2, 3, 5 or 7 days, followed by 3-hrs 
recovery. Mitochondrial biogenesis signaling, through PGC-1α mRNA, increased 14-fold 
after an acute bout of CCA. This was manifest in a 10-32% increase in COX activity, an 
indicator of mitochondrial content, between days 3-7, as well as a concomitant increase 
in the autophagic degradation of p62 and LC3-II protein. Preceding these adaptive events, 
UPRER transcripts ATF4, XBP1s, and BiP were elevated (1.3-3.8-fold) from 1-3 days 
while CHOP and chaperones BiP and HSP70 were elevated at both mRNA and protein 
levels (1.5-3.9-fold) from 1-7 days of CCA. Mitochondrial chaperones CPN10, HSP60, 
and mtHSP70, protease ClpP, and regulatory protein SirT3, of the UPRmt were 
concurrently induced 10-80% between 1-7 days. To test the role of the UPR in CCA-
induced remodeling, we treated animals with the ER stress suppressor TUDCA and 
subjected them to 2 or 7 days of CCA. TUDCA attenuated CHOP and HSP70 protein 
induction, however this failed to impact mitochondrial and cellular remodeling. Our data 
indicate that signaling to the UPR is rapidly activated following acute contractile activity, 
that this is attenuated with repeated bouts, and that the UPR is involved in chronic 
adaptations to CCA, however this appears to be independent of CHOP signaling.  
 
 53 
INTRODUCTION 
Skeletal muscle is a highly adaptable tissue, responsive to multiple stressors 
leading to changes in whole-body metabolism. It has been established that exercise 
induces many physiological adaptations that are beneficial for muscle performance 
capabilities, such as remodeling of the mitochondrial reticulum through mitochondrial 
biogenesis as well as the removal of damaged or dysfunctional organelles through a 
process termed autophagy (28, 39, 49). Mitochondria are the essential cellular organelles 
with primary roles in energy production in the form of ATP (27). At the onset of 
contractile activity, early signaling events involved in mitochondrial biogenesis are 
initiated within skeletal muscle and converge largely on the activation of the 
transcriptional coactivator PGC-1α (20, 27, 50, 52). The vast majority of component 
proteins are transcribed in the nucleus and require transport to the mitochondria via 
chaperone and import machineries to facilitate protein shuttling and organelle assembly 
(12, 25, 30, 63). Less than 1% of total mitochondrial proteins are derived from 
mitochondrial DNA (mtDNA) with the remainder provided by the nucleus (3, 24, 51). 
Therefore, to produce a functional organelle capable of adequate ATP supply, contractile-
activity-induced mitochondrial biogenesis requires the integration, coordination, and 
timely expression of the nuclear and mitochondrial genomes.  
Under conditions of cellular stress, such as unaccustomed exercise, proteins may 
become misfolded and unable to reach their appropriate destination within the 
mitochondrion, leading to a proteotoxic cellular environment (21, 46). However, the 
unfolded protein response (UPR) is gaining attention as a protective mechanism that 
helps to maintain homeostasis under cell stress. To date, two such UPR pathways have 
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been observed. The first, an endoplasmic reticulum-mediated UPR (UPRER) senses 
misfolded proteins within the ER lumen through the resident chaperone BiP (48). BiP 
preferentially binds unfolded proteins thus disassociating, and thereby activating, ER 
membrane-bound kinases IRE1α and PERK, as well as releasing a potent transcription 
factor ATF6 to increase a host of chaperones and proteases while simultaneously 
reducing global translation (53). The second is a mitochondrial UPR (UPRmt), which 
senses proteotoxic stress in the matrix and intermembrane space to independently activate 
a variety of mitochondria-specific chaperones and proteases and regain homeostasis (6, 
46, 58). Together, the UPRER and the UPRmt initiate an acute response to reduce protein 
load, and an adaptive response to increase protein-handling ability. Ultimately if 
homeostasis is not reached, autophagy will be induced (29, 46). 
The molecular mechanisms involved in the metabolic adaptations observed with 
exercise have yet to be fully elucidated. It has recently been found that exercise is capable 
of eliciting an unfolded protein response in untrained muscle, and in an intensity-
dependent manner (32, 42, 55, 61). However, despite these recent findings, no work has 
focused on the role of the UPRER, or the UPRmt, with exercise in relation to mitochondrial 
biogenesis and the induction of autophagy in skeletal muscle. Therefore, our objectives 
were to examine: 1) the chronology of the UPRER and UPRmt activation with contractile 
activity in relation to mitochondrial biogenesis and autophagy; and 2) whether the UPR is 
required for these exercise-associated adaptations by administering the chemical 
chaperone mimetic Tauroursodeoxycholic acid, a naturally occurring bile acid capable of 
blocking ER stress-induced UPR activation (44, 62). 
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METHODS 
Animals and chronic contractile activity. The chronic contractile activity (CCA) 
model has been described previously as a useful model of chronic exercise (33, 56). 
Briefly, male Sprague-Dawley rats (SD; Charles River, St. Constant, QC, Canada), 
weighing 350-550 g were anaesthetized with isofluorane. Wire electrodes (Medwire, 
Leico Industries, New York, NY) were passed unilaterally and subcutaneously from the 
left hindlimb to the top of the back to connect to an external stimulation unit secured with 
surgical tape. Animals were allowed 5-7 days of recovery following surgery before TA 
and EDL muscles were subjected to stimulation (6V, 10Hz, 0.1ms duration). For all 
animals, contractions were induced for 3 hrs/ day. Animals in the time-course study were 
for subjected to 1, 2, 3, 5, or 7 days of contractile activity, whereas vehicle/TUDCA 
treated animals were subjected to either 2 or 7 days of stimulation. Three hours following 
the final bout of contractile activity, animals were sacrificed and the TA and EDL of both 
control and stimulated hindlimbs were extracted and flash frozen in liquid nitrogen, and 
then pulverized into fine powder for subsequent experimental analysis. Immediately 
following tissue removal, animals were euthanized via cardiac excision. Animal protocols 
have been approved by the York University Animal Care Committee. 
TUDCA and vehicle treatment. Animals as described above, were randomly 
divided into TUDCA or vehicle-treated groups. TUDCA (EMD Millipore, Billerica, MA) 
was dissolved in phosphate buffered saline (PBS; Wisent Bio Products, Saint-Jean-
Baptiste, QC) at 200 mg/ml and pH of 7.5. Animals were administered 400 mg/kg of 
either TUDCA or equal volume of sterile PBS (vehicle) daily via intraperitoneal (IP) 
injection beginning 3 days prior to surgery. Injections continued throughout the recovery 
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and stimulation period and terminated one day prior to tissue extraction in order to avoid 
the acute effects of drug treatment.  
Cytochrome c oxidase activity.  Cytochrome c oxidase (COX) activity was used 
as a marker of mitochondrial content. Pulverized whole muscle homogenates were 
prepared and sonicated for 10 s on ice at a power output of 20–30%. A buffered test 
solution was prepared containing fully reduced horse heart cytochrome c (C-2506; 
Sigma, Oakville, ON, Canada). With the use of a multipipette, 240 µl of test solution 
were added to 50 µl of whole muscle homogenate in a 96-well plate. COX enzyme 
activity was determined spectrophotometrically as the maximal rate of oxidation of fully 
reduced cytochrome c (C-2506, Sigma, Oakville, ON, Canada), measured by the change 
in absorbance at 550 nm and temperature of 30°C in a Synergy HT (Bio-tek Instruments, 
Winooski, VT) microplate reader. For each sample, the COX activity measurement was 
calculated as an average of three trials.  
In vitro RNA isolation and reverse transcription. Total RNA was isolated from 
frozen, whole muscle TA powders as described previously (43). Briefly, Tissue powder 
(~70 mg) was added to TRIzol® reagent, homogenized, then mixed with chloroform. 
Samples were centrifuged at 4°C at 16,000 g for 15 min and the upper aqueous phase of 
the sample was transferred into a new tube along with isopropanol and left overnight at 
−20°C to precipitate. Samples were once again centrifuged at 4°C at 16,000 g for 10 min. 
The resultant supernate was discarded and pellet resuspended in 30 µl of molecular grade 
sterile H2O (Wisent Bio Products, Saint-Jean-Baptiste, QC). The concentration and purity 
of the RNA was measured using a Nano Drop 2000 Spectrophotometer. SuperScript® III 
reverse transcriptase (Invitrogen, Carlsbad, CA, USA) was used to reverse transcribe 1.5 
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µg of total RNA into cDNA. 
Real-time PCR. Using sequences from GenBank, primers were designed with 
Primer 3 v. 0.4.0 software (Massachusetts Institute of Technology, Cambridge, MA) for 
genes of interest (Table 1). Primer specificity was confirmed by OligoAnalyzer 3.1 
(Integrated DNA Technologies, Toronto, ON, Canada). mRNA expression was measured 
with SYBR® Green chemistry (PerfeCTa SYBR® Green SuperMix; ROX, Quanta 
BioSciences, Gaithersburg, MD). Each well contained: SYBR® Green SuperMix, 
forward and reverse primers (20 µM), sterile water, and 10 ng of cDNA. The detection of 
all real-time PCR amplification took place in a 96-well plate using a StepOnePlus® Real-
Time PCR System (Applied Biosystems, Foster City, CA). The final reaction volume of 
each well was 25 µl. Samples were run in duplicates to ensure accuracy. The PCR 
program consisted of an initial holding stage (95°C for 10 min), followed by 40 
amplification cycles (60°C for 1 min, 95°C for 15 s), and was completed with a final 
melting stage (95°C for 15 s, 60°C for 1 min, 95°C for 15 s). Nonspecific amplification 
and primer dimers were controlled for by the analysis of melt curves generated by the 
instrument for SYBR® Green analyses. Negative control wells contained water in place 
of cDNA.  
Real-time qPCR quantification. First, the threshold cycle (CT) number of the 
endogenous reference gene was subtracted from the CT number of the target gene [ΔCT 
= CT(target) − CT(reference)]. Next, the ΔCT value of the control tissue was subtracted 
from the ΔCT value of the experimental tissue [ΔΔCT = ΔCT(experimental) − 
ΔCT(control)]. Results were reported as fold-changes using the ΔΔCT method, calculated 
as  2−ΔΔCT.  Primers  detecting   ribosomal   protein   s12   along   with   glyceraldehyde-3-       
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Table 1. List of primer oligonucleotide sequences used in real-time qPCR analysis for 
Rattus norvegicus. Alternative names used in this paper are written in parenthesis. 
Gene,                                 
Size (bp) 
Accession 
Number Forward Primer Reverse Primer 
Ppargc1a       
(PGC-1α), 
142 
NM_031347.1 5'-CAT CGC AAT TCT CCC TTG TAT-3' 5'-CAG ACT CCC GCT TCT CAT ACT-3' 
ATF4,                           
107 NM_024403.2 5’-CTC TCG CCA AAG AGA TTC AGT A-3' 5’-ACA AGC ACA AAG CAC CTG ACT A-3’ 
Hspa5 
(BiP),           
137 
NM_013083.2 5’-TTG AAA CTG TGG GAG GTG T-3’ 5’-GGG TCG TTC ACC TTC GTA GA-3’ 
Ddit3 
(CHOP),        
130 
NM_001109986.1 5’-GAG CTG GAA GCC TGG TAT GA-3’ 5’-GGG ATG CAG GGT CAA GAG TA-3’ 
Clpp,                            
145 XM_217313.8 5’-GAG CGA TAC GTG GGA GAC A-3’ 5’-ACG TTG CTT CCT TAC TCA GCA-3’ 
Hspe1              
(CPN10), 
124 
NM_012966.1 5’-CAC GGA GGC ACC AAA GTA GT-3’ 5’-GGA ATG GGC AGC TTC ATG T-3’ 
Esr1 (Erα),                   
126 NM_012689.1 5’-CAT GAT GAA AGG CGG GAT A-3’ 5’-AGG TTG GCA GCT CTC ATG T-3’ 
GAPDH,                       
122 NM_017008.3 5'-CTC TCT GCT CCT CCC TGT TCT-3' 5'-GGT AAC CAG GCG TCC GAT AC-3' 
Hspd1                
(HSP60), 
138 
NM_022229.2 5’-AGG CAG GTT CCT CAC CAA TAA-3’ 5’-GCA TGG ACA ATG ACA GCA GTA-3’ 
Hspa4               
(HSP70), 
101 
NM_153629.1 5’-CAT GGT GCT GAC CAA GAT GA-3’ 5’-GCT GCG AGT CGT TGA AGT A-3’ 
Map1lc3            
(LC3), 101 NM_199500.2 5'-GCA CAG CAT GGT GAG TGT AT-3' 5'-AGG TTT CTT GGG AGG CAT AGA-3' 
Lonp1                
(LonP), 117 NM_133404.1 5’-CTT GTG GTT CCC AAG CAT GT-3’ 5’-CGT CAG CCA GTC CAG GTA GT-3’ 
Hspa9                 
(mtHSP70), 
116 
NM_001100658.2 5’-CCT TCT GTG GTT GCC TTT ACA-3’ 5’-CGT CCA ATA AGA CGC TTT GTA-3’ 
Bnip3l 
(NIX),           
133 
NM_080888.1 5'-CCC TGC ACA ACA ACA ACA AC-3' 5'-CCA TTC TTC CCA TTT CCA TTA C-3' 
Nqo1 
(NQO1),          
148 
NM_017000.3 5’-TTC TGT GGC TTC CAG GTC TTA-3’ 5’-GCT GCT TGG AGC AAA GTA GA-3’ 
Sqstm1 
(P62),          
117 
NM_175843.4 5'-GGA ACT GAT GGA GTC GGA TAA C-3' 5'-TCC GAT TCT GGC ATC TGT AG-3' 
Rps12 
(S12),           
127 
NM_031709.3 5'-ATG GAC GTC AAC ACT GCT CT-3' 5'-ATG CAA GCA CGC AGA GAT-3' 
SirT3,                        
118 NM_001106313.2 5’-GCC CAA TGT CGC TCA CTA CT-3’ 5’-CAG CTT TGA GGC AGG GAT A-3’ 
Uqcrc1,                      
135 NM_001004250.2 5’-TCG AGA GGT TTG CTC CAA GTA-3’     5’-CGC AGA CTT CCT GCC TAG A-3’     
XBP1s,                     
86 NM_001271731.1  5’-TGC TGA GTC CGC AGC AGG T-3’ 5’-AAT CTG AAG AGG CAA CAG CGT-3’ 
XBP1t,                     
114 NM_001271731.1 5’-CCT TCT CCC TTC AGC GAC AT-3’ 5’-CAG TGG TGG GTG GCT TTA GA-3’ 
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phosphate dehydrogenase (GAPDH) were chosen as endogenous reference genes.  
Immunoblotting. Whole muscle protein extracts were separated by 10–15% SDS-
PAGE and transferred to nitrocellulose membranes with a wet electrotransfer apparatus 
(Mini Trans-Blot electrophoretic transfer cell, Bio-Rad, Mississauga, Canada). 
Nitrocellulose membranes were blocked in a 5% skim milk solution and subsequently 
incubated overnight at 4°C with the appropriate concentration of primary antibody (see 
Table 2 for list of antibodies). Membranes were then washed and incubated with the 
suitable HRP-conjugated secondary antibody for 1 h at room temperature and visualized 
with enhanced chemiluminescence. Quantification was performed with Image J Software 
(NIH, Bethesda, MD, USA), and values were normalized to the appropriate loading 
control.  
Statistical Analysis. To compare control vs. stimulated muscles at a given time point and 
within vehicle/TUDCA conditions for mRNA, protein and cytochrome c oxidase activity 
experiments, a repeated-measures two-way analysis of variance (ANOVA) was 
performed followed by a Bonferroni post hoc test when necessary. mRNA analysis was 
performed using the ΔCT value. All statistical analyses were performed using Graphpad 
Prism 6 Software All values represent the mean ± SEM and significance was set at 
P<0.05. 
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Table 2: List of Antibodies Used 
 
Antibody Manufacturer Reference No. 
Aciculin In house See Reference (7) 
ATF4 Santa Cruz Biotechnology SC-200 
ATF6 Abcam ab203119 
BiP Cell Signaling 3183S 
CHOP Cell Signaling 2895 
COX IV Abcam ab140643 
CPN10 Enzo Life Sciences ADI-SPA-110 
eIF2a (p)  
[Ser 51] Invitrogen 44728G 
GAPDH Abcam Ab8245 
HSP60 Enzo Life Sciences ADI-SPA-806 
HSP70 Enzo Life Sciences ADI-SPA-810 
JNK (p) Cell Signaling 4668S 
LC3 II (A/B) Cell Signaling 4108S 
mtHSP70 Enzo Life Sciences ADI-SPA-825 
p62 Sigma P0067 
PGC-1a Millipore AB3242 
SirT3 Cell Signaling 5490S 
Uqcrc2 Abcam ab14745 
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RESULTS 
Chronic contractile activity induces changes in mitochondrial content. We sought to 
establish a time-course relationship between mitochondrial adaptations in response to the 
CCA protocol over 1-7 days. To observe the activation of mitochondrial biogenesis 
signaling, we measured the mRNA expression of the transcriptional coactivator PGC-1α, 
regarded as the master regulator of this process. A single 3-hour bout of contractile 
activity was sufficient to elicit a 14-fold increase in the transcript level, which remained 
markedly elevated throughout 7 days of CCA (P<0.05; Fig. 1A). In order to effectively 
quantify the changes in mitochondrial content we also measured whole muscle 
cytochrome c oxidase (COX) enzyme activity. COX activity displayed an 11% increase 
as early as 3 days (P=0.06), which progressed to 32% after 7 days of contractile activity 
(P<0.05; Fig. 1B). We corroborated these data with protein expression of PGC-1α, as 
well as integral nuclear-encoded ETC component proteins, cytochrome c oxidase subunit 
IV (COX IV) and the cytochrome bc1 complex III subunit 2 (Uqcrc2) after 7 days of 
chronic stimulation (Fig. 1C). CCA significantly induced Uqcrc2 by 1.9-fold with trends 
toward 1.3-1.4-fold increases in PGC-1α and COX IV, in line with previous reports from 
our laboratory (18, 26). 
Chronic contractile activity elicits an autophagy response. To focus on the autophagy 
response as it pertains to mitochondrial remodeling and removal of dysfunctional 
organelles (10), we selected the adapter protein p62, and the autophagosomal membrane 
protein LC3, which together play important roles in facilitating subsequent organelle 
degradation. The mRNA expression of p62 displayed a 2.3-fold increase at day 2 of CCA 
(P<0.05; Fig. 2A), while  LC3 mRNA  exhibited  no  changes  over  the  course of  7 days  
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Fig. 1 
 
 
Figure 1: Time-course of CCA-induced mitochondrial biogenesis and adaptations. 
(A) Fold-change in mRNA expression of the mitochondrial biogenesis transcriptional 
coactivator PGC-1α, and (B) indicator of mitochondrial content, cytochrome c oxidase 
(COX) enzyme activity, throughout 1-7 days of CCA (PGC-1α mRNA, and COX 
activity, n=6, per day). (C) Spliced western blot and associated graph of PGC-1α, and 
nuclear-encoded ETC components Uqcrc2, and COX IV protein content illustrating 
mitochondrial adaptation following 7 days of CCA, (PGC-1α, n=5; Uqcrc2, and COX 
IV, n=6, per day). Bars represent fold-change in stimulated muscle relative to matched 
controls; means ± SEM. *P<0.05, stimulated vs. control TA muscle at a given time point. 
†P<0.05, main effect of CCA relative to control across all conditions. 
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Fig. 2 
 
 
Figure 2: Time-course of CCA-induced autophagy induction. Fold-change in the 
transcript levels of autophagy markers (A) p62, and (B) LC3 over 1-7 days of CCA (p62, 
n=6; LC3, n=7, per day). Corresponding protein expression of (C) p62, and (D) the ratio 
of lipidated LC3-II to inactive LC3-I throughout the exercise protocol (LC3-II: LC3-I; 
n=6; p62, n=7, per time point). Bars represent fold-change in stimulated muscle relative 
to matched controls; means ± SEM. *P<0.05, stimulated vs. control TA muscle at a given 
time point. 
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(Fig. 2B). Corresponding western blot analysis detected a 2-fold elevation in p62 protein 
levels following 3 days of CCA that returned back to control levels by day 5 (P<0.05; 
Fig. 2C). We also measured protein expression of LC3, as a ratio of its inactive form, 
LC3-I, to the active form LC3-II. We found that the LC3-II: LC3-I ratio was significantly 
reduced by roughly 55-65% from 3-7 days following repeated bouts of contractile 
activity (Fig. 2D).  
Chronic contractile activity induces the UPRER as acute and adaptive responses. Given 
that we found an increase in mitochondrial content and autophagy signaling, we also 
measured selected UPRER transcripts and proteins as they relate to these adaptive 
mechanisms over the time-course of contractile activity. The activation of the PERK and 
IRE1α branches were assessed by the mRNA induction of their respective targets. In 
general, we detected a significant main effect of CCA (P<0.05) on the mRNA expression 
of all UPRER factors measured as early as day 1 and throughout our 7-day time-course. 
Specifically, ATF4, which is activated downstream of PERK, exhibited a 1.5-1.8-fold 
increase at days 2 and 3 (P<0.05), with levels returning back to control values by day 5 
(Fig. 3A). We found that XBP1s was similarly enhanced during the first 3 days of 
contractile activity, reaching a 3.3-fold increase at day 2, and by day 7 was reduced by 
45% in the stimulated, relative to the control, muscle (P<0.05; Fig. 3B).  We also 
extended our analysis to include downstream targets of the UPRER. The transcription 
factor CHOP, and ER chaperone BiP, were significantly enriched at the transcript level 
by 2.2-3.9-fold throughout 1-7 days of chronic stimulation (Fig. 3C, E). Furthermore, 
CHOP protein levels displayed a main effect of CCA at all time points leading to a 1.8-
fold  increase by  day 7 (P<0.05; Fig. 3D),  while BiP  protein remained  unchanged  until  
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Fig. 3 
 
 
Figure 3: Time-course of the CCA-induced UPRER. Fold-change in the mRNA levels 
of UPRER-associated transcription factors (A) ATF4, (B) active XBP1s, and (C) CHOP, 
as well as chaperones (E) BiP, and (G) HSP70 during 1-7 days of CCA (ATF4, XBP1s, 
CHOP, BiP, and HSP70, n=6, per day). Corresponding protein expression of (D) CHOP, 
(F) BiP, and (H) HSP70 (CHOP and BiP, n=7, per day; HSP70, n=6, days 1-5, n=5, for 
day 7). Bars represent fold-change in stimulated muscle relative to matched controls; 
means ± SEM. *P<0.05, stimulated vs. control TA muscle at a given time point. 
†P<0.05, main effect of CCA relative to control across all conditions. 
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day 7, where it trended toward an increase of 47% (P=0.2; Fig. 3F).  Lastly, the cytosolic 
HSP70 chaperone was markedly augmented throughout days 1-7 (P<0.05) at the mRNA 
level with a similar effect of CCA throughout our time-course, specifically reaching as 
high as 2.5-fold increases at days 2 and 5 (Fig. 3G & H). 
Chronic contractile activity elicits the UPRmt concurrent with the UPRER. To 
investigate whether the UPRmt plays a coordinated role in mitochondrial adaptations to 
exercise, we expanded our mRNA and protein analyses to include mitochondrial-specific 
factors. First, mRNA levels of the mitochondrial protease ClpP, which both senses and 
responds to unfolded matrix proteins (1, 6, 58), was significantly upregulated by CCA 
throughout the time-course, particularly reaching a 70% increase by day 2 and 
maintained a 45% elevation at days 5 and 7 (P<0.05; Fig. 4A). Likewise the 
mitochondrial regulatory protein SirT3 (45) displayed enhanced protein expression as a 
result of CCA following 2-7 days reaching elevations of 46% by day 7 (P<0.05; Fig. 4B). 
Finally, consistent 25-80% elevations in the mRNA levels of mitochondrial chaperones 
CPN10, HSP60, and mtHSP70 were observed throughout the 7-day contractile activity 
protocol (P<0.05; Fig. 4C, E, G). This was further reinforced by their changes in protein 
expression, which exhibited a main effect of CCA across all time points culminating in a 
75% enhancement of CPN10 by day 7 specifically (P<0.05; Fig. 4D, F, H). 
TUDCA treatment does not impact CCA-induced activation of the UPRER or UPRmt. 
TUDCA has previously been shown to be capable of preventing ER stress-associated 
UPR activation (16, 35, 44). Therefore we wanted to test the impact of the drug on 
mitochondrial adaptations, since our data illustrate that UPR activation seems to precede 
organelle remodeling in response to chronic muscle activity. Despite an approximate 50%  
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Fig. 4 
 
Figure 4: Time-course of the CCA-induced UPRmt. Fold-change in the mRNA levels 
of (A) mitochondrial protease ClpP, and mitochondrial chaperones (C) CPN10, (E) 
HSP60, and (G) mtHSP70 throughout 7 days of muscle contractile activity (CPN10, n=6; 
ClpP, HSP60, and mtHSP70,n=8, per day). Coterminous expression of (B) the UPRmt 
regulatory protein SirT3, and chaperone proteins (D) CPN10, (F) HSP60, and (H) 
mtHSP70 (SirT3, n=8; CPN10, HSP60 and mtHSP70, n=7, per day). Bars represent fold-
change in stimulated muscle relative to matched controls; means ± SEM. *P<0.05, 
stimulated vs. control TA muscle at a given time point. †P<0.05, main effect of CCA 
relative to control across all conditions. 
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attenuation (P<0.05) in the CCA-induced activation of CHOP protein (Fig. 5A, B), a 
hallmark of TUDCA activity (44, 57), along with a 31% reduction in the HSP70 
adaptation to CCA (P<0.05; Fig. 5D, E), we were unable to detect any discernable 
differences in the expression of other UPRER targets in vehicle- and TUDCA-treated 
animals. The principal mechanism of action of TUDCA is in facilitating protein handling 
and translation (8, 15), therefore it is no surprise that the mRNA expression of both 
CHOP (Fig. 5C), and HSP70 (Fig. 5F) were significantly enriched following 2 of muscle 
stimulation in either treatment group. The mRNA of ATF4 (Fig. 5G), XBP1s (Fig. 5H), 
and BiP (Fig. 5I) was markedly elevated at 2 days in both treatment groups, with levels 
dropping to equal, or below control following 7 days of CCA (P<0.05). In line with our 
earlier findings, CCA had a significant main effect on the mRNA of mitochondrial 
chaperones CPN10 (Fig. 6A), and HSP60 (Fig. 6C), and protease ClpP (Fig. 6D) in 
expression following 2 and 7 days of activity, with no significant difference detected 
between treatments. Specifically, CPN10 mRNA displayed roughly 60-80% increases 
(P<0.05) across all conditions while HSP60 followed the same trend and displayed a 
significant increase of 30% in TUDCA-treated animals subjected to 7 days of stimulation 
(P<0.05). Moreover, CPN10 protein increased approximately 20% after 2 days of CCA, 
and as much as 70% after 7 days, while TUDCA treatment did not have an effect on the 
level of induction relative to vehicle-treatment (P<0.05; Fig. 6B). 
TUDCA treatment has no effect on CCA-induced mitochondrial biogenesis or 
autophagy. We assessed changes in mitochondrial content through COX enzyme activity 
in animals treated with either vehicle or TUDCA, and subjected to either 2 or 7 days of 
CCA.   Consistent  with  our  earlier  results,   we  observed  22%  and  24%  increases  in 
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Fig. 5 
 
Figure 5. Effect of TUDCA on the CCA-induced UPRER. (A) CHOP protein expression 
represented as fold-change, and (B) relative control vs stimulated levels, for a given 
day/treatment. (D) HSP70 protein expressed as fold-change, and as (E) relative control vs. 
stimulated levels for a given day/treatment (CHOP, and HSP70, n=7, per day/condition). Relative 
mRNA levels of UPRER markers (C) CHOP, (F) HSP70, (G) ATF4, (H) XBP1s, and (I) BiP, in 
control and stimulated muscle of vehicle-, and TUDCA-treated animals subject to 2 or 7 days of 
muscle stimulation (ATF4, XBP1s, BiP, CHOP, and HSP70, n=8, per day/treatment). For mRNA 
and protein graphs, open grey, and open white bars represent control muscle in vehicle-, and 
TUDCA-treated animals, respectively; hatched grey, and hatched white bars represent stimulated 
muscle in vehicle-, and TUDCA-treated animals, respectively. For fold-change graphs of CHOP 
and HSP70 protein expression, grey, and black, bars represent vehicle-, and TUDCA-treated 
animals, respectively, expressed as fold-change in stimulated muscle relative to matched control. 
Values represent means ± SEM. *P<0.05, stimulated vs. control TA muscle at a given time point 
and treatment. #P<0.05, 2 days stimulated vs. 7 days stimulated for the same drug treatment. 
¶P<0.05, TUDCA vs. vehicle for a given time point. 
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Fig. 6 
 
Figure 6. Effect of TUDCA on the CCA-induced UPRmt. Relative transcript levels of 
mitochondrial chaperones (A) CPN10 and (C) HSP60, as well as the protease (D) ClpP in 
control and stimulated muscle of vehicle-, and TUDCA-treated animals following 2 or 7 
days of contractile activity (CPN10, and ClpP, n=8; HSP60, n=6 per day/treatment). (B) 
Corresponding protein expression of CPN10 (CPN10, n=8, per day/treatment). Open 
grey, and open white bars represent control muscle in vehicle-, and TUDCA-treated 
animals, respectively; hatched grey, and hatched white bars represent stimulated muscle 
in vehicle-, and TUDCA-treated animals, respectively. Values represent means ± SEM. 
*P<0.05, stimulated vs. control TA muscle at a given time point and treatment. †P<0.05, 
main effect of CCA relative to control across all conditions. 
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mitochondria with 7 days of contractile activity in vehicle-, and TUDCA-treated animals, 
respectively (P<0.05; Fig. 7A). Likewise, PGC-1α mRNA expression was significantly 
increased 6.6-8.4-fold in both treatment groups stimulated for 2 or 7 days, with no 
difference in mRNA induction observed as a result of drug administration (Fig. 7B). To 
reinforce these data, we measured the protein expression of Uqcrc2 and found similar 
1.7-2-fold increases in the stimulated leg relative to control across all groups as CCA 
exhibited a main effect in all conditions (P<0.05; Fig. 7C). Akin to our earlier findings, 
p62 mRNA exhibited a significant increase of approximately 1.7-fold after 2 days of 
stimulation in animals administered the drug (Fig. 8A). These trends in p62 were also 
evident at the protein level at 2 days in vehicle-, and TUDCA-treated animals, 
respectively (P<0.05; Fig. 8C), and were completely attenuated after 7 days of CCA. LC3 
mRNA and protein levels displayed no change in any condition/time point (Fig. 8B, D).  
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Fig. 7 
 
 
Figure 7. Effect of TUDCA treatment on CCA-induced mitochondrial content and 
biogenesis. (A) Relative changes in mitochondrial content observed via COX activity 
(n=8, per day/treatment) following 2 and 7 days of CCA in both vehicle-, and TUDCA-
treated rats. (B) Coactivator of mitochondrial biogenesis PGC-1α mRNA levels (n=8, per 
day/condition) and (C) protein expression of nuclear-encoded complex III subunit 2, 
Uqcrc2 (n=7, per day/condition). For the COX activity graph, grey, and black, bars 
represent vehicle-, and TUDCA-treated animals, respectively, expressed as fold-change 
in stimulated muscle relative to matched control. For mRNA and protein graphs, open 
grey, and open white bars represent control muscle in vehicle-, and TUDCA-treated 
animals, respectively; hatched grey, and hatched white bars represent stimulated muscle 
in vehicle-, and TUDCA-treated animals, respectively. Values represent means ± SEM. 
*P<0.05, stimulated vs. control TA muscle at a given time point and treatment. †P<0.05, 
main effect of CCA relative to control across all conditions. 
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Fig. 8 
 
 
Figure 8. Effect of TUDCA on CCA-induced autophagy induction. Relative mRNA 
expression of (A) p62 and (B) LC3 in vehicle-, and TUDCA-treated animals following 
either 2 or 7 days of CCA (p62, n=6; LC3, n=7, per day/treatment). Corresponding 
protein levels in (C) p62, and (D) ratio of lipidated LC3-II to inactive LC3-I (p62, n=7; 
LC3-II:I, n=8). Open grey, and open white bars represent control muscle in vehicle-, and 
TUDCA-treated animals, respectively; hatched grey, and hatched white bars represent 
stimulated muscle in vehicle-, and TUDCA-treated animals, respectively. Values 
represent means ± SEM. *P<0.05, stimulated vs. control TA muscle at a given time point 
and treatment. #P<0.05, 2 days stimulated vs. 7 days stimulated for the same drug 
treatment. 
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DISCUSSION 
Skeletal muscle accounts for a majority of the body mass, and thus is an important 
determinant of metabolic status and overall health (14, 27). Exercise has been studied for 
its ability to produce adaptations in skeletal muscle to achieve greater oxidative capacity 
as a byproduct of enhanced mitochondrial volume. However, the mechanism by which 
muscle achieves this new phenotype has yet to be fully resolved. Recently, the unfolded 
protein response (UPR) has been implicated in exercise, which suggests that it plays a 
role in sensing and initiating adaptive responses (31, 32, 41, 61). In this study, we set out 
to analyze the signaling events that facilitate skeletal muscle adaptations to exercise over 
a 7-day time-course of repeated bouts of contractile activity, employing a chronic 
contractile activity (CCA) model of exercise (33, 56). 
 CCA over the course of 7 days established an enhanced mitochondrial pool, 
corroborating previous work from our laboratory using this protocol (13, 18, 42, 56). Our 
observed increase in COX activity of 30% by day 7 is similar to the level of adaptation 
achieved with 6 weeks of regular endurance training (23), indicating that our 7-day 
protocol of chronic stimulation provides us with a useful time-course of the signaling 
responses as they contribute to a new muscle phenotype. Of particular note, 
mitochondrial biogenesis-specific signaling, indicated by increased PGC-1α mRNA, was 
markedly induced following a single bout of CCA. However, this induction did not 
manifest into detectable increases in mitochondrial content until day 3. Therefore, this 3-
day window of signaling preceding adaptation is of particular interest, since PGC-1α 
plays a fundamental role in regulating transcriptional activity of a host of nuclear-
encoded mitochondrial proteins integral to organelle biosynthesis (34). While it is known 
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that PGC-1α regulates mitochondrial content, only recently has it been suggested that it 
might also have a more functional role in balancing other adaptive responses such as 
autophagy, and the UPR through interaction with ATF6 (59–61). 
 When considering the beneficial adaptations to exercise, it is important to 
acknowledge the balance between mitochondrial biogenesis and autophagy in effectively 
maintaining a healthy organelle pool (22, 60). Autophagy is gaining recognition for its 
role in maintaining cell quality and viability beyond simply degradation (10). Evidence 
suggests that lack of adequate autophagy results in muscle degeneration, wasting, and 
reduced strength, as well as the accumulation of protein aggregates and dysfunctional 
organelles contributing to excessive oxidative stress (10, 19, 36, 37). Our data reinforce 
the notion of autophagy as a quality control mechanism in muscle adaptation, as we 
detected concomitant changes in autophagy markers from days 3-7 following CCA, 
matching the timing of the increases we observed in mitochondrial content. Specifically, 
the enhanced mRNA expression of p62 at day 2, followed by elevated protein at day 3 
suggests an increase in transcriptional drive to enhance the level of this adapter protein in 
readiness for autophagy. Consistent with this, we detected a reduction of LC3-II: LC3-I 
protein levels from days 3-7, as well as a return to control values by day 5 in p62 protein, 
indicating the subsequent degradation of these autophagosomal components as they are 
decomposed by the lysosome.  
 Given these observations, we proposed that an intermediate response could 
modulate, and coordinate, the balance between synthesis and degradation. In particular, 
we focused on the UPRER, and the UPRmt, as they have been implicated in mitochondrial 
adaptations (9, 38, 47, 54), and autophagy (5, 40, 45) in the presence of cellular stress. 
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We hypothesized that the drive for nuclear-encoded mitochondrial proteins through 
enhanced PGC-1α signaling may perturb the protein environment within the cell, and 
therefore, that the UPR would be integral to exercise-induced mitochondrial remodeling.  
Our observations indicate that the UPR responds to the CCA stimulus acutely, and 
persists to provide a level of adaptation to chronic stimulation. The UPRER transcription 
factors, ATF4 and XBP1s, were significantly induced from 1-3 days of CCA, preceding 
changes in mitochondria and autophagy, thus providing an early signaling response. 
Likewise, the transcription factor CHOP, which regulates cell fate by monitoring cellular 
stress (4), displayed marked elevations in both mRNA and protein throughout 1-7 days of 
CCA, implying a role for the protein in shifting from acute signaling, to chronic 
adaptations. The mRNA and protein expression changes of the ER and cytosolic 
chaperones BiP and HSP70 substantiate CHOP data, as they were also induced from 1-7 
days in response to CCA. Altogether, our results provide the first time-course relationship 
of UPR signaling over a period of progressive adaptation in skeletal muscle 
mitochondria, through exercise. 
 Another unique finding of our study was the parallel contractile activity-induced 
responses observed in both the UPRER and the UPRmt in skeletal muscle. To date, far less 
emphasis has been placed on the UPRmt, particularly in mammalian cells. Nonetheless, 
we were interested in this response, as it pertains directly to the protein folding capacity 
within mitochondria (11, 38). Our laboratory has previously found that mitochondrial-
specific chaperones are induced as an adaptive response to 7 days of CCA (42). Our 
current data confirm these results and suggest that, similar to the time-course of the 
UPRER, mitochondrial factors are induced immediately following a single bout of CCA, 
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and remain elevated throughout repeated contractile episodes. This further establishes the 
phasic nature of the UPR in providing rapid and adaptive protein handling relief within 
multiple subcellular compartments upon alterations in exercise-induced changes in 
proteostasis.  
Our results suggest that the UPR signaling is initiated early in the CCA protocol 
and precedes mitochondrial adaptations and cellular remodeling, and therefore may play 
a direct role in initiating and/or facilitating these events. As such, we utilized the 
chaperone mimetic drug TUDCA, a naturally occurring bile acid produced at low levels 
in the liver which is used in the treatment of various ER stress-associated diseases (2, 17, 
44). The effectiveness in TUDCA treatment is predominantly through augmenting 
protein handling, and by suppressing CHOP-, and caspase-12-mediated apoptosis during 
chronic ER stress (16, 35, 44, 57, 62). We found that TUDCA treatment was able to 
sufficiently attenuate the increase in CHOP protein expression after 2 days of CCA, and 
provided a similar reduction in HSP70 levels. Despite this, mRNA levels of both CHOP 
and HSP70 were unaffected by drug treatment, which corroborates the proposed 
mechanism of TUDCA action on protein handling and translation (8, 15). TUDCA also 
had no effect on the mRNA expression of UPRER transcription factors ATF4 and 
activated XBP1s, as well as the ER chaperone BiP, which all displayed similar increases 
in response to CCA in TUDCA-, and vehicle-treated animals. Since TUDCA facilitates 
protein handling, we next investigated the potential effect that it could have on the 
activation of the UPRmt. However, no effects on the signaling of mitochondrial protein 
quality control machinery ClpP, HSP60, and CPN10 were observed, indicating that the 
UPRmt responds separately from the UPRER.  
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While various UPR targets were still induced in response to CCA in the presence 
of TUDCA treatment, we wanted to investigate whether the attenuation in CHOP protein 
could affect the outcome of mitochondrial remodeling. CHOP has been implicated as a 
regulator of cell fate during chronic stress (4), as well as in exercise-induced apoptosis 
(61), indicating that it is capable of monitoring the intensity and duration of cellular 
stress, and provide signaling towards either remodeling (autophagy) or degradation 
(apoptosis). Despite effective attenuation of the CCA-induced CHOP expression by 
TUDCA, we observed no changes in mitochondrial content measured by COX enzyme 
activity and protein expression of the nuclear-encoded mitochondrial complex III subunit, 
Uqcrc2. Likewise, mitochondrial biogenesis signaling was unaffected, as PGC-1α 
mRNA was considerably induced across all conditions. We also found that autophagy 
was unaffected by TUDCA treatment, despite the reduced activation of CHOP, as p62 
and LC3 responded similarly to our initial time-course findings.  
A limiting factor in the application of TUDCA treatment is the lack of specificity 
in inhibiting the three main branches/factors of the UPR. Instead, TUDCA helps 
modulate protein handling within the cell to reduce the burden on the ER to prevent 
enhanced UPR activation, and subsequent apoptosis. Therefore, specifically knocking out 
upstream UPR factors would be worthy of pursuit in the context of exercise adaptations. 
However, given the usefulness of TUDCA in diminishing CHOP protein increases, we 
were able to analyze the role that CHOP has on CCA-induced adaptations in 
mitochondrial content, and autophagy as a process of cellular quality control. Our 
findings suggest that the potential UPRER regulation of mitochondrial biogenesis acts 
independently of CHOP in our CCA model of exercise. However, this does not exclude 
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the possibility that another UPRER-associated factor could influence this process. 
Specifically, ATF6 has been implicated in PGC-1α signaling (61), however we were 
unable to observe any notable changes in ATF6 as a result of CCA in our study (data not 
shown), possibly as a result of the transient nature of UPR activation. Future work to 
examine a time-course of UPR signaling following acute exercise would be useful to best 
elucidate which factors are the primary responders. The same study linking ATF6 and 
PGC-1α found that CHOP ablation partially rescued the exercise intolerance of muscle-
specific PGC-1α knockout mice. Our data suggest that CHOP attenuation had no impact, 
positive or negative, on the mitochondrial or autophagic adaptations to contractile 
activity. It is important to note that the CCA stimulus is low frequency (10Hz) 
stimulation localized to the tibialis anterior and extensor digitorum longus muscles, rather 
than whole body, maximal exercise. In studies of whole body exercise, it has recently 
been observed that the UPR is sensitive to exercise intensity, as the higher the intensity, 
or novelty, of the stimulus the greater the response (32, 41). We confirmed this trend, as 
UPRER transcription factor mRNAs returned to control levels by 5 days concomitant with 
enhanced protein handling ability and mitochondrial content. Therefore, future research 
avenues could investigate the effect that TUDCA has on adaptations during an enhanced 
CCA stimulus, either in duration or intensity to elicit a more stressful condition in the 
muscle and possibly inducing an increased reliance on CHOP activation. Conversely, 
inducing ER stress in order to activate the UPR prior to an exercise protocol could further 
demonstrate its functional role in adaptation. As it is clear that the UPR is involved in 
some capacity in exercise-induced remodeling, elucidating the specific mechanism of 
action will be of particular interest as it relates to whole body metabolic health. 
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FUTURE WORK 
1. Our data indicate that the UPRER and the UPRmt are involved in exercise-induced 
adaptations as both responses were induced from 1-7 days of CCA, and are capable 
of providing acute and chronic protein handling relief in the form of enhanced 
chaperones and proteases. However the specific mechanism that the UPR plays in 
exercise adaptations remains incompletely understood. We utilized TUDCA 
treatment as a global blockade of UPR activation through reduced ER stress, which 
was unable to diminish the activation of multiple UPR transcripts. However, the 
attenuated increase in CHOP had no effect in level of adaptation observed compared 
to vehicle-treated animals. With this considered, a potential avenue of future research 
would be to inhibit various downstream and upstream effectors of the UPR. Recently 
it has been found that ATF6 is coactivated by PGC-1α to help mediate adaptation, 
therefore this could provide a useful knockout target, likewise other transcription 
factors such as ATF4 or XBP1 could provide meaningful avenues of pursuit in the 
context of mitochondrial adaptations to exercise.  
2. In contrast to knocking out UPR factors, future work could take the opposite 
approach of transgenic/knock-in models in order to induce a heightened UPR 
activation. This would provide us the ability to observe whether a greater level of 
adaptation can be achieved. Furthermore, ER stress can be induced prior to a training 
program by administering potent ER stressors such as thapsigargin or tunicamycin, 
in order to elicit an early UPRER to similarly observe any impact this would have on 
the level of adaptation as the muscle is presumably more inclined to match the rates 
of protein synthesis.  
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3. Given the transient nature of the UPR and the dependence on kinase 
phosphorylation, it remains possible that our sampling of tissue 3 hours following the 
final bout of contractile activity was outside of the optimal window of UPR 
activation/signaling. We had difficulty obtaining consistent western blot results in 
phospho-proteins as well as ATF6 induction. Therefore, it would be equally useful to 
examine the acute signaling that takes place following a single bout of muscle 
stimulation by sampling over a time-course of 0, 3, 6, 12, and 24 hours after 
cessation of muscle contraction. In this way, we can elucidate the primary responders 
associated with UPR activation.  
4. Our study investigated the UPRER and the UPRmt by separately sampling the specific 
effectors of either pathway. It would be of benefit to observe the level of 
coordination of the two pathways by disturbing nuclear- and mitochondrial-derived 
protein incorporation into the mitochondrion. One way in which to accomplish this is 
by blocking import of nuclear transcribed proteins. This will ultimately create a 
backlog of proteins in multiple subcellular compartments and could provide some 
indication of the level of independence/integration of these signaling pathways.  
Particularly, studying this coordination within mammalian systems would be of 
special relevance given the lack of available literature.  
5. Our model of CCA has two distinct advantages: 1) stimulation of the peroneal nerve 
recruits all motor units that are innervated downstream, and 2) the level of intensity 
of stimulation mimics that found in slow-twitch type I motor units. Therefore it is 
possible that the adaptation we observe in our model is principally found in the 
glycolytic fast-twitch muscle fibers, which are less accustomed to exercise, while 
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having a minor effect in type I fibers. A potential avenue of investigation could elicit 
a stimulation of greater intensity or duration in order to completely fatigue all muscle 
fibers and achieve an even greater level of adaptation similar to high intensity, 
maximal exercise. Under this condition of hyper-activated protein synthesis leading 
to a more pronounced increase in mitochondrial content, it is possible that the UPR 
would be of even greater importance in establishing a new adaptive phenotype. Here, 
we could manipulate the protein-folding environment, similar to our current study, to 
once again analyze the impact of the UPR. 
6. Finally, the sampling of UPRER and UPRmt factors in this study were limited to 
protein and mRNA expression in order to establish a time-course and to get a 
framework of some of the most sensitive responders to proteotoxic stress within 
contracting muscle, as the UPR had not been well defined in this tissue. However, 
future research could expand the sampling to include more UPRmt factors in 
particular including transcription factors UBL5 and Sat5B, which are transcription 
factors involved in upregulating mitochondrial genes. Furthermore, it would also be 
useful to corroborate data on UPR activation with protein synthesis rates in 
contracting muscle. This could help establish a dose-response relationship between 
intensity of stimulation, protein synthesis, UPR activation, and subsequent 
adaptation. 
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Table 1: Cytochrome c oxidase activity during 7-day CCA time-course. 
 
 
 
 
 
 
 
Table 2A: mRNA expression of PGC-1α  during 7-day CCA time-course. 
 
 
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 18.69 15.42 21.89 19.19 18.4 20.82 22.89 26.2 17.84 24.68
2 19.07 18.99 22.6 20.14 18 24.8 21.75 25.03 16.96 22.37
3 16.3 16.5 17.81 19.4 20.85 23.47 19.92 25.26 19.19 23.03
4 12.8 14.59 16.43 15.49 21.23 22.57 18.19 23.01 17.49 24.04
5 18.18 20.9 15.48 15.42 21.37 21.58 20.8 22.02 19.21 27.13
6 20.83 18.03 13.99 15.49 20.73 19.56 18.27 20.34 19.02 23.41
Cytochrome c Oxidase Activity (U/g muscle)
1 Day 2 Days 3 Days 5 Days 7 Days
X 17.64 17.4 18.04 17.52 20.1 22.14 20.3 23.64 18.29 24.11
SEM 1.138 0.963 1.428 0.928 0.609 0.769 0.77 0.913 0.4 0.687
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.0003 *** Yes 1 0.2392 0.282 P > 0.05 ns
Days < 0.0001 **** Yes 2 0.5121 0.6036 P > 0.05 ns
CCA 0.0001 *** Yes 3 -2.038 2.402 P = 0.06 ns
Matching 0.0049 ** Yes 5 -3.342 3.939 P < 0.05 **
7 -5.823 6.862 P < 0.05 ****
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.004 0.057 0.005 0.005 0.006 0.067 0.004 0.042 0.006 0.075
2 0.006 0.057 0.006 0.052 0.007 0.062 0.007 0.046 0.004 0.041
3 0.005 0.031 0.005 0.04 0.007 0.059 0.004 0.036 0.005 0.03
4 0.004 0.054 0.006 0.045 0.004 0.087 0.007 0.038 0.005 0.042
5 0.006 0.108 0.007 0.065 0.007 0.068 0.007 0.046 0.004 0.05
6 0.004 0.084 0.006 0.038 0.004 0.058 0.006 0.051 0.003 0.037
PGC-1α mRNA - Control vs. CCA Stim (ΔCt)
1 Day 2 Days 3 Days 5 Days 7 Days
X 0.005 0.065 0.006 0.041 0.006 0.067 0.006 0.043 0.004 0.046
SEM 4E-04 0.011 3E-04 0.008 5E-04 0.004 6E-04 0.002 3E-04 0.006
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 4.244 * Yes 1 -0.06029 8.607 P < 0.05 ****
Days 4.176 * Yes 2 -0.03534 5.045 P < 0.05 ***
CCA 74.5 **** Yes 3 -0.06095 8.701 P < 0.05 ****
Matching 8.831 ns No 5 -0.03728 5.322 P < 0.05 ****
7 -0.04154 5.93 P < 0.05 ****
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
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Table 2B: mRNA expression of autophagy genes during 7-day CCA time-course. 
 
 
 
 
 
 
 
 
 
  
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.195 0.207 0.081 0.362 0.172 0.231 0.199 0.144 0.143 0.125
2 0.185 0.22 0.152 0.305 0.159 0.216 0.19 0.17 0.184 0.193
3 0.125 0.18 0.097 0.192 0.137 0.197 0.132 0.119 0.158 0.119
4 0.217 0.281 0.121 0.199 0.173 0.179 0.15 0.136 0.136 0.105
5 0.101 0.19 0.069 0.15 0.099 0.125 0.088 0.087 0.127 0.118
6 0.107 0.14 0.156 0.237 0.121 0.216 0.104 0.128 0.106 0.108
p62 mRNA - Control vs. CCA Stim (ΔCt)
1 Day 2 Days 3 Days 5 Days 7 Days
X 0.155 0.203 0.113 0.241 0.144 0.194 0.144 0.131 0.142 0.128
SEM 0.02 0.019 0.015 0.032 0.012 0.016 0.018 0.011 0.011 0.013
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.0292 * Yes 1 -0.04819 2.767 P > 0.05 ns
Days 0.0396 * Yes 2 -0.1281 7.356 P < 0.05 ****
CCA < 0.0001 **** Yes 3 -0.05064 2.908 P < 0.05 *
Matching 0.4327 ns No 5 0.01309 0.7513 P > 0.05 ns
7 0.0143 0.821 P > 0.05 ns
Bonferroni Post Hoc Test - Control vs CCA StimRM 2-Way ANOVA - Control vs CCA Stim
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.209 0.157 0.188 0.282 0.213 0.176 0.2 0.13 0.189 0.161
2 0.138 0.141 0.856 0.125 0.168 0.151 0.166 0.137 0.221 0.169
3 0.116 0.114 0.122 0.121 0.151 0.106 0.16 0.117 0.174 0.141
4 0.174 0.166 0.136 0.104 0.138 0.123 0.148 0.113 0.117 0.089
5 0.182 0.207 0.169 0.144 0.139 0.106 0.176 0.139 0.141 0.168
6 0.169 0.196 0.205 0.149 0.187 0.165 0.178 0.144 0.217 0.2
LC3 mRNA - Control vs. CCA Stim (ΔCt)
1 Day 2 Days 3 Days 5 Days 7 Days
X 0.165 0.163 0.279 0.154 0.166 0.138 0.171 0.13 0.176 0.155
SEM 0.013 0.014 0.116 0.026 0.012 0.012 0.007 0.005 0.017 0.015
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.5735 ns No 1 0.00135 0.02419 P > 0.05 ns
Days 0.4487 ns No 2 0.1252 2.252 P > 0.05 ns
CCA 0.0917 ns No 3 0.02825 0.5083 P > 0.05 ns
Matching 0.4994 ns No 5 0.04137 0.7442 P > 0.05 ns
7 0.0219 0.3941 P > 0.05 ns
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
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Table 2C: mRNA expression of UPRER genes during 7-day CCA time-course. 
 
 
 
 
 
 
 
 
 
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.059 0.055 0.069 0.067 0.073 0.125 0.071 0.053 0.084 0.052
2 0.066 0.086 0.074 0.132 0.094 0.141 0.098 0.079 0.082 0.06
3 0.104 0.159 0.124 0.178 0.082 0.134 0.095 0.125 0.107 0.08
4 0.136 0.208 0.21 0.445 0.18 0.349 0.196 0.216 0.172 0.115
5 0.09 0.118 0.094 0.229 0.098 0.129 0.111 0.089 0.113 0.073
6 0.058 0.071 0.057 0.111 0.079 0.086 0.05 0.061 0.07 0.082
ATF4 mRNA - Control vs. CCA Stim (ΔCt)
1 Day 2 Days 3 Days 5 Days 7 Days
X 0.085 0.116 0.105 0.194 0.101 0.161 0.103 0.104 0.105 0.077
SEM 0.013 0.024 0.023 0.055 0.016 0.038 0.021 0.025 0.015 0.009
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.003 ** Yes 1 -0.0309 1.544 P > 0.05 ns
Days 0.4711 ns No 2 -0.08887 4.441 P < 0.05 ***
CCA 0.0022 ** Yes 3 -0.05976 2.987 P < 0.05 *
Matching < 0.0001 **** Yes 5 -0.00058 0.02904 P > 0.05 ns
7 0.02772 1.385 P > 0.05 ns
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.002 0.004 7E-04 0.001 0.001 0.002 0.002 9E-04 0.001 6E-04
2 0.002 0.004 0.001 0.006 0.001 0.002 0.001 0.001 0.001 9E-04
3 0.001 0.001 0.002 0.004 0.002 0.005 0.002 9E-04 0.002 0.001
4 8E-04 0.001 0.002 0.004 0.003 0.003 0.002 0.001 0.002 8E-04
5 0.001 0.005 1E-03 0.002 0.001 0.002 0.001 8E-04 0.002 0.001
6 0.001 0.003 0.002 0.012 0.002 0.008 0.002 0.002 0.002 8E-04
XBP1s mRNA - Control vs. CCA Stim (ΔCt)         
1 Day 2 Days 3 Days 5 Days 7 Days
X 0.001 0.003 0.001 0.005 0.002 0.004 0.002 0.001 0.002 9E-04
SEM 2E-04 6E-04 2E-04 0.002 2E-04 0.001 1E-04 2E-04 1E-04 9E-05
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.0057 ** Yes 1 -0.00163 1.973 P > 0.05 ns
Days 0.0629 ns No 2 -0.00349 4.224 P < 0.05 **
CCA 0.0053 ** Yes 3 -0.00186 2.256 P > 0.05 ns
Matching 0.235 ns No 5 0.00057 0.6887 P > 0.05 ns
7 0.00077 0.9366 P > 0.05 ns
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
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n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.005 0.031 0.007 0.006 0.007 0.021 0.006 0.016 0.009 0.025
2 0.007 0.018 0.007 0.026 0.01 0.024 0.008 0.016 0.011 0.015
3 0.008 0.018 0.007 0.022 0.009 0.021 0.004 0.013 0.007 0.013
4 0.006 0.016 0.008 0.022 0.005 0.035 0.008 0.02 0.008 0.016
5 0.012 0.043 0.017 0.05 0.014 0.037 0.017 0.029 0.01 0.03
6 0.01 0.057 0.014 0.043 0.015 0.044 0.016 0.023 0.016 0.036
CHOP mRNA - Control vs. CCA Stim (ΔCt)
1 Day 2 Days 3 Days 5 Days 7 Days
X 0.008 0.03 0.01 0.028 0.01 0.03 0.01 0.019 0.01 0.022
SEM 0.001 0.007 0.002 0.007 0.002 0.004 0.002 0.002 0.001 0.004
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.1664 ns No 1 -0.02244 5.461 P < 0.05 ****
Days 0.7006 ns No 2 -0.01801 4.383 P < 0.05 ***
CCA < 0.0001 **** Yes 3 -0.02039 4.961 P < 0.05 ***
Matching 0.0231 * Yes 5 -0.00949 2.309 P > 0.05 ns
7 -0.01229 2.991 P < 0.05 *
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.058 0.128 0.044 0.039 0.053 0.117 0.045 0.071 0.059 0.073
2 0.066 0.128 0.064 0.32 0.059 0.145 0.062 0.078 0.051 0.112
3 0.047 0.067 0.049 0.217 0.058 0.288 0.068 0.069 0.063 0.097
4 0.036 0.075 0.054 0.184 0.048 0.068 0.049 0.067 0.046 0.074
5 0.07 0.118 0.054 0.134 0.082 0.119 0.068 0.074 0.076 0.107
6 0.079 0.201 0.072 0.479 0.076 0.395 0.103 0.137 0.103 0.102
BiP mRNA - Control vs. CCA Stim (ΔCt)
1 Day 2 Days 3 Days 5 Days 7 Days
X 0.059 0.119 0.056 0.229 0.063 0.188 0.066 0.083 0.066 0.094
SEM 0.006 0.02 0.004 0.063 0.005 0.051 0.009 0.011 0.008 0.007
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.0192 * Yes 1 -0.06004 1.707 P < 0.05 *
Days 0.1088 ns No 2 -0.1726 4.907 P < 0.05 ***
CCA < 0.0001 **** Yes 3 -0.1258 3.575 P < 0.05 **
Matching 0.2165 ns No 5 -0.01701 0.4835 P > 0.05 ns
7 -0.02792 0.7935 P < 0.05 *
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
 94 
 
 
 
 
 
 
Table 2D: mRNA expression of UPRmt genes during 7-day CCA time-course. 
 
 
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.464 36.36 0.278 0.365 0.422 1.867 0.458 3.726 0.476 1.315
2 0.439 20.25 0.428 17 0.421 3.394 0.568 2.213 0.401 2.829
3 0.191 2.107 0.224 4.412 0.237 1.45 0.36 1.495 0.249 2.217
4 0.307 42.6 0.498 8.475 0.349 1.752 0.455 1.049 0.39 0.892
5 0.091 8.773 0.163 7.049 0.117 0.811 0.13 0.576 0.115 0.596
6 0.111 5.74 0.102 3.414 0.232 0.866 0.075 0.545 0.057 0.385
HSP70 mRNA - Control vs. CCA Stim (ΔCt)
1 Day 2 Days 3 Days 5 Days 7 Days
X 0.267 19.3 0.282 6.785 0.296 1.69 0.341 1.601 0.281 1.372
SEM 0.066 6.892 0.063 2.348 0.05 0.385 0.08 0.496 0.069 0.394
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.0022 ** Yes 1 -19.04 5.867 P < 0.05 ****
Days 0.0028 ** Yes 2 -6.503 2.004 P > 0.05 ns
CCA 0.0005 *** Yes 3 -1.394 0.4296 P > 0.05 ns
Matching 0.4656 ns No 5 -1.26 0.3882 P > 0.05 ns
7 -1.091 0.3362 P > 0.05 ns
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.029 0.032 0.029 0.118 0.032 0.047 0.03 0.042 0.034 0.043
2 0.034 0.023 0.03 0.049 0.039 0.05 0.034 0.05 0.035 0.051
3 0.026 0.043 0.032 0.047 0.03 0.051 0.025 0.041 0.035 0.039
4 0.099 0.105 0.036 0.049 0.029 0.044 0.037 0.06 0.03 0.044
5 0.055 0.06 0.043 0.048 0.066 0.057 0.054 0.078 0.029 0.052
6 0.038 0.045 0.049 0.05 0.046 0.077 0.041 0.059 0.041 0.07
7 0.039 0.059 0.041 0.059 0.063 0.07 0.049 0.068 0.041 0.048
8 0.028 0.036 0.033 0.045 0.035 0.059 0.028 0.037 0.023 0.046
X 0.044 0.05 0.037 0.058 0.042 0.057 0.037 0.054 0.034 0.049
SEM 0.009 0.009 0.003 0.009 0.005 0.004 0.004 0.005 0.002 0.003
ClpP mRNA - Control vs. CCA Stim (ΔCt)
1 Day 2 Days 3 Days 5 Days 7 Days
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.4015 ns No 1 -0.00677 1.283 P > 0.05 ns
Days 0.8394 ns No 2 -0.02153 4.082 P < 0.05 **
CCA < 0.0001 **** Yes 3 -0.01436 2.724 P > 0.05 ns
Matching < 0.0001 **** Yes 5 -0.01707 3.237 P < 0.05 *
7 -0.01564 2.966 P < 0.05 *
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
 95 
 
 
 
 
 
 
 
 
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.095 0.177 0.076 0.152 0.102 0.201 0.102 0.205 0.109 0.161
2 0.098 0.157 0.097 0.209 0.103 0.182 0.106 0.18 0.111 0.236
3 0.095 0.113 0.093 0.157 0.099 0.214 0.095 0.162 0.1 0.234
4 0.251 0.276 0.224 0.283 0.182 0.255 0.229 0.27 0.218 0.284
5 0.208 0.241 0.111 0.241 0.14 0.272 0.168 0.258 0.118 0.23
6 0.135 0.204 0.135 0.238 0.15 0.273 0.155 0.238 0.166 0.223
CPN10 mRNA - Control vs. CCA Stim (ΔCt)
1 Day 2 Days 3 Days 5 Days 7 Days
X 0.147 0.195 0.122 0.213 0.129 0.233 0.143 0.219 0.137 0.228
SEM 0.027 0.024 0.022 0.021 0.014 0.016 0.021 0.018 0.019 0.016
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.0214 * Yes 1 -0.04771 4.184 P < 0.05 **
Days 0.9741 ns No 2 -0.09069 7.952 P < 0.05 ****
CCA < 0.0001 **** Yes 3 -0.1033 9.06 P < 0.05 ****
Matching < 0.0001 **** Yes 5 -0.07636 6.695 P < 0.05 ****
7 -0.09076 7.958 P < 0.05 ****
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.055 0.114 0.079 0.122 0.075 0.088 0.058 0.103 0.077 0.11
2 0.101 0.151 0.098 0.138 0.093 0.109 0.106 0.121 0.09 0.147
3 0.082 0.077 0.075 0.101 0.071 0.143 0.062 0.092 0.057 0.125
4 0.058 0.115 0.094 0.106 0.061 0.095 0.087 0.116 0.088 0.119
5 0.155 0.222 0.106 0.196 0.183 0.225 0.145 0.221 0.1 0.144
6 0.111 0.199 0.221 0.173 0.161 0.184 0.176 0.167 0.167 0.202
7 0.064 0.105 0.06 0.107 0.055 0.08 0.081 0.098 0.057 0.077
8 0.058 0.071 0.057 0.111 0.079 0.086 0.05 0.061 0.07 0.082
X 0.085 0.132 0.099 0.132 0.097 0.126 0.096 0.122 0.088 0.126
SEM 0.012 0.019 0.019 0.012 0.017 0.019 0.016 0.018 0.013 0.014
HSP60 mRNA - Control vs. CCA Stim (ΔCt)
1 Day 2 Days 3 Days 5 Days 7 Days
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.6459 ns No 1 -0.04649 4.722 P < 0.05 ***
Days 0.9961 ns No 2 -0.03295 3.347 P < 0.05 **
CCA < 0.0001 **** Yes 3 -0.02908 2.954 P < 0.05 *
Matching < 0.0001 **** Yes 5 -0.02685 2.727 P < 0.05 *
7 -0.03757 3.817 P < 0.05 **
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Table 3A: Protein expression of mitochondrial content and biogenesis markers 
following 7 days of CCA. 
 
 
n CTR STM CTR STM CTR STM
1 1.31984 1.87118 1.38979 1.24491 2.05575 2.36908
2 1.19298 1.15656 2.05575 2.36908 0.82086 1.05333
3 0.38098 0.8092 0.82086 1.05333 0.80999 1.36698
4 2.42568 1.90626 1.79755 1.64915 0.66357 0.80608
5 0.63097 1.13614 0.80999 1.36698 0.62852 0.85471
6 0.62852 0.85471 0.68635 1.0843
7 Day CCA PGC-1α, Uqcrc2, COX IV - Control vs CCA Stim
PGC-1α Uqcrc2 COX IV
X 1.19009 1.37587 1.25041 1.42302 0.94417 1.25575
SEM 0.35432 0.21833 0.24032 0.21914 0.22462 0.23702
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.0165 * Yes PGC-1α -0.1858 1.176 P > 0.05 ns
Days 0.9794 ns No COXIV -0.1683 1.261 P > 0.05 ns
CCA 0.0005 *** Yes Uqcrc2 -0.7254 5.435 P < 0.05 ***
Matching < 0.0001 **** Yes
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.048 0.065 0.046 0.087 0.061 0.091 0.05 0.095 0.053 0.1
2 0.057 0.041 0.05 0.071 0.046 0.079 0.064 0.082 0.041 0.075
3 0.052 0.046 0.05 0.074 0.071 0.104 0.048 0.07 0.038 0.078
4 0.032 0.042 0.058 0.069 0.045 0.072 0.062 0.086 0.044 0.063
5 0.032 0.043 0.019 0.027 0.026 0.036 0.031 0.029 0.022 0.038
6 0.033 0.055 0.049 0.055 0.041 0.075 0.045 0.073 0.036 0.055
7 0.028 0.042 0.029 0.035 0.018 0.043 0.051 0.064 0.047 0.047
8 0.021 0.024 0.02 0.036 0.027 0.033 0.02 0.028 0.019 0.032
X 0.038 0.045 0.04 0.057 0.042 0.067 0.046 0.066 0.037 0.061
SEM 0.005 0.004 0.005 0.008 0.006 0.009 0.005 0.009 0.004 0.008
mtHSP70 mRNA - Control vs. CCA Stim (ΔCt)         
1 Day 2 Days 3 Days 5 Days 7 Days
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.0618 ns No 1 -0.00683 1.491 P > 0.05 ns
Days 0.4909 ns No 2 -0.01625 3.548 P < 0.05 **
CCA < 0.0001 **** Yes 3 -0.02488 5.433 P < 0.05 ****
Matching < 0.0001 **** Yes 5 -0.01943 4.242 P < 0.05 ***
7 -0.02357 5.146 P < 0.05 ****
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Table 3B: Protein expression of autophagy markers during 7-day CCA time-course. 
 
 
 
 
 
 
 
 
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 1.207 0.833 0.609 1.104 0.633 1.233 1.123 1.609 1.121 0.848
2 0.965 0.644 0.924 1.387 0.967 1.175 1.065 1.197 0.983 0.881
3 1.538 1.284 0.706 0.834 0.616 1.015 0.509 0.619 0.683 0.72
4 1.329 0.742 0.749 0.949 0.713 0.854 0.756 1.074 0.714 0.861
5 0.792 0.996 0.635 0.663 0.501 2.456 1.539 1.849 1.274 1.519
6 1.551 2.701 2.797 2.282 2.132 3.029 1.325 1.686 2.591 2.592
7 0.889 0.88 0.783 0.978 0.911 1.479 3.169 1.134 1.013 1.116
p62 Protein - Control vs. CCA Stim
1 Day 2 Days 3 Days 5 Days 7 Days
X 1.182 1.154 1.029 1.171 0.925 1.606 1.355 1.31 1.197 1.22
SEM 0.116 0.269 0.297 0.204 0.211 0.309 0.329 0.162 0.246 0.249
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.1266 ns No 1 0.02747 0.1267 P > 0.05 ns
Days 0.9566 ns No 2 -0.1421 0.6554 P > 0.05 ns
CCA 0.1212 ns No 3 -0.6813 3.142 P < 0.05 *
Matching < 0.0001 **** Yes 5 0.04522 0.2086 P > 0.05 ns
7 -0.0225 0.1038 P > 0.05 ns
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 1.728 0.801 1.132 0.96 1.772 0.562 1.368 0.556 1.178 0.532
2 1.013 1.566 1.111 0.311 1.171 0.482 1.746 0.596 1.022 0.226
3 1.256 0.696 2.182 0.722 2.036 0.673 2.04 0.48 0.984 0.447
4 1.038 0.77 0.677 0.475 1.423 0.494 1.44 0.573 0.688 0.346
5 0.812 0.539 0.364 0.359 1.922 0.607 0.849 0.571 1.663 0.786
6 2.266 0.649 0.847 0.591 0.747 0.262 0.847 0.369 0.677 0.462
LC3-II:LC3-I Protein - Control vs. CCA Stim
1 Day 2 Days 3 Days 5 Days 7 Days
X 1.352 0.837 1.052 0.57 1.512 0.513 1.382 0.524 1.035 0.467
SEM 0.223 0.151 0.254 0.099 0.202 0.058 0.195 0.035 0.149 0.077
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.3047 ns No 1 0.5155 2.537 P > 0.05 ns
Days 0.2985 ns No 2 0.4824 2.374 P > 0.05 ns
CCA < 0.0001 **** Yes 3 0.9983 4.914 P < 0.05 ***
Matching 0.1566 ns No 5 0.8574 4.22 P < 0.05 **
7 0.5688 2.8 P < 0.05 *
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Table 3C: Protein expression of UPRER markers during 7-day CCA time-course. 
 
 
 
 
 
 
 
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.213 0.265 0.184 0.322 0.488 0.545 0.417 0.506 0.87 0.657
2 0.187 0.183 0.361 0.627 0.242 0.382 0.22 0.468 0.28 0.402
3 0.678 0.722 0.706 0.854 0.376 0.603 0.868 1.255 0.564 0.844
4 0.306 0.134 0.209 0.431 0.304 0.804 0.363 0.576 0.254 0.385
5 0.885 1.381 0.894 0.97 1.036 0.955 0.76 1.352 0.441 1.053
6 0.099 0.602 0.247 0.397 0.483 0.667 0.5 0.901 0.415 1.511
7 0.937 1.225 1.009 1.585 1.051 1.601 1.734 1.728 1.252 1.396
CHOP Protein - Control vs. CCA Stim
1 Day 2 Days 3 Days 5 Days 7 Days
X 0.472 0.645 0.516 0.741 0.569 0.794 0.695 0.97 0.582 0.893
SEM 0.133 0.189 0.131 0.168 0.127 0.151 0.193 0.184 0.136 0.17
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.8985 ns No 1 -0.1726 1.682 P > 0.05 ns
Days 0.7542 ns No 2 -0.225 2.193 P > 0.05 ns
CCA < 0.0001 **** Yes 3 -0.2252 2.195 P > 0.05 ns
Matching < 0.0001 **** Yes 5 -0.2748 2.679 P > 0.05 ns
7 -0.3103 3.025 P < 0.05 *
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 1.459 1.297 0.921 0.198 0.59 0.819 0.844 0.826 0.667 0.856
2 0.699 0.634 0.631 0.443 0.519 0.575 0.646 0.789 1.036 0.891
3 1.149 1.223 0.838 0.821 1.245 1.458 1.883 1.198 0.866 1.639
4 3.324 3.167 2.075 2.557 2.929 1.992 2.545 2.228 1.442 1.708
5 0.681 0.658 0.843 0.778 0.746 0.744 0.543 0.577 0.803 1.48
6 0.825 0.503 0.434 0.345 0.549 0.501 0.422 0.703 0.309 0.697
7 0.674 0.355 0.401 0.046 0.604 0.759 0.877 0.637 0.558 0.534
BiP Protein - Control vs. CCA Stim
1 Day 2 Days 3 Days 5 Days 7 Days
X 1.259 1.119 0.877 0.741 1.026 0.978 1.109 0.994 0.811 1.115
SEM 0.362 0.367 0.214 0.321 0.331 0.206 0.3 0.219 0.137 0.182
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.0824 ns No 1 0.1394 1.121 P > 0.05 ns
Days 0.8982 ns No 2 0.1363 1.096 P > 0.05 ns
CCA 0.6322 ns No 3 0.04771 0.3838 P > 0.05 ns
Matching < 0.0001 **** Yes 5 0.1145 0.9209 P > 0.05 ns
7 -0.3034 2.441 P > 0.05 ns
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
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Figure 3D: Protein expression of UPRmt markers during 7-day CCA time-course. 
 
 
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.359 1.027 1.022 1.067 0.848 1.304 1.086 1.525 0.294 1.581
2 0.445 0.875 0.287 0.659 0.462 1.035 0.48 0.957 0.677 1.037
3 0.55 1.109 0.327 0.557 0.368 1.09 0.415 1.262 0.373 0.823
4 2.216 2.876 1.449 5.155 2.134 1.93 1.255 4.156 0.794 2.001
5 0.32 0.39 0.251 0.804 0.67 1.255 0.33 0.986 0.547 1.628
6 0.271 0.465 0.322 1.01 0.444 1.129 0.519 1.305
HSP70 Protein - Control vs. CCA Stim
1 Day 2 Days 3 Days 5 Days 7 Days
X 0.693 1.124 0.609 1.542 0.821 1.291 0.681 1.698 0.537 1.414
SEM 0.307 0.37 0.206 0.727 0.272 0.134 0.158 0.499 0.093 0.213
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.6049 ns No 1 -0.4305 1.31 P > 0.05 ns
Days 0.9766 ns No 2 -0.9325 2.838 P < 0.05 *
CCA < 0.0001 **** Yes 3 -0.4696 1.429 P > 0.05 ns
Matching 0.0012 ** Yes 5 -1.018 3.098 P < 0.05 *
7 -0.8768 2.436 P > 0.05 ns
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.633 0.751 0.427 0.702 0.564 0.729 0.783 0.778 1.044 1.087
2 0.958 0.443 0.884 1.237 0.886 0.889 0.89 1.167 0.99 1.047
3 1.162 1.04 0.726 0.489 0.71 0.996 1.09 1.181 0.891 0.875
4 0.677 0.488 1.04 0.895 0.708 0.734 0.677 1.201 0.791 1.298
5 0.472 0.733 1.079 0.926 1.149 3.097 2.497 2.645 1.429 1.883
6 0.387 0.153 0.349 0.296 0.249 0.417 0.366 0.288 0.299 0.621
7 1.089 0.599 0.656 0.683 1.22 1.141 1.977 1.654 1.165 1.718
8 0.943 1.294 1.353 1.832 2.435 2.959 2.444 2.373 1.396 2.968
X 0.79 0.688 0.814 0.882 0.99 1.37 1.34 1.411 1.001 1.437
SEM 0.102 0.126 0.121 0.169 0.234 0.37 0.297 0.278 0.128 0.264
SirT3 Protein - Control vs. CCA Stim
1 Day 2 Days 3 Days 5 Days 7 Days
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.085 ns No 1 0.1024 0.6687 P > 0.05 ns
Days 0.2014 ns No 2 -0.06817 0.4451 P > 0.05 ns
CCA 0.0176 * Yes 3 -0.3803 2.483 P > 0.05 ns
Matching < 0.0001 **** Yes 5 -0.07031 0.4591 P > 0.05 ns
7 -0.4367 2.851 P < 0.05 *
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
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n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.706 0.838 0.718 1.435 0.466 0.713 0.732 0.738 0.315 0.509
2 0.546 0.931 0.545 0.756 0.471 0.936 0.92 1.12 1.098 1.714
3 0.911 0.795 1.17 0.852 1.274 1.391 1.725 2.804 1.335 3.33
4 1.716 1.508 1.276 1.257 1.455 0.922 0.545 0.989 0.873 1.292
5 1.302 1.075 1.883 1.21 0.913 1.452 0.891 1.663 0.956 1.484
6 0.564 0.689 0.535 0.658 0.521 0.503 0.354 0.31 0.524 0.8
7 1.214 2.017 1.967 2.4 2.3 2.664 2.005 1.916 1.65 3.314
CPN10 Protein - Control vs. CCA Stim
1 Day 2 Days 3 Days 5 Days 7 Days
X 0.994 1.122 1.156 1.224 1.057 1.226 1.025 1.363 0.964 1.778
SEM 0.165 0.18 0.226 0.224 0.256 0.272 0.231 0.315 0.173 0.427
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.0509 ns No 1 -0.128 0.6923 P > 0.05 ns
Days 0.9213 ns No 2 -0.06789 0.3673 P > 0.05 ns
CCA 0.0009 *** Yes 3 -0.1685 0.9117 P > 0.05 ns
Matching < 0.0001 **** Yes 5 -0.3382 1.829 P > 0.05 ns
7 -0.8132 4.399 P < 0.05 ***
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.822 1.307 1.14 1.49 1.409 1.803 1.204 1.335 1.444 1.804
2 0.786 0.824 0.761 0.757 0.884 1.104 1.044 0.895 1.011 0.967
3 0.55 1.068 0.304 0.421 0.577 0.92 0.766 0.975 0.375 0.576
4 4.081 3.879 4.091 4.354 3.747 2.65 2.52 3.164 1.883 2.406
5 0.419 0.453 0.629 1.168 0.989 1.159 0.845 1.104 0.544 1.192
6 1.032 0.969 1.255 1.102 1.247 1.166 1.089 1.145 1.22 1.149
7 0.718 0.723 0.878 0.747 1.255 1.356 1.266 1.128 1.375 1.509
HSP60 Protein - Control vs. CCA Stim
1 Day 2 Days 3 Days 5 Days 7 Days
X 1.201 1.318 1.294 1.434 1.444 1.451 1.248 1.392 1.122 1.372
SEM 0.486 0.439 0.481 0.504 0.398 0.226 0.223 0.3 0.199 0.227
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.7539 ns No 1 -0.1166 0.9275 P > 0.05 ns
Days 0.9948 ns No 2 -0.1402 1.115 P > 0.05 ns
CCA 0.026 * Yes 3 -0.00704 0.05601 P > 0.05 ns
Matching < 0.0001 **** Yes 5 -0.1447 1.152 P > 0.05 ns
7 -0.2499 1.989 P > 0.05 ns
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Table 4. Cytochome c oxidase activity following TUDCA/vehicle treatment with 2 or 
7 days of CCA. 
 
 
n CTR STM CTR STM CTR STM CTR STM CTR STM
1 0.512 0.649 0.683 0.719 0.579 0.629 0.643 0.683 0.633 0.692
2 1.857 0.161 1.187 1.12 1.218 1.377 1.497 1.777 1.59 1.823
3 1.245 0.895 0.941 0.891 1.026 1.457 0.937 1.41 0.842 0.944
4 1.084 0.876 1.26 1.214 0.974 1.266 1.125 1.358 0.996 1.352
5 0.472 0.617 0.875 0.741 0.827 1.271 0.187 0.335 0.273 0.449
6 0.316 0.327 0.332 0.353 0.273 0.371 0.692 0.8 0.774 1.631
7 1.093 1.521 2.074 3.186 3.19 3.385 3.08 2.941 2.906 3.456
mtHSP70 Protein - Control vs. CCA Stim
1 Day 2 Days 3 Days 5 Days 7 Days
X 0.94 0.721 1.05 1.175 1.155 1.394 1.166 1.329 1.145 1.478
SEM 0.205 0.167 0.207 0.352 0.359 0.366 0.355 0.327 0.33 0.379
Source of 
Variation P value
P value 
summary
Significant
? Days Difference t P value Summary
Interaction 0.1414 ns No 1 0.219 1.428 P > 0.05 ns
Days 0.7951 ns No 2 -0.1245 0.8121 P > 0.05 ns
CCA 0.0715 ns No 3 -0.2388 1.557 P > 0.05 ns
Matching < 0.0001 **** Yes 5 -0.1632 1.064 P > 0.05 ns
7 -0.3333 2.173 P > 0.05 ns
RM 2-Way ANOVA - Control vs CCA Stim Bonferroni Post Hoc Test - Control vs CCA Stim
P value  Summary Significant?
0.0567 ns No
0.9047 ns No
0.0965 ns No
< 0.0001 **** Yes
Days Difference t P value Summary
2 0.1909 0.2086 P > 0.05 ns
7 -2.496 2.729 P < 0.05 *
RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
Source of Variation
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
P value Summary Significant?
0.0042 ** Yes
0.5565 ns No
0.1122 ns No
< 0.0001 **** Yes
Days Difference t P value Summary
2 1.05 1.212 P > 0.05 ns
7 -3.128 3.609 P < 0.05 **
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
Source of Variation
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
Difference t P value Summary
-0.8233 0.406 P > 0.05 ns
1.398 0.69 P > 0.05 ns
0.2929 0.145 P > 0.05 ns
-2.868 1.416 P > 0.05 ns
1.976 0.976 P > 0.05 ns
-3.617 1.786 P > 0.05 ns
-0.2446 0.121 P > 0.05 ns
-0.4564 0.225 P > 0.05 ns
2 Days :VEH CON vs. 7 Days :VEH CON
2 Days :VEH CON vs. 2 Days :TUD CON
Comparison
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
2 Days :VEH STM vs. 7 Days :VEH STM
2 Days :VEH STM vs. 2 Days :TUD STM
2 Days :TUD CON vs. 7 Days :TUD CON
7 Days :VEH STM vs. 7 Days :TUD STM
7 Days :VEH CON vs. 7 Days :TUD CON
2 Days :TUD STM vs. 7 Days :TUD STM
n CTR STM CTR STM CTR STM CTR STM
1 17.395 19.783 21.165 25.567 18.888 18.922 19.382 24.68
2 14.69 16.857 11.056 14.537 21.686 17.497 14.392 21.14
3 16.166 16.431 18.188 21.652 19.613 14.81 17.378 22.334
4 20.926 20.517 21.635 25.977 18.009 19.715 19.911 21.259
5 27.529 24.057 17.761 23.929 24.356 22.274 24.407 26.898
6 20.065 16.763 18.58 19.954 19.161 19.434 14.383 18.043
Cytochrome c Oxidase Activity (U/g muscle)
VEHICLE TUDCA
2 Days 7 Days 2 Days 7 Days
X 19.462 19.068 18.064 21.936 20.285 18.775 18.309 22.392
SEM 1.8753 1.2201 1.5476 1.7535 0.9554 1.0156 1.5549 1.2558
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Table 5A: mRNA expression of UPRER markers following TUDCA/vehicle 
treatment with 2 or 7 days of CCA. 
 
  
n CTR STM CTR STM CTR STM CTR STM
1 0.7556 3.0221 0.823 0.38 1.3124 0.836 4.516 0.4109
2 0.8686 1.5147 1.0954 1.9107 0.9891 4.7321 1.0056 3.3428
3 0.8125 1.3205 0.7376 1.3482 0.7296 2.6633 0.6332 1.4906
4 1.1784 6.1581 0.9642 1.4267 1.1372 3.739 0.7254 1.6876
5 0.9282 1.8541 0.8711 1.1735 0.7785 3.2835 0.7335 1.7946
6 1.0973 3.3295 0.7676 1.0135 1.0911 4.0555 0.7447 1.5544
7 0.9473 2.926 1.1452 1.845 0.8943 3.242 0.3711 1.1107
8 1.028 2.4799 0.9784 1.7837 0.7733 1.6287 0.7331 1.5663
X 0.952 2.8256 0.9228 1.3602 0.9632 3.0225 1.1828 1.6197
SEM 0.0507 0.5421 0.0526 0.1812 0.073 0.4526 0.4801 0.2912
CHOP mRNA - Control vs. CCA Stim (ΔCt)
VEHICLE TUDCA
2 Days 7 Days 2 Days 7 Days
P value  Summary Significant?
0.0165 * Yes
0.0304 * Yes
0.0006 *** Yes
0.2756 ns No
Days Difference t P value Summary
2 -0.0187 5.021 P < 0.05 ***
7 -0.0044 1.172 P > 0.05 ns
RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
Source of Variation
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
P value Summary Significant?
0.0677 ns No
0.0754 ns No
0.0087 ** Yes
0.8511 ns No
Days Difference t P value Summary
2 -0.0206 3.554 P < 0.05 **
7 -0.0044 0.7541 P > 0.05 ns
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
Source of Variation
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
Difference t P value Summary
-0.0112 0.024 P > 0.05 ns
0.02917 0.063 P > 0.05 ns
-0.1969 0.425 P > 0.05 ns
1.465 3.165 P > 0.05 ns
-0.2196 0.474 P > 0.05 ns
1.403 3.03 P > 0.05 ns
-0.26 0.562 P > 0.05 ns
-0.2596 0.561 P > 0.05 ns
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
2:VEH CON vs. 2:TUD CON
2:VEH CON vs. 7:VEH CON
2:VEH STM vs. 2:TUD STM
2:VEH STM vs. 7:VEH STM
2:TUD CON vs. 7:TUD CON
2:TUD STM vs. 7:TUD STM
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
n VEH TUD VEH TUD
1 4 0.637 0.462 0.091
2 1.744 4.784 1.744 3.324
3 1.625 3.65 1.828 2.354
4 5.226 3.288 1.48 2.326
5 1.998 4.218 1.347 2.447
6 1.998 3.717 1.32 2.087
7 3.089 3.625 1.611 2.993
8 2.412 2.106 1.823 2.137
X 2.7615 3.25313 1.45188 2.21988
SEM 0.4498 0.46188 0.15805 0.33949
CHOP mRNA - CCA Stim/Cotnrol (ΔΔCt)
2 Days 7 Days
P value Summary Significant?
0.7137 ns No
0.0039 ** Yes
0.1022 ns No
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
Source of Variation
Interaction
Days
TUDCA
Difference t Summary
-0.4916 0.9325 ns
1.31 2.484 ns
0.5416 1.027 ns
1.801 3.417 *
1.033 1.96 ns
-0.768 1.457 ns
P value
P > 0.05
Comparison
2 Days :VEH vs. 2 Days :TUD
P > 0.05
P > 0.052 Days :VEH vs. 7 Days :TUD
2 Days :VEH vs. 7 Days :VEH
P < 0.05
P > 0.052 Days :TUD vs. 7 Days :TUD
2 Days :TUD vs. 7 Days :VEH
P > 0.057 Days :VEH vs. 7 Days :TUD
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
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n CTR STM CTR STM CTR STM CTR STM
1 0.2424 2.9989 0.3419 1.9592 0.2059 1.2149 0.6123 1.1165
2 0.5869 1.7258 0.2175 2.6524 0.252 23.212 0.4771 1.9475
3 0.4947 6.4169 0.3472 2.0077 0.9513 21.779 0.3551 2.5401
4 0.3531 21.721 1.2849 3.1979 0.3637 15.662 0.7513 3.9477
5 0.7259 15.7 0.4929 1.5292 0.5966 31.539 0.6546 4.0914
6 0.4607 35.105 1.7355 1.794 0.8391 9.0968 0.3734 3.8304
7 0.6024 32.807 0.6616 1.0653 0.6164 22.857 0.8875 4.4458
8 0.4611 9.663 0.6383 2.517 0.3373 3.541 0.4239 2.3536
X 0.4909 15.767 0.715 2.0903 0.5203 16.113 0.5669 3.0341
SEM 0.0533 4.5994 0.1864 0.2391 0.0974 3.7687 0.0678 0.4256
HSP70 mRNA - Control vs. CCA Stim (ΔCt)
VEHICLE TUDCA
2 Days 7 Days 2 Days 7 Days
P value  Summary Significant?
0.0091 ** Yes
0.0114 * Yes
0.0028 ** Yes
0.4933 ns No
Days Difference t P value Summary
2 -0.1528 4.697 P < 0.05 ***
7 -0.0138 0.4229 P > 0.05 ns
RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
Source of Variation
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
P value Summary Significant?
0.0036 ** Yes
0.0043 ** Yes
0.0003 *** Yes
0.4711 ns No
Days Difference t P value Summary
2 -0.1559 5.869 P < 0.05 ****
7 -0.0247 0.9287 P > 0.05 ns
Source of Variation
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
Difference t P value Summary
-0.0294 0.01 P > 0.05 ns
-0.2241 0.075 P > 0.05 ns
-0.3455 0.116 P > 0.05 ns
13.68 4.581 P < 0.05 ***
-0.0466 0.016 P > 0.05 ns
13.08 4.381 P < 0.05 **
0.1481 0.05 P > 0.05 ns
-0.9438 0.316 P > 0.05 ns
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
2:VEH CON vs. 2:TUD CON
2:VEH CON vs. 7:VEH CON
2:VEH STM vs. 2:TUD STM
2:VEH STM vs. 7:VEH STM
2:TUD CON vs. 7:TUD CON
2:TUD STM vs. 7:TUD STM
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
n VEH TUD VEH TUD
1 12.369 5.899 5.73 1.823
2 2.941 92.107 12.196 4.082
3 12.971 22.895 5.782 7.152
4 61.512 43.063 2.489 5.255
5 21.629 52.867 3.103 6.251
6 21.629 10.841 1.034 10.259
7 54.462 37.078 1.61 5.01
8 20.957 10.498 3.943 5.553
X 26.0588 34.406 4.48588 5.67313
SEM 7.34614 10.1983 1.26105 0.86122
HSP70 mRNA - CCA Stim/Cotnrol (ΔΔCt)
2 Days 7 Days
P value Summary Significant?
0.5762 ns No
0.0005 *** Yes
0.4577 ns No
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
Source of Variation
Interaction
Days
TUDCA
Difference t Summary
-8.347 0.9324 ns
21.57 2.41 ns
20.39 2.277 ns
29.92 3.342 *
28.73 3.209 *
-1.187 0.1326 ns
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
P value
P > 0.05
Comparison
2 Days :VEH vs. 2 Days :TUD
P > 0.05
P > 0.05
2 Days :VEH vs. 7 Days :VEH
2 Days :VEH vs. 7 Days :TUD
P < 0.05
P < 0.05
2 Days :TUD vs. 7 Days :VEH
2 Days :TUD vs. 7 Days :TUD
P > 0.057 Days :VEH vs. 7 Days :TUD
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n CTR STM CTR STM CTR STM CTR STM P value  Summary Significant?
1 1.2427 1.0687 1.4504 0.9628 1.1063 0.5357 1.1515 1.1509 0.0011 ** Yes
2 0.7392 0.9041 1.2853 0.7277 1.3618 2.4292 0.9743 0.8947 0.0732 ns No
3 1.0459 1.2385 1.6621 0.8984 1.0541 2.2443 1.2012 0.6639 0.4926 ns No
4 1.2263 2.6754 1.1224 0.6334 0.4517 0.9621 1.0916 0.6583 0.1756 ns No
5 1.1267 1.5339 1.0007 0.7826 1.2297 2.2519 1.0024 0.9637
6 1.1044 2.8245 1.0664 0.8071 1.5141 2.9653 1.0892 0.8491
7 1.0587 1.9735 1.349 1.0472 1.3313 2.7157 1.0799 0.9028 Days Difference t P value Summary
8 0.8863 1.0281 1.101 0.773 1.1061 0.6183 1.0155 0.6649 2 -0.0602 3.4 P < 0.05 **
X 1.0538 1.6558 1.2547 0.829 1.1444 1.8403 1.0757 0.8435 7 0.04256 2.404 P > 0.05 ns
SEM 0.0598 0.2672 0.0796 0.0472 0.1132 0.3453 0.0271 0.0618
P value Summary Significant?
Difference t P value Summary 0.007 ** Yes
-0.0906 0.3862 P > 0.05 ns 0.0272 * Yes
-0.2009 0.8562 P > 0.05 ns 0.137 ns No
-0.1845 0.7863 P > 0.05 ns 0.0807 ns No
0.8268 3.524 P < 0.05 *
0.0687 0.2928 P > 0.05 ns
0.9968 4.249 P < 0.05 ** Days Difference t P value Summary
0.1789 0.7627 P > 0.05 ns 2 -0.0696 3.348 P < 0.05 **
-0.0145 0.0618 P > 0.05 ns 7 0.02322 1.117 P > 0.05 ns
ATF4 mRNA - Control vs. CCA Stim (ΔCt)
VEHICLE TUDCA
2 Days 7 Days 2 Days 7 Days RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
Source of Variation
Source of Variation
Interaction
Interaction
Days
Days
CCA
CCA
Matching
Matching
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
2:VEH CON vs. 2:TUD CON
2:VEH CON vs. 7:VEH CON
2:VEH STM vs. 2:TUD STM
2:VEH STM vs. 7:VEH STM
2:TUD CON vs. 7:TUD CON
2:TUD STM vs. 7:TUD STM
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
P value Summary Significant?
0.7467 ns No
< 0.0001 **** Yes
0.2645 ns No
Difference t Summary
-0.215 1.036 ns
0.7304 3.518 **
0.6111 2.944 *
0.9454 4.554 ***
0.8261 3.98 **
-0.1193 0.5744 ns
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
Source of Variation
Interaction
Days
TUDCA
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
P value
P > 0.05
Comparison
2 Days :VEH vs. 2 Days :TUD
P < 0.05
P < 0.05
2 Days :VEH vs. 7 Days :VEH
2 Days :VEH vs. 7 Days :TUD
P < 0.05
P < 0.05
2 Days :TUD vs. 7 Days :VEH
2 Days :TUD vs. 7 Days :TUD
P > 0.057 Days :VEH vs. 7 Days :TUD
n VEH TUD VEH TUD
1 0.86 0.484 0.664 1
2 1.223 1.784 0.566 0.918
3 1.184 2.129 0.541 0.553
4 2.182 2.13 0.564 0.603
5 1.361 1.831 0.782 0.961
6 1.361 1.958 0.757 0.78
7 1.864 2.04 0.776 0.836
8 1.16 0.559 0.702 0.655
X 1.399 1.61438 0.669 0.78825
SEM 0.15 0.24265 0.03563 0.05995
ATF4 mRNA - CCA Stim/Cotnrol (ΔΔCt)
2 Days 7 Days
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n CTR STM CTR STM CTR STM CTR STM P value  Summary Significant?
1 1.1404 0.8391 1.5421 0.9739 1.4351 0.7626 1.3222 0.8147 0.014 * Yes
2 0.9079 2.5276 1.3647 0.555 1.3707 10.266 0.9619 0.6891 0.036 * Yes
3 0.9757 1.8008 2.7715 0.7353 1.4031 9.7295 1.8532 0.8036 0.0657 ns No
4 1.4397 14.92 1.3271 0.564 1.018 1.7526 1.6922 0.8009 0.4373 ns No
5 1.8593 6.9837 1.7803 1.0854 1.7778 14.615 2.1868 1.4964
6 1.2686 15.608 1.7756 0.5811 1.7186 10.526 1.0303 0.9786
7 0.9078 4.9679 1.2307 0.6995 1.2403 12.081 2.5317 1.3751 Days Difference t P value Summary
8 1.3393 1.8933 1.2302 1.1316 1.2661 1.499 1.2797 0.5763 2 -0.005 3.397 P < 0.05 **
X 1.2298 6.1926 1.6278 0.7907 1.4037 7.6539 1.6072 0.9418 7 0.00084 0.5729 P > 0.05 ns
SEM 0.1145 2.0994 0.1811 0.0844 0.0882 1.9255 0.198 0.1157
P value Summary Significant?
Difference t P value Summary 0.0025 ** Yes
-0.1739 0.1212 P > 0.05 ns 0.0058 ** Yes
-0.3979 0.2775 P > 0.05 ns 0.0101 * Yes
-1.461 1.019 P > 0.05 ns 0.4093 ns No
5.402 3.766 P < 0.05 *
-0.2035 0.1419 P > 0.05 ns
6.712 4.68 P < 0.05 *** Days Difference t P value Summary
0.0205 0.0143 P > 0.05 ns 2 -0.0063 4.703 P < 0.05 ***
-0.1511 0.1054 P > 0.05 ns 7 0.00067 0.5006 P > 0.05 ns
XBP1s mRNA - Control vs. CCA Stim (ΔCt)
VEHICLE TUDCA
2 Days 7 Days 2 Days 7 Days RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
Source of Variation
Source of Variation
Interaction
Interaction
Days
Days
CCA
CCA
Matching
Matching
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
2:VEH CON vs. 2:TUD CON
2:VEH CON vs. 7:VEH CON
2:VEH STM vs. 2:TUD STM
2:VEH STM vs. 7:VEH STM
2:TUD CON vs. 7:TUD CON
2:TUD STM vs. 7:TUD STM
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
n VEH TUD VEH TUD
1 0.736 0.531 0.632 0.616
2 2.784 7.489 0.407 0.716
3 1.846 6.934 0.265 0.434
4 10.363 1.722 0.425 0.473
5 3.756 8.221 0.61 0.684
6 3.756 6.125 0.327 0.95
7 5.473 9.741 0.568 0.543
8 1.414 1.184 0.92 0.45
X 3.766 5.24338 0.51925 0.60825
SEM 1.08396 1.25966 0.07404 0.06155
XBP1s mRNA - CCA Stim/Cotnrol (ΔΔCt)
2 Days 7 Days
P value Summary Significant?
0.4113 ns No
< 0.0001 **** Yes
0.3548 ns No
Difference t Summary
-1.477 1.255 ns
3.247 2.758 ns
3.158 2.683 ns
4.724 4.013 **
4.635 3.938 **
-0.089 0.07561 ns
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
Source of Variation
Interaction
Days
TUDCA
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
P value
P > 0.05
Comparison
2 Days :VEH vs. 2 Days :TUD
P > 0.05
P > 0.05
2 Days :VEH vs. 7 Days :VEH
2 Days :VEH vs. 7 Days :TUD
P < 0.05
P < 0.05
2 Days :TUD vs. 7 Days :VEH
2 Days :TUD vs. 7 Days :TUD
P > 0.057 Days :VEH vs. 7 Days :TUD
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n CTR STM CTR STM CTR STM CTR STM P value  Summary Significant?
1 0.4285 0.587 0.5028 0.682 0.4293 0.7316 0.397 0.5709 0.0379 * Yes
2 0.6006 1.2042 0.7097 1.0213 0.5976 3.8707 0.6839 1.1851 0.0797 ns No
3 0.471 0.6815 0.6863 0.5473 0.5272 2.9145 0.5929 0.6007 0.0174 * Yes
4 0.6866 4.5322 0.5513 0.7854 0.9404 3.0976 0.6007 0.6895 0.4171 ns No
5 0.5274 0.8216 0.5614 0.5356 0.5651 2.5362 0.6072 0.7256
6 0.4417 3.7677 0.6617 0.6413 0.4635 1.6914 0.4918 0.7315
7 0.4862 1.3579 0.6043 0.7422 0.5156 2.8782 0.3627 0.6107 Days Difference t P value Summary
8 0.5265 1.5411 0.496 0.6511 0.4518 1.2224 0.5129 0.6808 2 -0.1291 3.527 P < 0.05 **
X 0.5211 1.8116 0.5967 0.7008 0.5613 2.3678 0.5312 0.7244 7 -0.0104 0.2844 P > 0.05 ns
SEM 0.0306 0.5284 0.0291 0.0549 0.0578 0.3738 0.0392 0.0691
P value Summary Significant?
Difference t P value Summary 0.0004 *** Yes
-0.0403 0.1223 P > 0.05 ns 0.0014 ** Yes
-0.0757 0.2298 P > 0.05 ns < 0.0001 **** Yes
-0.5562 1.69 P > 0.05 ns 0.2395 ns No
1.111 3.375 P < 0.05 *
0.0302 0.0916 P > 0.05 ns
1.643 4.993 P < 0.05 *** Days Difference t P value Summary
0.0656 0.1992 P > 0.05 ns 2 -0.1807 7.348 P < 0.05 ****
-0.0236 0.0716 P > 0.05 ns 7 -0.0193 0.7858 P > 0.05 ns
BiP mRNA - Control vs. CCA Stim (ΔCt)
VEHICLE TUDCA
2 Days 7 Days 2 Days 7 Days RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
Source of Variation
Source of Variation
Interaction
Interaction
Days
Days
CCA
CCA
Matching
Matching
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
2:VEH CON vs. 2:TUD CON
2:VEH CON vs. 7:VEH CON
2:VEH STM vs. 2:TUD STM
2:VEH STM vs. 7:VEH STM
2:TUD CON vs. 7:TUD CON
2:TUD STM vs. 7:TUD STM
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
n VEH TUD VEH TUD
1 1.37 1.704 1.356 1.438
2 2.005 6.478 1.439 1.733
3 1.447 5.529 0.797 1.013
4 6.601 3.294 1.425 1.148
5 1.558 4.488 0.954 1.195
6 1.558 3.649 0.969 1.487
7 2.793 5.582 1.228 1.684
8 2.927 2.705 1.313 1.327
X 2.53238 4.17863 1.18513 1.37813
SEM 0.61938 0.5753 0.08662 0.09037
BiP mRNA - CCA Stim/Cotnrol (ΔΔCt)
2 Days 7 Days
P value Summary Significant?
0.1001 ns No
< 0.0001 **** Yes
0.0401 * Yes
Difference t Summary
-1.646 2.724 ns
1.347 2.23 ns
1.154 1.91 ns
2.994 4.954 ***
2.801 4.635 ***
-0.193 0.3194 ns
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
Source of Variation
Interaction
Days
TUDCA
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
P value
P > 0.05
Comparison
2 Days :VEH vs. 2 Days :TUD
P > 0.05
P > 0.05
2 Days :VEH vs. 7 Days :VEH
2 Days :VEH vs. 7 Days :TUD
P < 0.05
P < 0.05
2 Days :TUD vs. 7 Days :VEH
2 Days :TUD vs. 7 Days :TUD
P > 0.057 Days :VEH vs. 7 Days :TUD
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Table 5B: mRNA expression of UPRmt markers following TUDCA/vehicle treatment 
with 2 or 7 days of CCA. 
 
 
 
n CTR STM CTR STM CTR STM CTR STM P value  Summary Significant?
1 0.8172 1.6738 1.0066 2.0313 0.7933 1.1418 0.7987 2.0462 0.9759 ns No
2 0.7691 1.0536 0.9909 1.7024 0.7477 1.6532 0.8827 1.6976 0.6199 ns No
3 0.8135 1.1151 0.9123 1.5452 0.8842 1.5434 0.9051 1.5103 < 0.0001 **** Yes
4 1.1842 1.9704 1.0257 1.3504 0.9551 1.8814 0.9497 1.2744 0.0587 ns No
5 0.8703 1.2898 0.9527 1.4215 0.9141 1.6442 0.8925 1.4726
6 0.8477 1.5045 0.8099 1.3706 0.828 1.3843 0.7508 1.24
7 0.8591 1.7832 0.8448 1.5171 0.8343 1.217 0.7477 1.364 Days Difference t P value Summary
8 1.0285 1.6342 1.0251 1.4356 0.855 1.1686 0.7417 1.3419 2 -0.0604 7.34 P < 0.05 ****
X 0.8987 1.5031 0.946 1.5468 0.8515 1.4542 0.8336 1.4934 7 -0.0601 7.297 P < 0.05 ****
SEM 0.0489 0.115 0.0293 0.0799 0.0234 0.0951 0.0294 0.0945
P value Summary Significant?
Difference t P value Summary 0.6667 ns No
0.0472 0.4595 P > 0.05 ns 0.8879 ns No
-0.0473 0.4602 P > 0.05 ns < 0.0001 **** Yes
0.0488 0.4751 P > 0.05 ns 0.3105 ns No
-0.0437 0.4253 P > 0.05 ns
0.0179 0.1737 P > 0.05 ns
-0.0391 0.3808 P > 0.05 ns Days Difference t P value Summary
0.1124 1.093 P > 0.05 ns 2 -0.0603 6.579 P < 0.05 ****
0.0534 0.5196 P > 0.05 ns 7 -0.066 7.202 P < 0.05 ****
CPN10 mRNA - Control vs. CCA Stim (ΔCt)
VEHICLE TUDCA
2 Days 7 Days 2 Days 7 Days RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
Source of Variation
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
Source of Variation
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
2:VEH CON vs. 2:TUD CON
2:VEH CON vs. 7:VEH CON
2:VEH STM vs. 2:TUD STM
2:VEH STM vs. 7:VEH STM
2:TUD CON vs. 7:TUD CON
2:TUD STM vs. 7:TUD STM
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
n VEH TUD VEH TUD
1 2.048 1.439 2.018 2.562
2 1.37 2.211 1.718 1.923
3 1.371 1.746 1.694 1.669
4 1.664 1.97 1.317 1.342
5 1.482 1.799 1.492 1.65
6 1.482 1.672 1.692 1.652
7 2.076 1.459 1.796 1.824
8 1.589 1.367 1.4 1.809
X 1.635 1.70788 1.64088 1.80388
SEM 0.1 0.10206 0.08048 0.12447
CPN10 mRNA - CCA Stim/Cotnrol (ΔΔCt)
2 Days 7 Days
P value Summary Significant?
0.6637 ns No
0.6251 ns No
0.2616 ns No
Difference t Summary
-0.0726 0.4994 ns
-0.0056 0.03868 ns
-0.1686 1.16 ns
0.067 0.4607 ns
-0.096 0.6602 ns
-0.163 1.121 ns
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
Source of Variation
Interaction
Days
TUDCA
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison P value
2 Days :VEH vs. 2 Days :TUD P > 0.05
2 Days :VEH vs. 7 Days :VEH P > 0.05
2 Days :VEH vs. 7 Days :TUD P > 0.05
2 Days :TUD vs. 7 Days :VEH P > 0.05
2 Days :TUD vs. 7 Days :TUD P > 0.05
7 Days :VEH vs. 7 Days :TUD P > 0.05
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P value  Summary Significant?
0.23 ns No
n CTR STM CTR STM CTR STM CTR STM 0.1578 ns No
1 0.7626 1.1203 0.9245 0.9393 0.5555 0.6962 0.5842 1.1922 0.0346 * Yes
2 0.8107 0.8606 1.0075 1.2533 0.8232 1.3092 0.8939 1.2347 0.4714 ns No
3 0.7871 0.5311 0.8341 1.091 0.5666 0.8757 0.6863 0.9249
4 0.9361 0.7659 0.7373 1.0466 0.7774 0.7736 0.7718 0.8036
5 0.8269 1.272 0.7842 1.2159 0.878 0.9313 0.3786 0.5789 Days Difference t P value Summary
6 0.8405 0.8602 0.7853 0.9514 0.64 0.6523 0.6068 1.0878 2 -0.0074 0.8243 P > 0.05 ns
X 0.8273 0.9017 0.8455 1.0829 0.7068 0.8731 0.6536 0.9703 7 -0.0237 2.632 P > 0.05 ns
SEM 0.0246 0.1071 0.0415 0.0535 0.0562 0.0972 0.072 0.1026
P value Summary Significant?
Difference t P value Summary 0.2228 ns No
0.1392 1.578 P > 0.05 ns 0.8363 ns No
-0.0242 0.2741 P > 0.05 ns 0.0019 ** Yes
-0.0754 0.8552 P > 0.05 ns 0.0391 * Yes
-0.1437 1.628 P > 0.05 ns
0.0187 0.2115 P > 0.05 ns
-0.0381 0.4322 P > 0.05 ns Days Difference t P value Summary
0.182 2.063 P > 0.05 ns 2 -0.0166 2.032 P > 0.05 ns
0.0301 0.3411 P > 0.05 ns 7 -0.0317 3.87 P < 0.05 **
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
2:TUD CON vs. 7:TUD CON Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
2:TUD STM vs. 7:TUD STM
2:VEH STM vs. 2:TUD STM Matching
2:VEH STM vs. 7:VEH STM
2:VEH CON vs. 2:TUD CON
2:VEH CON vs. 7:VEH CON CCA
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
HSP60 mRNA - Control vs. CCA Stim (ΔCt)
VEHICLE TUDCA
2 Days 7 Days 2 Days 7 Days
RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
Source of Variation
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
Source of Variation
Interaction
Days
n VEH TUD VEH TUD
1 1.469 1.253 1.016 2.041
2 1.062 1.59 1.244 1.381
3 0.675 1.546 1.308 1.348
4 0.933 0.995 1.42 1.041
5 1.538 1.061 1.551 1.529
6 1.023 1.019 1.212 1.793
X 1.11667 1.244 1.29183 1.52217
SEM 0.13444 0.1091 0.07497 0.14426
HSP60 mRNA - CCA Stim/Cotnrol (ΔΔCt)
2 Days 7 Days P value Summary Significant?
0.6692 ns No
0.0708 ns No
0.1477 ns No
Difference t Summary
-0.1273 0.7582 ns
-0.1752 1.043 ns
-0.4055 2.414 ns
-0.0478 0.2848 ns
-0.2782 1.656 ns
-0.2303 1.371 ns7 Days :VEH vs. 7 Days :TUD P > 0.05
2 Days :TUD vs. 7 Days :VEH P > 0.05
2 Days :TUD vs. 7 Days :TUD P > 0.05
2 Days :VEH vs. 7 Days :VEH P > 0.05
2 Days :VEH vs. 7 Days :TUD P > 0.05
Comparison P value
2 Days :VEH vs. 2 Days :TUD P > 0.05
Interaction
Days
TUDCA
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
Source of Variation
 109 
  
n CTR STM CTR STM CTR STM CTR STM P value  Summary Significant?
1 0.3004 0.4236 0.4319 0.5045 0.3104 0.8868 0.1992 0.4481 0.5307 ns No
2 0.2907 0.4503 0.3279 0.4404 0.2838 0.523 0.3509 0.5195 0.7946 ns No
3 0.2983 0.2891 0.3249 0.322 0.2707 0.4009 0.1934 0.3876 0.0276 * Yes
4 0.4186 1.461 0.4481 0.4375 2.1871 2.703 0.3477 0.543 0.2011 ns No
5 0.2547 0.3298 0.3237 0.3433 0.279 0.3421 0.3357 0.4186
6 0.2619 0.4014 0.2259 0.4181 0.3201 0.3646 0.3029 0.4957
7 0.2694 0.2953 0.2365 0.5865 0.2844 0.4144 0.1865 0.2293 Days Difference t P value Summary
8 0.4594 0.5123 0.3949 0.6037 0.3135 0.7982 0.3257 0.54 2 -0.0002 2.193 P > 0.05 ns
X 0.3192 0.5203 0.3392 0.457 0.5311 0.8041 0.2803 0.4477 7 -0.0001 1.284 P > 0.05 ns
SEM 0.0271 0.1372 0.0291 0.0363 0.2367 0.2807 0.0261 0.0371
P value Summary Significant?
Difference t P value Summary 0.2139 ns No
-0.212 1.065 P > 0.05 ns 0.2596 ns No
-0.0201 0.1007 P > 0.05 ns < 0.0001 **** Yes
-0.2838 1.425 P > 0.05 ns < 0.0001 **** Yes
0.0634 0.3181 P > 0.05 ns
0.2509 1.26 P > 0.05 ns
0.3564 1.79 P > 0.05 ns Days Difference t P value Summary
0.059 0.2961 P > 0.05 ns 2 -0.0003 4.764 P < 0.05 ***
0.0093 0.0465 P > 0.05 ns 7 -0.0002 2.923 P < 0.05 *
ClpP mRNA - Control vs. CCA Stim (ΔCt)
VEHICLE TUDCA
2 Days 7 Days 2 Days 7 Days RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
Source of Variation
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
Source of Variation
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
2:VEH CON vs. 2:TUD CON
2:VEH CON vs. 7:VEH CON
2:VEH STM vs. 2:TUD STM
2:VEH STM vs. 7:VEH STM
2:TUD CON vs. 7:TUD CON
2:TUD STM vs. 7:TUD STM
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
n VEH TUD VEH TUD
1 1.41 2.857 1.168 2.25
2 1.549 1.843 1.343 1.48
3 0.969 1.481 0.991 2.004
4 3.49 1.236 0.976 1.562
5 1.295 1.226 1.061 1.247
6 1.295 1.139 1.851 1.637
7 1.096 1.457 2.48 1.23
8 1.115 2.546 1.529 1.658
X 1.52738 1.72313 1.42488 1.6335
SEM 0.28791 0.22883 0.18422 0.12384
ClpP mRNA - CCA Stim/Cotnrol (ΔΔCt)
2 Days 7 Days
P value Summary Significant?
0.9763 ns No
0.6581 ns No
0.3546 ns No
Difference t Summary
-0.1958 0.6444 ns
0.1025 0.3374 ns
-0.1061 0.3494 ns
0.2983 0.9819 ns
0.08963 0.2951 ns
-0.2086 0.6868 ns
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
Source of Variation
Interaction
Days
TUDCA
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison P value
2 Days :VEH vs. 2 Days :TUD P > 0.05
2 Days :VEH vs. 7 Days :VEH P > 0.05
2 Days :VEH vs. 7 Days :TUD P > 0.05
2 Days :TUD vs. 7 Days :VEH P > 0.05
2 Days :TUD vs. 7 Days :TUD P > 0.05
7 Days :VEH vs. 7 Days :TUD P > 0.05
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Table 5C: mRNA expression of PGC-1α  following TUDCA/vehicle treatment with 2 
or 7 days of CCA. 
 
 
  
n CTR STM CTR STM CTR STM CTR STM P value  Summary Significant?
1 0.408 6.5656 0.5495 3.0756 0.2388 0.9916 0.2522 4.7204 0.9023 ns No
2 0.6022 2.3407 0.8689 6.5926 0.7103 6.0618 0.7161 6.417 0.7607 ns No
3 0.4973 3.2151 0.4761 5.1879 0.2678 4.4429 0.4061 3.9583 < 0.0001 **** Yes
4 0.4166 1.1524 0.656 2.4948 0.422 4.3953 0.4133 1.758 0.2557 ns No
5 0.7844 4.4202 0.8264 2.3656 0.8827 4.9149 0.6749 3.3711
6 0.56 2.5276 0.4495 5.3152 0.661 4.7758 0.5398 2.5571
7 1.2298 8.8428 1.7781 7.0187 1.2111 7.5937 0.4025 4.5247 Days Difference t P value Summary
8 0.7 4.8954 0.5854 3.9069 0.4658 2.4299 0.6242 2.9293 2 -0.036 5.057 P < 0.05 ***
X 0.6498 4.245 0.7737 4.4946 0.6074 4.4507 0.5037 3.7795 7 -0.0372 5.233 P < 0.05 ***
SEM 0.0948 0.8882 0.1532 0.6383 0.1164 0.7177 0.0569 0.5158
P value Summary Significant?
Difference t P value Summary 0.495 ns No
0.0424 0.0595 P > 0.05 ns 0.4375 ns No
-0.1239 0.1741 P > 0.05 ns < 0.0001 **** Yes
-0.2058 0.2891 P > 0.05 ns 0.2546 ns No
-0.2497 0.3508 P > 0.05 ns
0.1038 0.1458 P > 0.05 ns
0.6712 0.943 P > 0.05 ns Days Difference t P value Summary
0.2701 0.3794 P > 0.05 ns 2 -0.0384 6.711 P < 0.05 ****
0.7152 1.005 P > 0.05 ns 7 -0.0328 5.72 P < 0.05 ***
PGC-1α mRNA - Control vs. CCA Stim (ΔCt)
VEHICLE TUDCA
2 Days 7 Days 2 Days 7 Days RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
Source of Variation
Source of Variation
Interaction
Interaction
Days
Days
CCA
CCA
Matching
Matching
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
2:VEH CON vs. 2:TUD CON
2:VEH CON vs. 7:VEH CON
2:VEH STM vs. 2:TUD STM
2:VEH STM vs. 7:VEH STM
2:TUD CON vs. 7:TUD CON
2:TUD STM vs. 7:TUD STM
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
n VEH TUD VEH TUD
1 16.093 4.152 5.597 18.716
2 3.887 8.535 7.587 8.961
3 6.465 16.591 10.898 9.746
4 2.766 10.416 3.803 4.254
5 5.635 5.568 2.862 4.995
6 5.635 7.225 11.826 4.737
7 7.19 6.27 3.947 11.243
8 6.994 5.217 6.673 4.693
X 6.83313 7.99675 6.64913 8.41813
SEM 1.42757 1.41414 1.16943 1.75545
PGC-1α mRNA - CCA Stim/Cotnrol (ΔΔCt)
2 Days 7 Days
P value Summary Significant?
0.8369 ns No
0.9356 ns No
0.3227 ns No
Difference t Summary
-1.164 0.5649 ns
0.184 0.08932 ns
-1.585 0.7694 ns
1.348 0.6542 ns
-0.4214 0.2046 ns
-1.769 0.8588 ns
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
Source of Variation
Interaction
Days
TUDCA
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
P value
P > 0.05
Comparison
2 Days :VEH vs. 2 Days :TUD
P > 0.05
P > 0.05
2 Days :VEH vs. 7 Days :VEH
2 Days :VEH vs. 7 Days :TUD
P > 0.05
P > 0.05
2 Days :TUD vs. 7 Days :VEH
2 Days :TUD vs. 7 Days :TUD
P > 0.057 Days :VEH vs. 7 Days :TUD
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Table 5D: mRNA expression of autophagy markers following TUDCA/vehicle 
treatment with 2 or 7 days of CCA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
P value  Summary Significant?
0.0038 ** Yes
n CTR STM CTR STM CTR STM CTR STM 0.0397 * Yes
1 0.1468 0.2505 0.2503 0.1662 0.1785 0.3055 0.2148 0.1583 0.0315 * Yes
2 0.2137 0.4475 0.1973 0.1719 0.293 0.3647 0.2067 0.2233 0.1693 ns No
3 0.1397 0.226 0.1432 0.1374 0.16 0.2755 0.1503 0.1282
4 0.1914 0.5728 0.205 0.1663 0.2353 0.4854 0.2015 0.1844
5 0.1565 0.2483 0.1665 0.1422 0.1935 0.3625 0.2439 0.2036 Days Difference t P value Summary
6 0.1916 0.2605 0.1564 0.1423 0.1998 0.4213 0.1798 0.2186 2 -0.161 4.413 P < 0.05 **
X 0.1733 0.3343 0.1864 0.1544 0.21 0.3692 0.1995 0.1861 7 0.03206 0.8789 P > 0.05 ns
SEM 0.0121 0.0581 0.016 0.0062 0.0195 0.0312 0.013 0.0151
P value Summary Significant?
Difference t P value Summary 0.0002 *** Yes
-0.0368 0.9853 P > 0.05 ns 0.0032 ** Yes
-0.0132 0.3534 P > 0.05 ns 0.0009 *** Yes
-0.0349 0.9353 P > 0.05 ns 0.0736 ns No
0.1799 4.822 P < 0.05 ***
0.0105 0.2824 P > 0.05 ns
0.1831 4.908 P < 0.05 *** Days Difference t P value Summary
-0.013 0.3496 P > 0.05 ns 2 -0.1591 7.223 P < 0.05 ****
-0.0317 0.8492 P > 0.05 ns 7 0.01342 0.6092 P > 0.05 ns
2:TUD CON vs. 7:TUD CON
2:TUD STM vs. 7:TUD STM
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
2:VEH CON vs. 7:VEH CON
2:VEH STM vs. 2:TUD STM
2:VEH STM vs. 7:VEH STM
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
2:VEH CON vs. 2:TUD CON
p62 mRNA - Control vs. CCA Stim (ΔCt)
VEHICLE TUDCA
2 Days 7 Days 2 Days 7 Days
RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
Source of Variation
Interaction
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
Days
CCA
Matching
Matching
CCA
Days
Interaction
Source of Variation
Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
n VEH TUD VEH TUD
1 1.706 1.711 0.664 0.737
2 2.094 1.245 0.871 1.08
3 1.618 1.722 0.96 0.853
4 1.618 2.063 0.811 0.915
5 1.587 1.873 0.854 0.835
6 1.36 2.108 0.91 1.216
X 1.664 1.787 0.845 0.93933
SEM 0.098 0.12785 0.04168 0.07216
p62 mRNA - CCA Stim/Cotnrol (ΔΔCt)
2 Days 7 Days P value Summary Significant?
0.8754 ns No
< 0.0001 **** Yes
0.2447 ns No
Difference t Summary
-0.1232 0.9598 ns
0.8188 6.381 ****
0.7245 5.646 ****
0.942 7.341 ****
0.8477 6.606 ****
-0.0943 0.7351 ns
2 Days :TUD vs. 7 Days :VEH P < 0.05
2 Days :TUD vs. 7 Days :TUD P < 0.05
7 Days :VEH vs. 7 Days :TUD P > 0.05
2 Days :VEH vs. 2 Days :TUD P > 0.05
2 Days :VEH vs. 7 Days :VEH P < 0.05
2 Days :VEH vs. 7 Days :TUD P < 0.05
Days
TUDCA
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison P value
Source of Variation
Interaction
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
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P value  Summary Significant?
n CTR STM CTR STM CTR STM CTR STM 0.497 ns No
1 0.9199 0.8327 1.2557 1.0074 1.3838 0.9313 1.0577 0.8917 0.6788 ns No
2 1.615 1.7059 2.2917 1.8048 2.1117 1.8999 2.666 1.7513 0.0474 * Yes
3 1.7717 1.4959 1.8096 1.5554 2.2806 2.1897 1.555 1.6048 0.0009 *** Yes
4 1.546 1.7037 1.624 1.7522 1.7705 1.4413 1.8206 1.8198
5 1.7087 1.854 1.7494 1.4282 2.0739 2.0252 1.6722 1.4487
6 1.5564 1.1371 1.3593 1.3817 1.8834 1.6563 3.0556 2.2654 Days Difference t P value Summary
7 1.7905 1.5522 1.5825 1.5342 1.9061 2.2628 1.3162 1.3005 2 0.00895 1.067 P > 0.05 ns
X 1.5583 1.4688 1.6675 1.4948 1.9157 1.7724 1.8776 1.5832 7 0.01726 2.057 P > 0.05 ns
SEM 0.1127 0.1365 0.1282 0.1003 0.1093 0.1776 0.2737 0.1638
P value Summary Significant?
Difference t P value Summary 0.4138 ns No
-0.3574 1.586 P > 0.05 ns 0.6628 ns No
-0.1092 0.4845 P > 0.05 ns 0.0304 * Yes
-0.3036 1.347 P > 0.05 ns 0.0005 *** Yes
-0.026 0.1156 P > 0.05 ns
0.0381 0.1692 P > 0.05 ns
0.1892 0.8398 P > 0.05 ns Days Difference t P value Summary
-0.2101 0.9328 P > 0.05 ns 2 0.01434 1.136 P > 0.05 ns
-0.0883 0.392 P > 0.05 ns 7 0.02945 2.333 P > 0.05 ns
LC3 mRNA - Control vs. CCA Stim (ΔCt)
VEHICLE TUDCA
2 Days 7 Days 2 Days 7 Days
RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
Source of Variation
Interaction
Days
CCA
Matching
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
Source of Variation
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
2:VEH CON vs. 2:TUD CON
2:VEH CON vs. 7:VEH CON
2:VEH STM vs. 2:TUD STM
2:VEH STM vs. 7:VEH STM
2:TUD CON vs. 7:TUD CON
2:TUD STM vs. 7:TUD STM
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
n VEH TUD VEH TUD
1 0.905 0.673 0.802 0.843
2 1.056 0.9 0.788 0.657
3 0.844 0.96 0.86 1.032
4 1.102 0.814 1.079 1
5 1.102 0.977 0.816 0.866
6 0.731 0.879 1.016 0.741
7 0.867 1.187 0.969 0.988
X 0.944 0.91286 0.90429 0.87529
SEM 0.055 0.05978 0.0439 0.05337
LC3 mRNA - CCA Stim/Cotnrol (ΔΔCt)
2 Days 7 Days P value Summary Significant?
0.9852 ns No
0.4757 ns No
0.5782 ns No
Difference t Summary
0.031 0.4118 ns
0.03957 0.5257 ns
0.06857 0.911 ns
0.00857 0.1139 ns
0.03757 0.4991 ns
0.029 0.3853 ns
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
Source of Variation
Interaction
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison P value
2 Days :VEH vs. 2 Days :TUD P > 0.05
2 Days :VEH vs. 7 Days :VEH P > 0.05
2 Days :VEH vs. 7 Days :TUD P > 0.05
2 Days :TUD vs. 7 Days :VEH P > 0.05
2 Days :TUD vs. 7 Days :TUD P > 0.05
7 Days :VEH vs. 7 Days :TUD P > 0.05
Days
TUDCA
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Table 6A: Protein expression of UPRER markers following TUDCA/vehicle 
treatment with 2 or 7 days of CCA. 
 
 
 
 
 
  
P value  Summary Significant?
n CTR STM CTR STM CTR STM CTR STM 0.4342 ns No
1 0.2548 1.1821 0.6716 1.2495 0.2591 0.5041 0.5048 0.9653 0.0888 ns No
2 0.3759 0.5395 0.5872 0.9137 0.568 0.7024 0.4526 0.8297 < 0.0001 **** Yes
3 0.8474 1.219 0.9031 1.6216 0.4841 0.7203 1.1661 1.7257 0.0061 ** Yes
4 0.5119 1.1257 1.2902 1.3714 0.3329 0.588 0.5861 0.8635
5 0.6491 1.422 0.6407 1.3778 0.6865 0.9926 0.3667 0.9291
6 0.0562 0.3674 0.3387 0.4361 0.3378 0.4293 0.213 0.4553 Days Difference t P value Summary
7 0.1793 0.8262 0.7364 0.8384 0.5166 1.0974 0.5074 1.445 2 -0.4821 4.664 P < 0.05 ***
X 0.4107 0.9546 0.7383 1.1155 0.455 0.7192 0.5424 1.0305 7 -0.3644 3.526 P < 0.05 **
SEM 0.1049 0.1466 0.1121 0.1533 0.0573 0.0933 0.1135 0.1595
P value Summary Significant?
Difference t P value Summary 0.102 ns No
-0.1067 0.6623 P > 0.05 ns 0.4288 ns No
-0.3301 2.048 P > 0.05 ns < 0.0001 **** Yes
0.1024 0.6355 P > 0.05 ns 0.0001 *** Yes
-0.2124 1.318 P > 0.05 ns
-0.0329 0.2041 P > 0.05 ns
-0.2093 1.299 P > 0.05 ns Days Difference t P value Summary
0.1905 1.182 P > 0.05 ns 2 -0.273 3.83 P < 0.05 **
0.1055 0.6548 P > 0.05 ns 7 -0.4494 6.305 P < 0.05 ****
CHOP Protein - Control vs. CCA Stim
VEHICLE TUDCA RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
Source of Variation2 Days 7 Days 2 Days 7 Days
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
Source of Variation
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
2:VEH CON vs. 2:TUD CON
2:VEH CON vs. 7:VEH CON
2:VEH STM vs. 2:TUD STM
2:VEH STM vs. 7:VEH STM
2:TUD CON vs. 7:TUD CON
2:TUD STM vs. 7:TUD STM
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
n VEH TUD VEH TUD
1 4.639 1.946 1.86 1.912
2 1.435 1.237 1.556 1.833
3 1.439 1.488 1.796 1.48
4 2.199 1.767 1.063 1.473
5 2.191 1.446 2.15 2.533
6 6.541 1.271 1.287 2.138
7 4.607 2.124 1.139 2.848
X 3.293 1.61129 1.55014 2.031
SEM 0.746 0.12887 0.15368 0.19514
CHOP Protein - CCA Stim/Cotnrol
2 Days 7 Days P value Summary Significant?
0.0121 * Yes
0.1099 ns No
0.1449 ns No
Difference t Summary
1.682 2.984 *
1.743 3.093 *
1.262 2.239 ns
0.06114 0.1085 ns
-0.4197 0.7448 ns
-0.4809 0.8533 ns
2:TUD vs. 7:VEH P > 0.05
2:TUD vs. 7:TUD P > 0.05
7:VEH vs. 7:TUD P > 0.05
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
Source of Variation
Interaction
Days
TUDCA
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison P value
2:VEH vs. 2:TUD P < 0.05
2:VEH vs. 7:VEH P < 0.05
2:VEH vs. 7:TUD P > 0.05
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P value  Summary Significant?
n CTR STM CTR STM CTR STM CTR STM 0.226 ns No
1 0.2217 0.7085 0.4166 1.0958 0.412 0.6684 0.5515 0.7848 0.2773 ns No
2 0.3986 1.1017 0.5246 1.1224 0.8067 1.4004 0.7528 2.1326 < 0.0001 **** Yes
3 0.5772 1.5342 0.6707 1.6621 0.8221 1.5232 0.6456 0.9512 0.0341 * Yes
4 0.5468 1.3475 1.2406 1.3867 0.7142 1.4061 0.6427 0.826
5 0.6559 1.1109 0.6641 0.9862 0.5059 0.863 0.4821 0.9494
6 0.3257 0.8324 0.4207 0.9951 0.4748 0.8548 0.473 1.0483 Days Difference t P value Summary
7 0.3619 0.8942 0.4628 0.9656 0.4826 0.7714 0.3948 1.2394 2 -0.7045 7.757 P < 0.05 ****
X 0.4543 1.1059 0.6562 1.2081 0.6226 1.1193 0.5913 1.1154 7 -0.5419 5.966 P < 0.05 ****
SEM 0.0678 0.1258 0.1254 0.1084 0.0735 0.1487 0.0444 0.2071
P value Summary Significant?
Difference t P value Summary 0.442 ns No
-0.1428 1.028 P > 0.05 ns 0.8032 ns No
-0.2018 1.452 P > 0.05 ns < 0.0001 **** Yes
0.0613 0.4413 P > 0.05 ns 0.0677 ns No
-0.0391 0.2815 P > 0.05 ns
0.0343 0.2466 P > 0.05 ns
-0.0986 0.71 P > 0.05 ns Days Difference t P value Summary
0.0932 0.671 P > 0.05 ns 2 -0.5004 4.214 P < 0.05 **
0.0018 0.0128 P > 0.05 ns 7 -0.6333 5.333 P < 0.05 ***
2:TUD STM vs. 7:TUD STM
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
2:VEH STM vs. 2:TUD STM Matching
2:VEH STM vs. 7:VEH STM
2:TUD CON vs. 7:TUD CON Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
2:VEH CON vs. 2:TUD CON
2:VEH CON vs. 7:VEH CON CCA
RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
Source of Variation
Interaction
Days
CCA
Matching
HSP70 Protein - Control vs. CCA Stim
VEHICLE TUDCA
2 Days 7 Days 2 Days 7 Days
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
Source of Variation
Interaction
Days
n VEH TUD VEH TUD
1 3.196 1.623 2.63 1.423
2 2.764 1.736 2.14 2.833
3 2.658 1.853 2.478 1.473
4 2.464 1.969 1.118 1.285
5 1.694 1.706 1.485 1.969
6 2.555 1.8 2.365 2.216
7 2.47 1.599 2.086 3.14
X 2.543 1.75514 2.04314 2.04843
SEM 0.171 0.04927 0.20792 0.27371
2 Days 7 Days
HSP70 Protein - CCA Stim/Cotnrol
P value Summary Significant?
0.0514 ns No
0.5983 ns No
0.0544 ns No
Difference t Summary
0.7879 2.88 *
0.4999 1.827 ns
0.4946 1.808 ns
-0.288 1.053 ns
-0.2933 1.072 ns
-0.0053 0.01932 ns
2:TUD vs. 7:TUD P > 0.05
7:VEH vs. 7:TUD P > 0.05
2:VEH vs. 7:VEH P > 0.05
2:VEH vs. 7:TUD P > 0.05
2:TUD vs. 7:VEH P > 0.05
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison P value
2:VEH vs. 2:TUD P < 0.05
Interaction
Days
TUDCA
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
Source of Variation
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Table 6B: Protein expression of UPRmt markers following TUDCA/vehicle 
treatment with 2 or 7 days of CCA. 
 
 
 
 
  
n CTR STM CTR STM CTR STM CTR STM P value  Summary Significant?
1 0.7959 1.3119 1.0376 1.5589 1.0277 1.6373 1.1594 1.3506 0.018 * Yes
2 0.7109 0.8269 0.4714 0.9839 0.7437 0.8444 0.6442 1.0828 0.2019 ns No
3 0.4732 0.4977 0.6995 1.0928 0.6797 0.9713 1.0027 1.355 0.0002 *** Yes
4 0.5749 0.5273 0.6086 0.7993 0.5294 0.6235 0.5725 1.0751 0.0002 *** Yes
5 0.825 0.8583 0.6212 0.8346 0.907 0.7624 0.573 1.0622
6 1.009 0.8205 0.4018 0.5259 0.5165 0.4711 0.386 0.7618
7 0.7535 0.9437 0.9157 1.4559 0.9561 0.8933 0.7571 1.31 Days Difference t P value Summary
8 0.2139 0.4872 1.0516 1.5728 0.8485 1.1231 0.9846 1.8714 2 -0.1146 1.655 P > 0.05 ns
X 0.6695 0.7842 0.7259 1.103 0.7761 0.9158 0.7599 1.2336 7 -0.3771 5.445 P < 0.05 ***
SEM 0.0865 0.099 0.0881 0.1379 0.0677 0.1253 0.0938 0.115
P value Summary Significant?
Difference t P value Summary 0.01 * Yes
-0.1065 0.725 P > 0.05 ns 0.2798 ns No
-0.0564 0.3838 P > 0.05 ns < 0.0001 **** Yes
-0.1316 0.8957 P > 0.05 ns 0.0012 ** Yes
-0.3188 2.17 P > 0.05 ns
0.0161 0.1097 P > 0.05 ns
-0.3178 2.163 P > 0.05 ns Days Difference t P value Summary
-0.034 0.2315 P > 0.05 ns 2 -0.1397 1.761 P > 0.05 ns
-0.1306 0.8888 P > 0.05 ns 7 -0.4737 5.97 P < 0.05 ****
2:TUD STM vs. 7:TUD STM
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
2:VEH STM vs. 2:TUD STM Matching
2:VEH STM vs. 7:VEH STM
2:TUD CON vs. 7:TUD CON Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
2:VEH CON vs. 2:TUD CON
2:VEH CON vs. 7:VEH CON CCA
CPN10 Protein - Control vs. CCA Stim
VEHICLE TUDCA
RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
Source of Variation
2 Days 7 Days 2 Days 7 Days
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
Source of Variation
Interaction
Days
n VEH TUD VEH TUD
1 1.648 1.593 1.502 1.165
2 1.163 1.135 2.087 1.681
3 1.052 1.429 1.562 1.351
4 0.917 1.178 1.313 1.878
5 1.04 0.841 1.343 1.854
6 0.813 0.912 1.309 1.973
7 1.252 0.934 1.59 1.73
8 2.278 1.324 1.496 1.901
X 1.27 1.16825 1.52525 1.69163
SEM 0.169 0.09463 0.0894 0.10169
2 Days 7 Days
CPN10 Protein - CCA Stim/Cotnrol
P value Summary Significant?
0.2659 ns No
0.0027 ** Yes
0.7879 ns No
Difference t Summary
0.1021 0.6106 ns
-0.2549 1.524 ns
-0.4213 2.519 ns
-0.357 2.135 ns
-0.5234 3.129 *
-0.1664 0.9948 ns
2 Days :TUD vs. 7 Days :TUD P < 0.05
7 Days :VEH vs. 7 Days :TUD P > 0.05
2 Days :VEH vs. 7 Days :VEH P > 0.05
2 Days :VEH vs. 7 Days :TUD P > 0.05
2 Days :TUD vs. 7 Days :VEH P > 0.05
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison P value
2 Days :VEH vs. 2 Days :TUD P > 0.05
Interaction
Days
TUDCA
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
Source of Variation
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Table 6C: Protein expression of Uqcrc2 following TUDCA/vehicle treatment with 2 
or 7 days of CCA. 
 
   
P value  Summary Significant?
n CTR STM CTR STM CTR STM CTR STM 0.888 ns No
1 0.9757 1.0663 0.775 1.491 0.2873 0.7757 0.6121 1.2933 0.2868 ns No
2 0.2208 0.4578 0.4772 0.9282 0.1247 0.1744 0.9401 1.1358 < 0.0001 **** Yes
3 0.6119 1.0395 0.8522 1.1477 0.5444 0.613 0.8225 0.85 0.0332 * Yes
4 0.3453 0.6345 0.4189 0.9534 0.6581 0.7583 0.8349 0.934
5 0.5319 1.2056 0.5053 1.0403 0.6159 1.6533 0.2752 0.8361
6 0.4219 0.6741 0.4532 0.5548 0.6269 0.7067 0.4873 0.5208 Days Difference t P value Summary
7 0.2599 1.2367 0.9255 1.0955 0.751 1.038 0.5942 1.3723 2 -0.421 4.177 P < 0.05 **
X 0.4811 0.9021 0.6296 1.0301 0.5155 0.8171 0.6523 0.9918 7 -0.4005 3.974 P < 0.05 **
SEM 0.098 0.1166 0.0805 0.1061 0.0851 0.1704 0.0872 0.1119
P value Summary Significant?
Difference t P value Summary 0.84 ns No
-0.0344 0.2205 P > 0.05 ns 0.29 ns No
-0.1485 0.9521 P > 0.05 ns 0.0044 ** Yes
0.085 0.545 P > 0.05 ns 0.0758 ns No
-0.128 0.8207 P > 0.05 ns
-0.1369 0.8773 P > 0.05 ns
-0.1747 1.12 P > 0.05 ns Days Difference t P value Summary
-0.0227 0.1456 P > 0.05 ns 2 -0.3016 2.327 P > 0.05 ns
0.0384 0.2459 P > 0.05 ns 7 -0.3394 2.618 P < 0.05 *
2:TUD STM vs. 7:TUD STM
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
2:VEH STM vs. 2:TUD STM Matching
2:VEH STM vs. 7:VEH STM
2:TUD CON vs. 7:TUD CON Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
2:VEH CON vs. 2:TUD CON
2:VEH CON vs. 7:VEH CON CCA
Uqcrc2 Protein - Control vs. CCA Stim
VEHICLE TUDCA RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
Source of Variation2 Days 7 Days 2 Days 7 Days
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
Source of Variation
Interaction
Days
n VEH TUD VEH TUD
1 1.093 2.7 1.924 2.113
2 2.074 1.399 1.945 1.208
3 1.699 1.126 1.347 1.033
4 1.838 1.152 2.276 1.119
5 2.266 2.684 2.059 3.038
6 1.598 1.127 1.224 1.069
7 4.758 1.382 1.184 2.309
X 2.189 1.65286 1.70843 1.69843
SEM 0.451 0.27179 0.16817 0.29898
2 Days 7 Days
Uqcrc2 Protein - CCA Stim/Cotnrol
P value Summary Significant?
0.4102 ns No
0.4949 ns No
0.3929 ns No
Difference t Summary
0.5366 1.208 ns
0.481 1.083 ns
0.491 1.105 ns
-0.0556 0.1251 ns
-0.0456 0.1026 ns
0.01 0.02251 ns
2 Days :TUD vs. 7 Days :TUD P > 0.05
7 Days :VEH vs. 7 Days :TUD P > 0.05
2 Days :VEH vs. 7 Days :VEH P > 0.05
2 Days :VEH vs. 7 Days :TUD P > 0.05
2 Days :TUD vs. 7 Days :VEH P > 0.05
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison P value
2 Days :VEH vs. 2 Days :TUD P > 0.05
Interaction
Days
TUDCA
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
Source of Variation
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Table 6D: Protein expression of autophagy markers following TUDCA/vehicle 
treatment with 2 or 7 days of CCA. 
 
 
 
 
 
 
P value  Summary Significant?
n CTR STM CTR STM CTR STM CTR STM 0.0929 ns No
1 0.6866 0.9562 1.2332 1.5689 0.8754 2.0209 1.373 1.1471 0.9307 ns No
2 1.1338 1.6761 0.8139 0.8418 0.9243 1.0935 1.0527 1.4119 0.0853 ns No
3 1.3134 1.6527 1.4971 1.1799 1.1734 1.8217 0.9 1.343 0.0002 *** Yes
4 0.4677 0.666 0.4613 0.6809 0.7539 1.168 0.6132 0.8277
5 0.5058 0.6971 0.4575 0.5821 0.599 0.865 0.4345 0.4852
6 0.8275 0.8513 0.8718 0.3284 0.498 0.9678 1.1535 1.5923 Days Difference t P value Summary
7 0.3664 0.5445 0.6975 0.8735 0.4189 0.6178 0.7062 0.6416 2 -0.249 2.617 P < 0.05 *
X 0.6626 1.0063 0.754 0.8651 0.6554 1.2221 0.7791 1.0641 7 -0.0033 0.03489 P > 0.05 ns
SEM 0.1502 0.1771 0.1661 0.1541 0.1276 0.1936 0.1547 0.1584
P value Summary Significant?
Difference t P value Summary 0.09 ns No
0.0083 0.0389 P > 0.05 ns 0.9666 ns No
-0.1045 0.489 P > 0.05 ns 0.0018 ** Yes
-0.2158 1.01 P > 0.05 ns 0.0026 ** Yes
0.1412 0.6608 P > 0.05 ns
-0.1415 0.6621 P > 0.05 ns
0.158 0.7396 P > 0.05 ns Days Difference t P value Summary
-0.0287 0.1342 P > 0.05 ns 2 -0.4731 4.121 P < 0.05 **
-0.199 0.9316 P > 0.05 ns 7 -0.1737 1.513 P > 0.05 ns
2:TUD STM vs. 7:TUD STM
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
2:VEH STM vs. 2:TUD STM Matching
2:VEH STM vs. 7:VEH STM
2:TUD CON vs. 7:TUD CON Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
2:VEH CON vs. 2:TUD CON
2:VEH CON vs. 7:VEH CON CCA
p62 Protein - Control vs. CCA Stim
VEHICLE TUDCA RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
Source of Variation2 Days 7 Days 2 Days 7 Days
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
Source of Variation
Interaction
Days
n VEH TUD VEH TUD
1 1.393 2.309 1.272 0.835
2 1.478 1.183 1.034 1.341
3 1.258 1.552 0.788 1.492
4 1.424 1.549 1.476 1.35
5 1.378 1.444 1.272 1.117
6 1.029 1.943 0.377 1.38
7 1.486 1.475 1.252 0.909
X 1.349 1.63643 1.06729 1.20343
SEM 0.061 0.14056 0.14147 0.09571
2 Days 7 Days
p62 Protein - CCA Stim/Cotnrol
P value Summary Significant?
0.517 ns No
0.0047 ** Yes
0.0774 ns No
Difference t Summary
-0.287 1.77 ns
0.2821 1.74 ns
0.146 0.9002 ns
0.5691 3.509 *
0.433 2.67 ns
-0.1361 0.8394 ns
2 Days :TUD vs. 7 Days :TUD P > 0.05
7 Days :VEH vs. 7 Days :TUD P > 0.05
2 Days :VEH vs. 7 Days :VEH P > 0.05
2 Days :VEH vs. 7 Days :TUD P > 0.05
2 Days :TUD vs. 7 Days :VEH P < 0.05
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison P value
2 Days :VEH vs. 2 Days :TUD P > 0.05
Interaction
Days
TUDCA
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
Source of Variation
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n CTR STM CTR STM CTR STM CTR STM P value  Summary Significant?
1 0.4702 0.9213 0.5324 0.6221 0.8336 0.9733 0.6116 0.6239 0.7914 ns No
2 0.2321 0.3757 0.3971 0.8829 0.4576 0.4232 1.2508 0.9229 0.2992 ns No
3 0.3204 0.3433 0.4988 0.4437 1.1166 0.6296 0.3589 0.4028 0.2891 ns No
4 0.6297 0.4163 0.8418 0.4583 0.782 0.7959 0.2296 0.4209 0.0336 * Yes
5 0.9813 0.565 1.2649 0.9449 0.4025 0.2953 0.5844 0.3164
6 0.5357 0.4289 0.7453 0.5335 0.1739 0.2531 1.0657 0.8049
7 0.3309 0.5239 1.6659 1.0351 0.7824 0.6055 1.8978 0.8523 Days Difference t P value Summary
8 1.2385 0.5829 0.233 0.3004 0.1839 0.6949 0.8339 0.9762 2 0.07269 0.5885 P > 0.05 ns
X 0.5923 0.5197 0.7724 0.6526 0.5916 0.5839 0.8541 0.665 7 0.1198 0.9698 P > 0.05 ns
SEM 0.124 0.0652 0.1696 0.095 0.1196 0.0876 0.1917 0.0916
P value Summary Significant?
Difference t P value Summary 0.3129 ns No
-0.18 0.9612 P > 0.05 ns 0.3051 ns No
-0.18 0.9612 P > 0.05 ns 0.2752 ns No
-0.1329 0.7098 P > 0.05 ns 0.0132 * Yes
-0.1329 0.7098 P > 0.05 ns
-0.0817 0.4362 P > 0.05 ns
-0.0124 0.0664 P > 0.05 ns Days Difference t P value Summary
-0.0817 0.4362 P > 0.05 ns 2 0.00769 0.06277 P > 0.05 ns
-0.0124 0.0664 P > 0.05 ns 7 0.1891 1.543 P > 0.05 ns
RM 2-Way ANOVA - TUDCA- Control vs CCA Stim
Source of Variation
Interaction
Days
Interaction
Days
CCA
Matching
Bonferroni Post Hoc Test - VEHICLE - Control vs CCA Stim
LC3-II: LC3-I Protein - Control vs. CCA Stim
VEHICLE TUDCA
RM 2-Way ANOVA - VEHICLE - Control vs CCA Stim
Source of Variation
2 Days 7 Days 2 Days 7 Days
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison
2:VEH CON vs. 2:TUD CON
2:VEH CON vs. 7:VEH CON CCA
2:VEH STM vs. 2:TUD STM Matching
2:VEH STM vs. 7:VEH STM
2:TUD CON vs. 7:TUD CON Bonferroni Post Hoc Test - TUDCA - Control vs CCA Stim
2:TUD STM vs. 7:TUD STM
7:VEH CON vs. 7:TUD CON
7:VEH STM vs. 7:TUD STM
n VEH TUD VEH TUD
1 1.959 1.168 1.168 1.02
2 1.619 0.925 2.224 0.738
3 1.071 0.564 0.889 1.122
4 0.661 1.018 0.544 1.833
5 0.576 0.734 0.747 0.541
6 0.801 1.456 0.716 0.755
7 1.583 0.774 0.621 0.449
8 0.471 3.778 1.29 1.171
X 1.093 1.30213 1.02488 0.95363
SEM 0.198 0.36696 0.1943 0.15608
LC3-II: LC3-I Protein - CCA Stim/Cotnrol
2 Days 7 Days
P value Summary Significant?
0.5679 ns No
0.3987 ns No
0.778 ns No
Difference t Summary
-0.2095 0.61 ns
0.06775 0.1973 ns
0.139 0.4047 ns
0.2773 0.8072 ns
0.3485 1.015 ns
0.07125 0.2074 ns
2-Way ANOVA - RELATIVE CHANGE - CCA Stim/Control
Source of Variation
Interaction
Days
TUDCA
Bonferroni Post Hoc Test - MULTIPLE COMPARISONS - Control vs CCA Stim
Comparison P value
2 Days :VEH vs. 2 Days :TUD P > 0.05
2 Days :TUD vs. 7 Days :TUD P > 0.05
7 Days :VEH vs. 7 Days :TUD P > 0.05
2 Days :VEH vs. 7 Days :VEH P > 0.05
2 Days :VEH vs. 7 Days :TUD P > 0.05
2 Days :TUD vs. 7 Days :VEH P > 0.05
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APPENDIX B: SUPPLEMENTARY AND ADDITIONAL DATA 
(STATISTIC TABLES NOT SHOWN) 
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Fig. S1 
 
 
Figure S1. Fold-change in protein level of mitochondrial biogenesis marker (A) PGC-1α, 
and ETC components (B) COX IV and (C) Uqcrc2 (PGC-1α, n=5; COX IV, Uqcrc2, 
n=6, per day), and (D) mRNA expression of complex III subunit 1, Uqcrc1, throughout 
1-7 days of CCA (n=7, per day). Bars represent fold-change in stimulated muscle relative 
to matched controls; means ± SEM. *P<0.05, stimulated vs. control TA muscle at a 
given time point. 
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Fig. S2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. Time-course in the mRNA expression of mitophagy marker NIX following 1-
7 days of CCA (n=6, per day). Bars represent fold-change in stimulated muscle relative to 
matched controls; means ± SEM. *P<0.05, stimulated vs. control TA muscle at a given 
time point. 
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Fig. S3 
 
 
 
Figure S3. Fold-change in the (A) full length mRNA expression of UPRER transcription 
factor XBP1t, and (B) the antioxidant transcript NQO1, following repeated contractile 
bouts from 1-7 days (XBP1t, and NQO1, n=6). Associated protein expression of (C) 
ATF4, (D) ATF6, and (E) p-eIF2α (ATF6, n=7; p-eIF2α, and ATF4, n=6, per day). Bars 
represent fold-change in stimulated muscle relative to matched controls; means ± SEM. 
*P<0.05, stimulated vs. control TA muscle at a given time point. 
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Fig. S4 
 
 
Figure S4. Fold-change in the mRNA expression of UPRmt factors (A) ERα, (B) SirT3, 
(C) LonP, and (D) protein phosphorylation of activating kinase JNK throughout 1-7 days 
of muscle contractile activity (all graphs, n=6, per day). Bars represent fold-change in 
control TA muscle at a given time point. 
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Fig. S5 
 
 
Figure S5. CCA-induced changes in protein expression of (A) phosphorylated eIF2α and 
(B) BiP thought repeated muscle contractile activity over 1-7 days (p-eIF2α, n=8; BiP, 
n=7, per day/treatment). Open grey, and open white bars represent control muscle in 
vehicle-, and TUDCA-treated animals, respectively; hatched grey, and hatched white bars 
represent stimulated muscle in vehicle-, and TUDCA-treated animals, respectively. 
Values represent means ± SEM. *P<0.05, stimulated vs. control TA muscle at a given 
time point and treatment. 
 
 
 
2 7
0.0
0.5
1.0
1.5
Bi
P 
Pr
ot
ein
 
(A
.
U
.
)
Days of Stimulation
*
2 7
0.0
0.5
1.0
1.5
p-
eI
F2
α
 
Pr
o
te
in
 
(A
.
U
.
)
**
*
*
Days of Stimulation
p-eIF2α 
GAPDH 
C     S      C     S      C     S      C     S 
VEH        TUD        VEH       TUD   
2                              7 
A 
BiP 
GAPDH 
C     S      C     S      C     S      C     S 
VEH        TUD        VEH       TUD   
2                              7 
B 
VEH CON
VEH STM 
TUD CON
TUD STM
 125 
Fig. S6 
 
Figure S6. 1-7 days of CCA-induced changes in (A) mtHSP70 mRNA levels, and (B) 
phosphorylated JNK protein expression (mtHSP70, n=8; pJNK, n=7). Open grey, and 
open white bars represent control muscle in vehicle-, and TUDCA-treated animals, 
respectively; hatched grey, and hatched white bars represent stimulated muscle in 
vehicle-, and TUDCA-treated animals, respectively. Values represent means ± SEM. 
*P<0.05, stimulated vs. control TA muscle at a given time point and treatment. 
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APPENDIX C: LABORATORY METHODS AND PROTOCOLS 
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CHRONIC CONTRACTILE ACTIVITY SURGICAL PROCEDURE 
 
Sterilize all surgical tools prior to commencing the surgical procedures outlined below 
and also keep lab bench as sterile as possible by wiping it down thoroughly with ethanol. 
 
1. Shave the skin over the spinal column (between the apex of the scapulae) and over the 
left hindlimb just posterior of the knee joint. Wipe with iodine. 
2. With animal lying on its stomach, carefully make a skin incision between scapular 
apexes along the center of the back (approximately 5-10mm in length).  
3. Turn animal onto its right side so that the left hindlimb is upwards facing. In this 
position, make a small (10-15mm) skin incision from approximately 5mm posterior 
of the knee joint towards the top of the gastrocnemius muscle. Gently separate skin 
from superficial muscle. 
4. Make a small horizontal cut into the underlying left hindlimb muscle (biceps femoris) 
and blunt through the muscle to expose the peroneal nerve.   
5. Once the nerve has been exposed, affix the wire electrodes to the tunneler by folding 
over the end-piece (one with the slot) of the tunneler and carefully tunnel the 
electrodes from the left hindlimb to exit out the back being sure not to damage the 
electrodes.  
6. Use 4 retractors gain a larger exposure of the nerve and underlying musculature. 
7. Gently remove insulation to expose wire and make a coil of the wire ends. Tie a knot 
that attaches the suture silk to the last loop of the electrode.   
8. Using forceps (with sharp teeth), pinch a small amount (between 0.5-1.0 mm) of 
muscle that is flanking the peroneal nerve.  Place needle through the pinched 
muscle section and proceed to tie down the loop section of the electrode to the 
underlying muscle.  Once the loop section has been tied down, tie down a proximal 
section of the electrode to another thin section of muscle that is 3-4mm away from 
the loop portion. Tie down a third section using the same method as the previous. 
9.  Repeat steps 7 and 8 for the other electrode lead this time suturing the electrode to the 
other side of the peroneal nerve. 
10. Once both electrodes are sutured to the underlying muscle, the incision is closed with 
3-5 independent sutures (5.0 silk). Leave a coil of excess wire under the skin in the 
hip region to allow for movement. At this point, the skin closure is stapled shut. 
11. Once the hindlimb is complete, turn animal back on to their stomach to complete 
connection to the external stimulator. Cut folded wire that remains at the top of the 
back to give two wire ends and once again remove insulation to expose metal wire 
(approximately 5mm of exposed wire). 
12. Place exposed wire into socket pin and solder into place using solder iron. Repeat for 
other lead wire. 
13. Pass wires into simulator casing through the hole located on the underside (ensure 
gauze is played between casing and incision). Insert pins and add 2 CR2016 3V 
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Lithium Ion batteries into stimulation unit. Affix the stimulation unit to the casing 
using sticky-tack.  
14. Using surgical tape, carefully fasten stimulation unit and casing around the torso of 
the rat. Provide approximately 2-3 layers of tape to the top of the casing to prevent 
ambient light from triggering the IR sensors. Finally, secure everything in place by 
wrapping a final strip of tape around the sides of the casing.  
15. Test the stimulation unit by turning the unit on with the digital stroboscope (ON/OFF: 
1-flash).  Palpate the muscle to ensure adequate stimulation.  
 
 
 
CYTOCHROME C OXIDASE (COX) ASSAY FOR MICROPLATE READER 
 
Cell extract containing cytochrome c oxidase is added to the test solution containing fully 
reduced cytochrome c. The rate of cytochrome c oxidation is measured over time as a 
reduction in absorbance at 550 nm. The reaction is carried out at 30o C. 
 
Reagents 
1. Horse Heart Cytochrome c (Sigma, C-2506) 
2. Sodium Dithionite 
3. 100 mM K-Phosphate Buffer (KPO4; pH to 7.0) 
-make and mix equal proportions of 0.1 M KH2PO4 and 0.1 M K2HPO4.3H2O 
4. 10 mM K-Phosphate Buffer 
 -dilute 100 mM K-Phosphate Buffer 1:10 with ddH2O 
 
Procedure 
1. Add 50µl of muscle enzyme extraxtion buffer into labelled eppendorfs, weigh 5-
7.5mg of powdered tissue into tubes and record values. 
2. Volume up with appropriate amount of buffer to achieve a 20-fold dilution.  
3. Stir on ice for 15 minutes. While tubes are stirring prepare test solution below; 
§ weigh out 20 mg of horses heart cytochrome c 
§ add 1 ml of 10 mM KPO4 buffer and fully dissolve cytochrome c 
§ make up a small volume of 10 mg/ ml sodium dithionite- 10 mM KPO4 stock 
solution Note: make fresh each experiment and use within 20 minutes) 
§ add 40 µl of dithionite stock solution to the Test Solution and observe the red 
to orange colour change 
§ add 8 ml of ddH2O 
§ add 1 ml of 100 mM KPO4 buffer (Note: the Test Solution becomes light 
sensitive at this step; make sure to the cover vial with aluminum foil and 
place in oven at 30°C). 
4. Once samples have stirred for 15 minutes, sonicate samples 3x 30% power on ice. 
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5.  Once samples are sonicated make 80-fold diluted samples in separate labelled 
eppendorfs (i.e. add 50µl of 20-fold sample extract with 150µl of muscle enzyme 
extraction buffer). 
6.   Add 300 µl of Test Solution into 4-8 wells of a 96-well microplate and incubate at 
30°C for 10 minutes to stabilize the temperature and absorbance. 
7. Open KC4 plate reader program. Select CONTROL icon, then PRE-HEATING 
tab, enter 30°C and select ON  (Do not run assay until KC4 temperature has 
reached 30°C). 
8. Set-up of COX activity protocol on computer. 
9. Select WIZARD icon, then READING PARAMETERS icon. 
§ Select Kinetic for Reading Type. 
§ Select Absorbance for Reader and 550 nm for wavelength (drop-down). 
§ Select Sweep for Read Mode. 
§ Select 96 Well Plate (default) for Plate Type. 
§ Enter first and last well to be read (eg. A1 and A4 if reading 4 samples 
simultaneously). 
§ Select Yes and Pre-heating and enter 30 for Temperature Control. 
§ For Shaking enter 0 for both intensity and duration (shaking is not 
necessary and it will delay the first reading).  
§ Do not select either of the two options for Pre-reading. 
§ Click on the KINETIC… rectangular tile to open the Kinetic window. 
§ Enter run time (1 minute is recommended) and select MINIMUM for 
Interval time (under these conditions the minimum Interval time should be 
3 seconds). 
§ Select Allow Well Zoom During Read to see data in real time (optional). 
§ Under Scales, checkmarks should appear for both Auto check boxes.  Do 
not select Individual Well Auto Scaling. 
§ Press OK to return to Reading Parameters window.  Press OK to return to 
Wizard window.  Press OK.  Do not save the protocol. 
10. Set the micropipette to 240 µl and secure 4-8 tips on the white projections (make 
sure they are on tight and all the same height). 
11. In a second, clean 96 well plate, pipette 50µl of 80-fold samples into 4-8 empty 
wells (start with A1).  
12. Remove microplate with Test Solution from the incubator (as long as it has been 
incubating for 10 minutes).  Place this plate beside the plate with the sample 
extracts in it. 
13. On KC4 program, select the READ icon and press the START READING icon, 
then press the READ PLATE button.  A box will appear that says, “Insert plate 
and start reading”.  Do not press OK yet, but move the mouse so that the cursor 
hovers over the OK button. 
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14. Using the micropipette (set to 240 µl) carefully draw up the Test Solution.  Make 
sure the volume is equal in all the pipette tips, and that no significant air bubbles 
have entered any of the tips. 
15. Pipette the Test Solution into the wells with the sample extracts (the second 
plate).  As soon as all the Test Solution has been expelled from the tips (do not 
wait for the second push from the multipipette), place the plate onto the tray of the 
plate reader and with the other hand on the mouse, press the OK button.  (Speed at 
this point is paramount, as there is an unavoidable latency period between the 
time of pressing the OK button and the time of the first reading.)  
16. If desired, add 5 µl KCN to one of the wells to measure any absorbance changes 
in the presence of the CYTOX inhibitor. 
17. Once reading is complete, hold the CTRL key on the keyboard, and use the mouse 
to click once on each of the squares corresponding to a well that had sample in it.  
Once all the desired wells have been highlighted by a black square (up to a 
maximum of 8 wells), let go of the CTRL key and a large graph will appear with 
lines on it representing each sample.   
18. To obtain the rate of change of absorbance over different time periods, select 
Options and enter the amount of time for which you would like a rate of change of 
absorbance to be calculated.  The graph, along with one rate (at whichever time 
interval is selected) for each sample can be printed on a single sheet of paper, and 
the results can be saved. 
19. The delta absorbance will appear in units of mOD/min and the number given will 
be negative.  Convert this to OD/min by dividing by 1000 and omit the negative 
sign in the calculation.  (eg. if Mean V: -394.8 mOD/mn, then use 0.395 OD/min). 
 
Calculation 
 
CYTOX activity =  mean dealta absorbance/ minute x total volume (ml) x 1000 
        18.5 (µmol/ml extinction coeff.) x sample volume (ml) x total µg/ well 
 
Example Calculation:  
 
55 µl of enzyme extraction   COX activity = (0.5843)(0.285)(1000) 
230 µl of Test Solution                (18.5)(0.055)(3.023 x 55) 
Mean V: -584.30 mOD/mn 
Protein concentration: 3.023 µg/ µl  COX activity = 0.967 nmol/min/µg protein 
Total µg/ well: 151.15 
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GEL ELECTROPHORESIS (SDS-PAGE) – PROTEIN BIO-RAD SYSTEM 
 
Reagents: 
1. Acrylamide/Bis-Acrylamide, 30% Solution 37.5:1 (BioShop 10.502) 
a. Store at 4°C 
2. Under Tris Buffer 
a. 1M Tris-HCl, pH 8.8 (60.5g/500ml) 
b. Store at 4°C 
3. Over Tris Buffer 
a. 1M Tris-HCl, pH 6.8 (12.1g/100ml) 
b. Bromophenol Blue (for colour) 
c. Store at 4°C 
4. Ammonium Persulfate (APS) 
a. 10% (w/v) APS in ddH20 (1g/10ml) 
b. Stored at 4°C 
5. Sodium Dodecyl Sulfate (SDS) 
a. 10% (w/v) in ddH20 (1g/10ml) 
b. Store at room temperature 
6. TEMED (Sigma T-9281) 
7. Electrophoresis Buffer, pH 8.3 (10L) 
a. 25mM Tris 30.34g, 192mM Glycine 144g, 0.1% SDS 10g 
b. Volume to 10L with ddH20 
c. Store at room temperature 
8. 6X SDS 
a. Warm 100% glycerol in water bath at 65°C for 30 minutes 
b. Combine 1.2g SDS, 0.06g Bromophenol Blue, 3mls of 1M Tris, pH 6.8 
and 1ml of ddH20 and stir at 4°C for 5 minutes 
c. Add 3mls of 100% glycerol, stir and aliquot mixture. 
d. Store at -20°C 
e. Add 5% (v/v) ß-mercaptoethanol (Sigma M6250) to 6X SDS just prior to 
use 
9. tetra-Amyl alcohol ReagentPlus, 99% (Sigma 152463) 
 
 
 
Procedure: 
 
1. Prepare electrophoresis rack: 
a. Clean glass plates thoroughly with 
soap followed by 95% ethanol then 
ddH20.  
b. Dry carefully with a kimwipe.  
c. Assemble glass plates as shown 
below: 
d. Check the seal y adding a small 
volume of ddH20 then pour off and 
let dry.  
2. Prepare separating gels: 
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a. Mini Protean 3 Bio-Rad System volumes: 
 8% 10% 12% 15% 18% 
Acrylamide 2.7 ml 3.3 ml 4.0 ml 5.0 ml 6.0 ml 
ddH20 4.1 ml 3.5 ml 2.8 ml 1.8 ml 0.8 ml 
Under Tris 3.0 ml 3.0 ml 3.0 ml 3.0 ml 3.0 ml 
SDS 100µl 100µl 100µl 100µl 100µl 
APS 100µl 100µl 100µl 100µl 100µl 
TEMED 10µl 10µl 10µl 10µl 10µl 
b. Mix the contents of the separating gel without adding APS or TEMED. 
Stir.  
c. Add APS and TEMED. Stir.  
d. Slowly pour the entire volume of the solution into the space between the 
two plates while keeping plates tilted to prevent bubble formation. 
e.  Add tert-Amyl alcohol to coat top surface of gel solution. 
f. Allow 30 minutes for gel polymerization.  
g. Remove tert-Amyl alcohol by pouring it off and remove any remainder 
with a kimwipe. Rinse with ddH20. 
 
3. Prepare stacking gel: 
a. For a single mini gel use the following volumes: 
 
Acrylamide 500 µl 
Over Tris 625 µl 
ddH20 3.75 ml 
SDS 50 µl 
APS 50 µl 
TEMED 7.5 µl 
 
b. Mix the contents of the stacking gel without adding APS or TEMED. Stir.  
c. Add APS and TEMED. Stir.  
d. Using a Pasteur pipette slowly add the entire volume from the beaker in 
between the plates.  
e. Add comb for desired number of wells. 
f. Allow 30 minutes for gel polymerization. 
4. Prepare samples: 
a. Turn of the block heater to 95ºC.  
b. Pipette required volume of sample into new eppendorf with 6X SDS (1 
volume of sample to 1/6 sample volume of 6X SDS). Keep samples on ice 
until all samples are prepared. 
c. Briefly spin each sample to bring volume to the bottom of the eppendorf. 
d. Incubate each sample at 95 ºC for 5 minutes in the heating block to 
denature the proteins.  
e. Briefly spin again to return volume to the bottom of the eppendorf. 
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5. Assemble Mini-PROTEAN gel caster 
system: 
a. See images below 
b. If you are only running one gel a 
plastic rectangular pseudo plate 
must be clamped on the other 
side of the caster.  
c. Fill with electrophoresis buffer 
between the plates and outside of 
the plates in the chamber.  
d. Slowly remove the comb using 
both hands (one on each side) by 
pulling the comb straight 
upwards.  
e. Fix any wells that are deformed using a small spatula.  
f. Clean out the wells using a syringe filled with electrophoresis buffer.  
g. Withdraw the entire volume of the sample using a Hamilton syringe. Inject 
volume slowly into the bottom of the well.  
 
6. Gel electrophoresis  
a. Immediately after all samples are loaded place the lid on the gel chamber. 
b. Place positive and negative plugs into the power supply and turn on power 
supply.  
c. Set power supply to 120V. Gel will run for ~2 hours depending on percent 
gel made. 
d. When the bromophenol blue has run off the bottom of the gel turn off the 
power supply. Remove plugs from power supply and remove lid. 
e. Prepare for electrotransfer of proteins from the gel to nitrocellulose 
membrane.  
 
 
 
 
WESTERN BLOTTING AND IMMUNODETECTION 
 
Reagents: 
1. Transfer Buffer 
a. 0.025M Tris-HCl pH 8.3  12.14g 
b. 0.15M Glycine   45.05g 
c. 20% Methanol   800ml 
d. make up to 4L with ddH20 
e. store at 4°C 
2. Ponceau S stain 
a. 0.1% (w/v) Ponceau S  
b. 0.5% (v/v) Acetic Acid 
c. Store at room temperature 
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3. Wash Buffer 
a. Tris-HCl pH 7.5  12g 
b. NaCl   58.5g 
c. 0.1% Tween  10ml 
d. Store at room temperature 
4. Blocking Solution 
a. 5% (w/v) skim milk power in wash buffer OR 
b. 5% (w/v) BSA in wash buffer 
5. Enhanced Chemiluminescence Fluid (ECL; Santa Cruz sc-2048) 
6. Film/Developer/Fixer 
Procedure: 
1. Transfer Procedure 
a. Remove electrophoresis plates from chamber and separate the plates. 
b. Cut away unnecessary parts of the gel using a spatula and measure 
remaining gel size. 
c. Using a paper cutter cut 6 pieces of Whatman paper per gel to the same 
size as the gel. Wearing gloves cut nitrocellulose membrane (GE 
Healthcare RPN303D) to the dimensions of the gel.  
d. Assemble Whatman paper, nitrocellulose memebrane and gel as shown 
below: 
 
e. Close the cassette and place in the transfer chamber with the black side of 
the cassette facing the back side of the chamber.  
f. Place ice pack in the chamber. 
g. Place lid on the chamber and connect the leads to the power supply.  
h. Turn on the power supply and run at 120V for 2 hours. This can vary 
depending on the size of the protein of interest. 
 
2. Removal of transfer membrane: 
a. Turn off the power supply and disconnect leads from the power supply 
then remove the lid from the chamber. 
b. Remove the cassette from the chamber.  
c. With gloves on, remove the Whatman paper and gel and place the 
nitrocellulose membrane in a plastic dish.  
d. Add Ponceau S stain on the membrane and gently swirl.  
e. Drain off the remaining Ponceau S and save for reuse. 
f. Rinse the membrane with ddH20 to reduce the red background. Wrap 
membrane in saran wrap and scan image. 
g. Cut the membrane while protein bands are still visible at the desired 
molecular weight. 
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h. Rotate membrane at room temperature in wash buffer until remaining 
Ponceau S has been removed. 
i. Incubate membrane for 1 hour with rotation in blocking solution.  
j. Incubate membrane with desired antibody diluted in blocking solution 
overnight at 4ºC. Membrane is placed face down into the solution on a 
glass plate covered in parafilm. To maintain a moist environment 
overnight, wet a small kimwipe and form it into a ball and place in each 
corner of the dish. Cover the dish with saran wrap. 
 
3. Immunodetection 
a. Wash the blots in wash buffer with gentle rotation for 5 minutes 3X. 
b. Incubate the blots for 1-2 hours with the appropriate secondary antibody 
diluted in blocking solution. 
c. Membrane is placed face down in solution on a glass plate covered with 
parafilm. Place moist kimwipes in each corner of the dish and cover the 
dish with saran wrap. 
d. Following the incubation, wash the membrane 3X for 5 minutes with wash 
buffer. 
 
4. Enhanced Chemiluminescence Detection 
a. Mix ECl fluids “A” and “B” in a 1:1 ratio in a disposable Rohr tube. 
b. Place blots on saran wrap face up and apply ECL solution for 2 minutes.  
c. Dab off excess ECL on a kimwipe and place blots face down on a fresh 
piece of saran wrap and wrap tightly. 
d. Expose blot to film (time will vary depending on protein and antibody).  
e. Place film into developer (time will vary). 
f. Once image appears place film into fixer for 2 minutes. Wash with fresh 
water when complete. 
 
 
 
RNA ISOLATION 
Procedure: 
 
1) Homogenize (approximately 30 sec. @ 30-40% power) tissues (100 mg) at  
 30% in 1 ml Trizol in a 13 ml Sarstedt tube; 
OR 
Homogenize (approximately 30 sec. @ 30-40% power) tissues (200 mg) at  
30% in 1.25 ml solution D + 1.25 ml phenol + 0.125 ml 2M sodium acetate  
(pH 4.0) in a 13 ml Sarstedt tube 
**Note: The homogenizer must be sterilized in 0.1M NaOH and rinsed in sterile water 
prior to use.  Rinse in sterile water between samples. 
2) Let stand for 5 min at room temperature; 
3) Add 0.4 ml chloroform and shake vigorously for 15 sec, let stand for 2-3 min at 
room temperature; 
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4) Spin at 12,000 g for 15 min at 4°C; 
5) Transfer aqueous phase to 13 ml Sarstedt tube; 
6) Add 1 ml isopropanol, gently shake, and allow precipitation of RNA for 5-10 min 
at room temperature; 
7) Spin at 12,000 g for 10 min at 4°C; 
8) Remove supernatant and add 0.7 ml 75% ethanol; 
9) Transfer RNA to eppendorf tube; 
10) Rinse 13 ml Sarstedt tube with 0.3 ml 70% ethanol, add to eppendorf tube and 
mix by vortexing; 
11) Spin 5 min in eppendorf centrifuge at 4°C; 
12) Discard supernatant; 
13) Dry pellet under a vacuum in dessicator (DO NOT DRY PELLET WITH 
CENTRIFUGATION UNDER A VACUUM); 
14) Dissolve pellet in 50-200 µl sterile distilled DEPC water and measure absorbance 
at 260 nm and 280 nm. 
Reagents: 
1. Solution D  (Denaturing solution) 
4 M Guanidinium Thiocyanate     125 g  
25 mM of 1 M stock NaCitrate (pH 7.0)   6.6 ml 
N-Lauroyl Sarcosine;Sigma L-5125 (0.5% Sarcosyl) 1.32 g  
ddH2O        160 ml  
**Note: make up solution D and store at RT for up to 3 months.  On the 
day of the experiment, mix 50 ml of Solution D with 0.36 ml of beta-
Mercaptoethanol (0.1 M b-MEtOH) 
 
2. Phenol (Nucleic acid grade) 
a) Melt solid phenol at 68 °C (cap loose) in H2O; 
b) Add 0.25 g 8-hydroxyquinoline to 250 ml of phenol, mix; 
c) Add 250 ml 1.0 M Tris HCl (pH 8.0) and stir overnight at 4 °C covered in foil 
d) Remove supernatant;  
e) Add 250 ml 0.1 M Tris-HCl containing 0.2 % b-MEtOH (0.178 ml/100 ml for 
S.G. = 1.12) and mix thoroughly;  
f) Allow solution to settle and remove supernatant; 
g) Repeat 2 more times as above or until pH of phenol is > 7.6 (test with pH paper). 
h) Store in 25-50 ml aliquots at -20 °C. 
 
3. 2.0 M Na Acetate (pH 4.0) 
10.88 g/100 ml sterile H2O 
 
4. 75% ethanol in sterile H2O  
(75 ml ethanol + 25 ml dH2O) 
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RNA FORMALDEHYDE GEL 
 
Reagents: 
• 0.1% SDS (sodium dodecyl sulphate) 
• 10x MOPS (morpholinepropanesulfonic acid) 
  41.86g MOPS powder 
  3.72g EDTA (ethylenediaminetetraacetic acid) powder 
  900ml ddH2O, pH solution to 7.4 
  Volume up to 1L, aliquot into smaller containers and autoclave 
• Agarose powder 
• sterile ddH2O 
• 0.5mg/ml ethidium bromide 
• RNA sample buffer 
  100% deionized formamide 
  37% formaldehyde 
  1M MOPS (pH 7.4) 
  0.5M EDTA 
  100% glycerol 
  1% dyes (10mg bromphenol blue, 10mg xylene cyanol) 
10% SDS 
• Sanitized pipettes and sterilized pipette tips/Eppendorfs to be used at all times 
 
Procedure: 
1. Prepare the gel and electrophoresis chamber after overnight or 1 hr sterilization with 
0.1% SDS; 
2. Rinse the gel plates, electrophoresis chamber, and comb with sterile ddH2O, and wipe 
dry; 
 
Running Buffer: 
 
 
 
 
 
Agarose Gel: 
 
 
 
 
  
 
 
 
 
Small Chamber Large Chamber 
30ml 10x MOPS 200ml 10x MOPS 
270ml Sterile ddH2O 1800ml Sterile ddH2O 
Small Gel  Large Gel  
0.4g agarose 1.7g agarose 
4ml 10x MOPS 17ml 10x MOPS 
34ml sterile ddH2O 144ml sterile ddH2O 
Weigh solution and record weight. Melt in microwave until all solute 
has been dissolved. Re-weigh and make up volume with sterile ddH2O. 
Under the fume hood, add formaldehyde. 
2ml 37% formaldehyde 8.5ml 37% formaldehyde 
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3. Allow gel to coll for 15 minutes, pour, and let gel set for 30 minutes. Transfer the plate 
with the gel to an electrophoresis chamber, and place the end with the wells at the 
negative electrode; 
4. Calculate the volume of RNA and sample buffer required for desired amount of RNA. 
Combine in a sterile eppendorf tube: 
i. RNA      x µl 
ii. EtBr      4 µl 
iii. Sample buffer     x µl 
NOTE: use at least a 1:1 ratio of buffer to RNA volume (max. volume of 30 µl). 
5. Mix the samples by tapping; 
6. Denature the samples at 65°C for 10 min, quick cool; 
7. Spin down volume briefly in microfuge; 
8. Pipette the entire volume into each well of the gel; 
9. Run the gel at ~80V until second dye band, Xylene Cyanol, is 2/3 from the end; 
10. Visualize and photograph the gel under UV light. 
 
 
REVERSE TRANSCRIPTION, FIRST STRAND CDNA SYNTHESIS 
 
First-strand cDNA synthesis is performed following the manufacturer's recommendations 
that are outlined below: 
 
Reagents: 
 
1. total RNA (isolated as described) 
2. Oligo(dT)12-18 
3. 10 mM dNTPs (dATP, dTTP, dCTP, dGTP; 10 mM each) 
4. Sterile ddH20  
5. RNAse OUT (40 units/ µl) 
6. 0.1 M DTT 
7. 5X First-strand Buffer 
8. SuperScript II RT 
 *Note: All reagents except RNA are supplied with the SSII kit from Invitrogen. 
 
Procedure: 
 
1. Add following components to a nuclease/ RNA-free 500 µl eppendorf: 
   Oligo(dT)12-18   1 µl 
   1 µg of RNA   x µl 
   dNTP mix    1 µl 
   Sterile ddH20   to 20 µl 
 
2. Heat mixture to 65°C for 5 minutes and quick chill on ice.  Collect the contents with a 
quick spin in a tabletop microcentrifuge and then add: 
   5X First-strand buffer  4 µl 
   0.1 M DTT   2 µl 
   RNAse OUT   1 µl 
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3. Mix contents of tube gently and incubate at 42°C for 2 minutes. 
4. Add 1 µl (200 units) of Superscript II RT and mix by pipetting gently up and down. 
5. Incubate at 42°C for 50 minutes. 
6. Inactivate the reaction by heating at 70°C for 15 minutes. 
7. cDNA is ready for use in PCR amplification.  
 
 
 
OLIGONUCTEOTIDE PRIMER DESIGN 
 
 
Websites required: 
• Pubmed	Nucleotide	Search	
• Primer3	Primer	Design	Program	–	http://bioinfo.ut.ee/primer3/	
• BLAST	–	http://www.ncbi.nlm.nih.gov/tools/primer-blast/	
• IDT	website	–	http://www.idtdna.com/calc/analyzer	
 1. Know	the	gene	of	interest.	2. Use	the	Pubmed.com	nucleotide	search	and	choose	the	most	complete	cDNA	or	mRNA	version	of	the	gene.	3. Copy	the	sequence	and	insert	it	into	the	Primer3	program.	4. Remove	numbers	 from	the	copied	sequence	because	the	program	will	 treat	 them	as	nucleotides.	5. In	the	text	box	for	Product	Size	Ranges,	input	100-150.	6. In	the	text	box	for	Number	to	Return,	input	10	(or	whatever	you	want).	7. Under	the	heading	General	Primer	Picking	Conditions	go	to	Primer	Size	and	enter	10-20-22	from	min	to	max.	8. For	Primer	Tm	enter	58-60-62	from	min	to	max.	9. For	Max	Tm	Difference	enter	2.	10. For	Primer	GC%	enter	40-50-60	from	min	to	max.	11. For	Max	Self	Complementary	enter	6.	12. For	Max	Ploy-X	enter	3.	13. Under	 the	 heading	 Objective	 Function	 Penalty	 Weights	 for	 Primer	 go	 to	 End	
Stability	and	enter	9.	14. Click	on	the	“Pick	Primers”	button.	15. Examine	the	primers	on	the	list.	3’	end	of	primer	must	not	end	with	a	G	or	C.	No	more	than	three	G	or	C	in	last	five	nucleotides	at	3’	end.	16. Check	specificity	using	BLAST.	17. Calculate	 the	 ΔG	 to	 estimate	 secondary	 structures	 that	 can	 form.	 Go	 to	 the	 IDT	website.	18. Enter	each	oligo	one	at	a	time	and	press	“Analyze”.	ΔG	must	be	greater	than	or	equal	to	-9	to	continue.	19. Continue	down	the	list	selecting	Hairpin,	Self-Dimer,	Hetero-Dimer,	Tm	Mismatch.	Check	ΔG	for	each	one.		
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REAL-TIME POLYMERASE CHAIN REACTION (qPCR) 
 
1) 2 ug of RNA is converted to 2 ug of cDNA (STOCK cDNA).     
2) We dilute STOCK cDNA to 1:30 (2 uL STOCK cDNA added to 58 uL nuclease-free 
ddH₂O). 
3) We add 2 µL of diluted cDNA, per well. 
4) For SYBR Green analyses, primers were optimized, diluted and mixed with PerfeCTa 
SYBR® Green SuperMix, ROX Master Mix and nuclease-free ddH₂O. 
5) Total reaction volumes were always 25 µL. 
6) Samples must be duplicated to ensure accuracy. 
7) Use negative wells to monitor contamination, using nuclease-free ddH₂O in place of 
cDNA. 
8) Check for nonspecific amplification and primer dimers by analyzing melt curves. 
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